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ABSTRACT 
 
Inflammation has emerged as an important process in the effective 
growth/regeneration of skeletal muscle tissue. As the therapeutic target of the non-
steroidal anti-inflammatory drugs (NSAIDs), the cyclooxygenase (COX) pathway which 
regulates the production of autocrine/paracrine lipid mediators known as prostaglandins 
(PGs) from free intracellular fatty acids, plays an important role in mediating the 
inflammatory response. The aim of this thesis was to examine the role of inflammatory 
signaling in skeletal muscle adaptation with a particular focus on the molecular links 
between the COX pathway, PGs, and molecular control of myofibre growth 
Whereas certain PGs (i.e. PGF2α) appear anabolic, others (PGE2) have been 
implicated in skeletal muscle tissue catabolism. Additionally, PG synthesis is 
accompanied by increased production of other AA derived eicosanoids via parallel 
lipooxygenase (LOX) pathways including the leukotrienes (LTs) and lipoxins (LX). The 
purpose of study one was to determine the effect of heightened endogenous synthesis of 
inflammatory eicosanoids on skeletal muscle cell growth. AA supplementation increased 
the synthesis/release of PGs and this was associated with markedly enhanced myotube 
growth. The effect of supplemental AA on muscle cell growth was blocked by non-
selective and COX-2 selective NSAIDs, specifically implicating downstream PG species. 
These findings implicate heightened endogenous synthesis of pro-inflammatory PGs as a 
potent anabolic stimulus for muscle cell growth. 
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PGs act locally via cell surface receptors to influence cell biology. In particular, 
PGF2α has been previously implicated in skeletal muscle cell development, although the 
mechanisms by which this occurs are unclear. In the second study, the intracellular 
signaling response to PGF2α in skeletal muscle cells was investigated.  PGF2α stimulated 
intracellular signaling via the growth related extracellular receptor kinase (ERK) and 
mammalian target of rapamycin (mTOR) pathways. A novel mechanism of a mTOR 
pathway activation was discovered downstream of the type F prostanoid receptor by 
which PGF2α signals via PI3K-ERK-mTOR, distinct from the traditional PI3K-Akt-
mTOR pathway employed by the known growth factors (i.e. insulin/IGF-1). These data 
establish PGF2α as a previously uncharacterised endogenous stimulus to the mTOR 
pathway which plays an important role in the control of skeletal muscle growth. 
In study 3 the eicosanoid response to exercise–induced skeletal muscle injury was 
investigated in human subject’s in-vivo. Increased serum levels of PGs including PGD2, 
PGE2, PGF2α, and TXB2, as well as the EPA derived equivalents, were observed in the 
acute post-exercise period (0-3 hrs post-exercise). Elevated circulating levels of other 
inflammatory mediators including the AA derived LTs (eg LTB4) and purported anti-
inflammatory/pro-resolution lipid mediators including AA derived LXs and EPA/DHA 
derived resolvins (RVs) were also detected. This study is the first to comprehensively 
assess the eicosanoid response to exercise-induced skeletal muscle injury and 
characterizes a complex lipid derived inflammatory mediator response in the early hours 
of recovery post-resistance exercise. 
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In study 4 the effect of treatment with the non-steroidal anti-inflammatory drug 
(NSAID) ibuprofen on the human skeletal muscle translational signaling responses to 
resistance exercise were investigated. Ibuprofen ingestion was found to blunt resistance 
exercise-induced increases in the phosphorylation of ERK (Thr202/Tyr204), RSK 
(Ser380), p70S6K (Thr421/Ser424) and S6 (ser240/244) in skeletal muscle biopsies 3 hrs 
post-exercise. In contrast, the phosphorylation of Akt (Ser473) and p70S6K (Thr389) 
were not influenced by ibuprofen ingestion. These findings establish inflammatory 
signalling as an important contributor to contraction-induced adaptive signaling 
responses in human skeletal muscle. 
The results of this thesis expand our understanding of the role of inflammatory 
signaling molecules in the molecular control of skeletal muscle cell growth. Due to the 
complex role of fatty acid derived eicosanoids such as the PGs in the inflammatory 
response, further research is required to understand the physiological links between 
inflammatory signaling and skeletal muscle growth/regeneration. 
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1 CHAPTER ONE - REVIEW OF THE LITERATURE 
 
1.1  Skeletal Muscle Cell Growth  
 
Skeletal muscle tissue undergoes structural and functional adaptation in response 
to the mechanical demands placed upon it (94). Whereas prolonged sub-maximal muscle 
activity favours an aerobic cardiovascular and metabolic phenotype with little effect on 
muscle size, intense or unaccustomed skeletal muscle activity ultimately promotes 
adaptive increases in muscle mass and strength (160). In contrast, skeletal muscle wasting 
attributable to unloading or disuse is a major clinical problem in situations of 
immobilization, bed rest, neuromuscular disorders, ageing or microgravity (23, 65, 97). 
Progressively overloading the musculoskeletal system through resistance exercise 
training is an effective means by which to gain, preserve or restore skeletal muscle mass 
in order to enhance athletic performance, alter body aesthetics, improve/restore 
musculoskeletal health or combat disuse/ageing related atrophy (101, 107, 160). 
During embryonic myogenesis, muscle precursor cells known as myoblasts 
proliferate, differentiate and fuse to form mature multinucleated myotubes (138). As a 
consequence, adult muscle fibres are terminally differentiated and adaptive increases in 
muscle size are predominantly thought to occur as a result of an increase in the size of 
pre-existing myofibres (cell hypertrophy) (101, 301). Adaptive mechanisms which induce 
myofibre contractile fibre protein accretion within pre-existing muscle cells through 
altered rates of protein turnover thus play a major role in skeletal muscle growth. In 
addition, skeletal muscle growth is thought to be accompanied by proportional changes in 
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myonuclear content such that the area of cytoplasm regulated by a single nucleus or 
‘myonuclear domain’ is maintained.  
 
1.1.1 Protein turnover 
 
Skeletal myofibre size is ultimately determined by the balance between rates of 
muscle protein synthesis and muscle protein degradation. Skeletal muscle loading is a 
potent stimulator of skeletal muscle protein turnover. Heightened rates of mixed muscle 
protein synthesis are observed in fasted human subjects as early as 1 hour following a 
single bout of unaccustomed resistance exercise (78), and are sustained for up to 48 hours 
into recovery (236). Such a response occurs following both concentric (shortening) and 
eccentric (lengthening) muscular contractions (236), although maximal lengthening 
contractions appear to induce a relatively greater protein synthesis response (207). Rates 
of skeletal muscle protein breakdown are additionally heightened in response to a single 
bout of resistance exercise, however to a lesser extent than increases in protein synthesis, 
such that net protein balance is improved (236). In contrast, skeletal muscle disuse is 
characterised by myofibre atrophy attributable to both reduced rates of protein synthesis 
and increases in protein degradation (147). In humans it appears that disuse atrophy is 
predominantly be due reduced rate of skeletal muscle protein synthesis triggered by the 
removal of antigravity load (97).  Acute changes in muscle protein turnover appear at 
least qualitatively predictive of long term phenotypic changes in muscle mass and 
strength (122, 337, 339). However, myonuclear recruitment may ultimately be required to 
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replace nuclei lost through cellular injury/degeneration and/or sustain the elevated DNA 
requirements of the growing myofibre. 
 
1.1.2 Myonuclear addition 
 
Myonuclei of mature myofibres are post-mitotic, and thus nuclear addition is 
dependant on activation of a local pool of quiescent muscle precursor cells located 
between the basal lamina and cell membrane termed satellite cells (3). The role of 
satellite cells has been most firmly established in models of degenerative muscle injury 
and subsequent regeneration. Under such circumstances satellite cells fuse with damaged 
but viable myofibres to promote repair, or alternatively initiate de novo myofibre 
formation to replace those destroyed by injury. The critical role of satellite cells in 
skeletal muscle regeneration following degenerative injury has been established utilizing 
selective irradiation to prevent proliferation of satellite cells without influencing 
differentiated myofibres (118, 250). The role of satellite cells in hypertrophic growth of 
pre-existing adult skeletal muscle is less clear and has been widely debated (192, 218) 
Significant overload induced skeletal muscle hypertrophy may require satellite 
cell dependant addition of myonuclei into mature myofibres such that the myonuclear 
domain is maintained (3, 218). Irradiated muscle fibres fail to hypertrophy in response to 
synergist ablation overload (4). In contrast, irradiation impaired re-growth of the soleus 
muscle after hind limb suspension induced atrophy by only 50% and the plantaris muscle 
has been found to recover normally irrespective of irradiation (204). A complicating 
factor in such studies is the potential for ionizing radiation to inhibit protein synthesis 
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which could inhibit overload induced growth independent of any changes to satellite cell 
function (39). Indeed a recent study utilizing a genetic model to specifically ablate 
satellite cells in adult skeletal muscle reported effective hypertrophy of satellite cell 
depleted myofibers in response to synergist ablation overload (193). These results further 
emphasize that some degree of skeletal muscle growth can occur independent of 
proliferating satellite cells. The relative contribution of protein turnover vs. myonuclear 
addition may vary across different muscle types and/or loading stimuli. Nevertheless, 
adaptive hypertrophy in humans is associated by satellite cell activity and myonuclear 
addition. Increased myofibre cross-sectional area following strength training in humans is 
accompanied by proportional increases in both myonuclear and satellite cell number 
(151). Additionally, satellite cell proliferation is enhanced as early as 24 hours following 
a single bout of eccentric exercise in human subjects (77) and remains elevated for at 
least 7 days (57). Thus, myonuclear addition is associated with human hypertrophy and 
appears to occur at later stages following an acute loading stimulus than changes in rates 
of muscle protein turnover.  
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1.2 Skeletal Muscle Damage and Inflammation 
 
Strenuous or unaccustomed muscular activity, whilst being a potent stimulator of 
muscle cell growth, can result in structural damage to muscle fibres leading to acutely 
impaired muscle performance and delayed onset muscle soreness (DOMS) (53). This 
response is especially apparent following eccentric muscle actions in which muscles 
lengthen as they exert force (105). Eccentric muscle actions exert more tension and 
higher levels of strain on muscle fibres, although fewer motor units are recruited, leading 
to significantly more cellular damage than concentric contractions (292). The trauma to 
muscle tissue following skeletal muscle injury or modified use initiates an inflammatory 
response characterized by movement of fluid and plasma proteins into the injured tissue, 
and the infiltration of inflammatory cell populations (308). Inflammation occurs in 
response not only to degenerative injury, but also to a diverse range of loading stimuli 
including eccentric exercise (17, 18, 96, 120, 150, 184, 187, 230, 235, 241, 268), 
synergist ablation (71, 215, 305), and reloading after atrophy (87, 103, 104, 213, 290, 
310, 311). Inflammation has been proposed to contribute to both secondary muscle 
injury/soreness/loss of function, as well as subsequent adaptive growth/regeneration (269, 
308, 309).  
 
1.2.1 Inflammatory cell response to injury 
 
Neutrophils rapidly invade injured tissue and are the first cells to accumulate in 
muscle following modified use (308). Injured skeletal muscle cells release pro-
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inflammatory cytokines which promote neutrophil chemotaxis (234). Significant 
infiltration of neutrophils into skeletal muscle is detectable as soon as 1-2 hours 
following exercise-induced muscle damage (96, 241, 268), or reloading after atrophy 
(103, 310). Additionally, neutrophil infiltration has been reported in overloaded skeletal 
muscle 1 day following synergist ablation overload (71). Neutrophils destroy necrotic 
tissue via release of proteolytic enzymes and oxygen radicals and produce chemotactic 
agents which signal to other inflammatory cells (309). As part of this process, neutrophils 
can damage healthy muscle or bystander tissues causing secondary injury (40, 87, 239). 
Thus neutrophils have been proposed to be responsible for muscle damage worsening 
during the days following acute damage, peaking at 24-48 hours after the initial 
mechanical insult (309). Whilst evidence exists that neutrophils may exacerbate muscle 
damage, a role of neutrophils in promoting regeneration and growth is less apparent 
(213). 
Macrophages are the predominant inflammatory cell type at all stages of 
inflammation following the first 12 hours post injury (308). Macrophage infiltration of 
skeletal muscle also occurs in response to modified muscle use, peaking at ~3 days of 
reloading after hind limb suspension (104, 310) or ~5 days post synergist ablation 
overload (71, 215). Additionally, macrophages have been observed within human skeletal 
muscle from 24 h r to 12 days after exercise (17, 18, 120, 150, 187, 230, 235). Like 
neutrophils, macrophages are phagocytic, contribute to removal of debris, and have been 
proposed to be capable of secondarily injuring muscle cells. However, macrophages are a 
rich source of a number of cytokines and growth factors which play an important role in 
facilitating muscle repair and remodeling. Conditioned media from macrophage cell 
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cultures has been found to increase the rate of proliferation of skeletal myoblasts in-vitro 
(47, 48, 189). Thus, macrophages appear to play an important role in stimulating 
myogenesis, and the inflammatory response may be important in skeletal muscle 
remodeling in-vivo. 
 
1.2.2 Non-steroidal anti-inflammatory drugs (NSAIDs) 
 
The proposed mechanism of exercise-induced muscle damage and inflammation 
has led to interest in treatments to improve recovery and reduce DOMS (22, 140). In 
particular, anti-inflammatory strategies are common in the treatment of exercise-induced 
muscle injury. Such strategies include cyrotherapy, compression, and the use of non-
steroidal anti-inflammatory drugs (NSAIDs) (52). In particular, the prevalence of NSAID 
use amongst athletes has been reported to be very high (~30%), especially those in speed 
and power sports (6, 19, 55, 141). The ability of NSAIDs to suppress inflammation is 
primarily attributed to their ability to inhibit the cyclooxygenase (COX) enzyme, thus 
limiting the production of pro-inflammatory molecules known as prostaglandins (PGs) 
(98, 323). COX mediates the synthesis of PGs from free intracellular arachidonic acid 
(AA), derived from cell membrane phospholipids by the action of phopholipase enzymes. 
Initially, COX catalyzes the conversion of AA to the precursor prostaglandins PGG2 and 
PGH2 (85) (Figure 1-1). Subsequently, PGH2 is converted to  the major primary 
prostanoids PGD2, PGE2, PGF2α, PGI2 and thromboxane (TX) A2 by specific PG/TX 
synthase enzymes (85). Localized synthesis of PGs and TXs promotes tissue 
inflammation via regulating blood flow, vascular tissue permeability, platelet 
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aggregation, leukocyte chemotaxis and sensitizing sensory nerves to pain (63). Whilst 
omega-6 AA is the predominant substrate utilized for PG and TX synthesis in humans, 
omega-3 eicosapentaenoic acid (EPA) can also serve as a COX substrate for synthesis of 
the series 3 prostanoids (291). EPA derived equivalents (PGD3, PGE3, PGF3α, PGI3 and 
TXA3) whilst sharing cellular effects, exhibit significantly reduced agonist activity at 
eicoasnoid receptors and are thus less inflammatory or anti-inflammatory (291). 
 
 
        
Figure 1-1: Cyclooxygenase (COX) mediated prostanoid synthesis 
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Early experiments identified the presence of two different COX isoforms (COX-1 
and COX-2) which are derived from different genes (283). Whilst both enzymes carry out 
the same catalytic reaction, COX-1 is constitutively expressed in many tissues, whereas 
COX-2 expression is largely undetectable under normal circumstances and highly 
inducible in response to pro-inflammatory stimuli (115). Consistent with this expression 
pattern, COX-1 has been established to be responsible for a variety of homeostatic 
functions in a diverse range of tissues (208). Conversely, COX-2 has been implicated in 
the acute inflammatory response to tissue injury (88) and is highly expressed in 
chronically inflamed tissues (9, 154).  The identification of multiple COX isoforms lead 
to studies being undertaken to identify the degree of specificity with which various 
NSAIDs act (70, 287). The results of such investigations showed that many NSAIDS 
were highly non-specific and acted to inhibit both COX-1 and COX-2 with various 
degrees of efficiency (70, 287). Non-specific inhibition of COX-1 has been associated 
with numerous adverse side effects of NSAIDs due to its role in homeostasis and has led 
to the development of drugs which specifically inhibit COX-2 for use in the treatment of 
inflammation (COXIBs). By blocking local prostaglandin synthesis from free cellular 
arachidonic acid, non-selective (NSAIDs) or COX-2 selective (COXIBs) drugs act to 
reduce the cardinal signs of inflammation: pain, redness, swelling, heat and loss of 
function. 
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1.2.3 The prostaglandin (PG) response to exercise-induced muscle injury 
 
Given the role of COX mediated PG synthesis in inflammation, PGs have been 
proposed to contribute to DOMS and loss of function following eccentric exercise (14). 
Thus, the consumption of over-the-counter NSAIDs after exercise that causes muscle 
soreness is very prevalent (6, 19, 55, 141). Despite this, few studies have investigated the 
eicosanoid response to intense eccentric muscular contraction and associated exercise-
induced muscle injury/delayed onset muscle soreness (DOMs). Elevated circulating 
prostaglandins have been observed concurrent to the onset of DOMs 24-72 hrs following 
traditional resistance exercise including bench press  (50-90% 1RM) (PGE2) (319), 
barbell squat (70% 1RM) (13,14-dihydro-15-keto-PGF2α) (24) and step-up (body weight) 
(PGE2) (300). Furthermore, eccentric bench press loading (110% 1RM) promoted 
significantly greater increases in serum PGE2 when compared to lower intensities (319). 
In contrast, no significant elevation in circulation PGE2 levels occurred following intense 
eccentric knee extensor (60, 61) or elbow flexor (20, 38, 129) exercise across a range of 
post-exercise time-points spanning 0-4 days. Similarly, downhill running has been found 
to have either no effect (immediately post, 24 hr & 48 hr post exercise) (42), or no greater 
effect (immediately post exercise) when compared to level surface high intensity running 
(232), on circulating PGE2 levels. The reasons for such conflicting findings across 
different exercise protocols is unclear, but may be related to differences in the intensity of 
skeletal muscle loading (down hill running (42, 232) vs. resistance exercise (300, 319)) 
and the volume of active muscle mass (unilateral/isolation (20, 38, 60, 61, 129) vs. 
bilateral/compound exercises (24, 76, 300, 319)).  
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In addition to studies measuring the systemic prostanoid concentrations in venous 
blood, few studies have investigated the local prostaglandin response to exercise within 
the active musculotendonous unit itself. COX-2 mRNA expression is elevated in skeletal 
muscle biopsies obtained from human subjects during recovery from a single bout of 
resistance exercise (316, 332). Intramuscular PGF2α, but not PGE2, has been reported to 
be significantly increased within skeletal muscle biopsy tissue 24 hr post eccentric 
resistance exercise of the knee extensors (316). Skeletal muscle interstitial PGF2α 
concentration as determined by microdialysis was increased 5-6 and 8-9 hrs post-
resistance exercise, but had returned to basal levels by 24 hrs post-exercise (314). Thus, 
skeletal myofibres themselves and/or associated cells (satellite cells, fibroblasts, 
infiltration leukocytes, and local vasculature) appear to be a major source of exercise-
induced PGF2α. 
PGs have been better characterized in the acute physiological responses to sub-
maximal exercise. During and immediately following continuous sub-maximal exercise, 
heightened circulating levels of PGE2 (68, 173, 216, 232, 326), PGF2α (68, 74), and 6-
keto-PGF1α (49, 68, 95, 173, 197, 209, 249, 328) have been consistently reported. The 
effect of exercise on TXB2 synthesis is less clear. Low intensity sub-maximal exercise 
has generally been associated with relatively greater increases in the release of the 
vasodilator/antiaggregator PGI2, accompanied by no (27, 209, 217, 333), or minimal 
(177), changes in  the release of the vasoconstrictor/platelet aggregator TXB2. In 
contrast, maximal exercise (95, 172, 195, 197) (or exercise at higher relative intensities 
(312)) has been reported to  induce significant elevation of circulating TXB2 in most, but 
not all (328) studies. These PG/TX response to sub-maximal exercise is short lived, 
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returning to basline levels soon following cessation of contraction and under appears 
involved in the regulation of cardiovascular changes (muscle hyperemia and presser 
reflex) with exercise rather than muscle damage/inflammation (35, 36, 56, 58, 62, 64, 
153, 212, 265, 270). 
 
1.2.4 Effect of NSAIDs on exercise-induced skeletal muscle injury 
 
The efficacy of NSAID treatment of exercise-induced skeletal muscle injury is 
unclear. Positive short terms effects have been reported including reduced swelling (86), 
DOMs (13, 46, 73, 86, 123, 128, 174, 220, 230, 242, 246, 266, 299, 313),  circulating 
creatine kinase (220, 238, 242, 246, 299, 313), and improved strength (13, 34, 86, 123, 
174, 266). Conversely, other studies have failed to find any significant influence of 
NSAID treatment on post-exercise swelling (230, 245), DOMs (16, 24, 34, 61, 72, 116, 
145, 165, 166, 181, 201, 214, 238, 245, 271, 293, 316, 317), elevated circulating creatine 
kinase (24, 34, 61, 73, 123, 128, 174, 214, 230, 271), or muscle strength loss (46, 61, 116, 
201, 230, 238, 242, 293, 313). The reason for such conflicting findings is unknown but 
appears unrelated to any obvious differences in NSAID drug type, route of administration 
(oral, topical, intramuscular), exercise mode, or participants (gender, age, training status). 
On this basis, the efficacy of NSAID treatment in terms of muscle soreness, damage and 
recovery of strength has not been clearly established. 
 
1.2.5 Role of the cyclooxygenase/PGs in skeletal muscle growth/regeneration 
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Early animal studies investigating the effects of NSAID treatment of skeletal 
muscle injury observed reduced inflammation, necrosis, and secondary damage, in 
association with short term improvements in muscle strength/function (8, 51, 170, 171, 
203, 222). These findings support the hypothesis that inflammation may contribute to 
secondary tissue injury/loss of function. In some, but not all models of skeletal muscle 
injury (307, 327) however, NSAID treatment was found to be accompanied by evidence 
of delayed/impaired tissue regeneration (8, 203, 222) and longer term functional deficit 
(203). Subsequent studies with selective COX inhibitors and genetic knock-out mice have 
supported these findings and specifically implicated the inducible COX-2 isoform as 
essential in the effective regeneration of skeletal muscle tissue following injury (31, 275, 
276, 278). The role for COX-2 in skeletal muscle tissue appears applicable not only to 
degenerative myofibre injury/regeneration (freeze injury (31) and laceration (275, 278)), 
but adaptive skeletal muscle cell growth in general including post-atrophy re-growth 
upon return to ambulatory loading (32) and compensatory hypertrophy (synergist 
ablation) (32, 206, 215, 288). 
Despite the lack of consensus with regard a clear benefit of NSAIDs in post-
exercise recovery, there is some evidence to suggest that they may be detrimental to 
human skeletal muscle growth, a major goal of strength training programs. The eccentric 
exercise-induced rise in skeletal muscle protein synthesis that occurs in the acute post-
exercise period has been found to be significantly blunted in humans orally ingesting the 
non-selective NSAID ibuprofen (1200 mg/day) (317). On the other hand, intramuscular 
infusion of the non-selective NSAID indomethacin failed to have any effect on post-
exercise rates of muscle protein synthesis (202). The satellite cell proliferative response, 
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thought to be important in maintaining the DNA requirements of myofibre hypertrophy 
and/or repair was additionally found to be abolished following endurance (185) or 
resistance exercise (201) in the presence of NSAID treatment. In contrast to animal 
studies specifically implicating the COX-2 isoform in skeletal muscle 
growth/regeneration (31, 32, 215, 275, 278), the COX-2 selective inhibitor Celecoxib had 
no influence on post-exercise skeletal muscle protein synthesis (43) or satellite cell 
proliferation  (230) responses in human subjects. The underlying mechanisms by which 
NSAIDs may negatively influence acute skeletal muscle responses to resistance exercise 
are currently also unclear, however impaired satellite cell proliferation with non-selective 
NSAID treatment was not found to be associated with any significant effect on the 
expression growth factors, extracellular matrix-related genes and pro-inflammatory 
cytokines (202). 
 The relevance any acute negative effects of NSAIDs in terms of long term gains 
in human muscle size/strength in response to a resistance exercise training program has 
recently been brought into question. Ingestion of 400mg/day oral ibuprofen had no 
significant influence on skeletal muscle hypertrophy and strength gains in response to 6 
weeks of resistance training of the elbow flexors in young healthy males (165). It is 
important to note however that this dosage is one third of that used in the earlier acute 
exercise study (316, 317).  Furthermore, gains in skeletal muscle size and strength by 
older adults over 12 weeks of resistance training were recently reported to in fact be 
significantly greater in those ingesting ibuprofen daily (315). As ageing is associated with 
chronic low-grade inflammation and associated skeletal muscle atrophy, this finding may 
be at least partially reflective of an attenuation of ageing associated loss of skeletal 
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muscle mass in response to combined NSAID treatment and resistance exercise. Indeed 
NSAID administration has been found to have beneficial effects in the prevention of 
skeletal muscle wasting in animal models of chronic inflammatory disease including 
cancer cachexia (191, 285, 294), arthritis (113) and ageing associated sarcopenia (248, 
315). 
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1.3 Regulation of Skeletal Muscle by PGs 
 
Evidence supports an important role of COX activity in skeletal muscle 
growth/regeneration. The potentially deleterious effects of NSAIDs on skeletal muscle 
growth may be secondary to effects on other cell types associated with the 
inflammatory/regenerative process or attributable to direct effects on skeletal muscle cells 
themselves (pre-existing myofibres and/or satellite cells). As the COX pathway plays a 
key role in promoting acute inflammatory processes in injured tissue, the most likely 
muscle extrinsic explanation is a blunting of the inflammatory cell response.  
 
1.3.1 Inflammatory cells  
 
Effective tissue regeneration following injury involves complex interaction 
between muscle and inflammatory cells. For example, muscle regeneration is impaired 
when inflammatory cells are depleted and stimulated when they are increased (179). In 
addition to phagocytosis, macrophages secrete growth factors, cytokines and PGs, many 
of which have been implicated in myogenesis (47, 48). Indeed, blunted skeletal muscle 
regeneration following degenerative injury with COX-2 inhibition (31, 275), or genetic 
deficiency (31, 278), is associated with impaired inflammatory cell infiltration of 
damaged muscle. Impaired skeletal muscle regeneration could be attributable to either 
impaired clearing of necrotic tissue, or decreased release of leukocyte derived factors 
leading to delayed myogenesis.  
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In addition to being involved in regeneration, macrophages have been shown to 
contribute to normal adaptive skeletal muscle growth. For example, macrophage 
depletion in rodents impairs re-growth after atrophy induced by hindlimb suspension 
(311). Moreover, macrophage depletion attenuates adaptive skeletal hypertrophy in 
response to synergist ablation overload (71). Thus, macrophages which infiltrate 
overloaded skeletal muscle appear to contribute to subsequent adaptive growth. 
Consistent with the hypothesis that the role of COX-2 in skeletal muscle growth may be 
attributable to inflammatory cells, the macrophage response to loading is impaired with 
COX-2 inhibition (32, 215). In this regard, impaired re-growth of atrophied skeletal 
muscle following hind limb suspension in mice treated with the COX-2 inhibitor was 
accompanied by a 61% reduction in Mac1+ cells in the soleus at day 3 of reloading (32). 
Although this method does not distinguish between neutrophils and macrophages, the 
time point analyzed strongly suggests that the majority of such cells are macrophages as 
they are the predominant inflammatory cell found >12 hours following overload (309). 
Additionally, the detrimental effect of the COX-2 inhibitor NS-398 on skeletal muscle 
hypertrophy in response to synergist ablation was associated with an 80% reduction in 
the number of infiltrating macrophages 5 days ablation (215). In contrast, the acute 
neutrophil response peaked 1 day post ablation and was unaffected by COX-2 inhibition 
in this model (215). Given recent evidence of an important role of macrophages in 
skeletal muscle growth, the deleterious effects of COX-2 inhibition may be hypothesized 
to be due to decreased presence of macrophages. It is important to note however that 
human studies have failed to find a significant effect of non-selective (235, 313) or COX-
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2 selective (230) NSAIDs on exercise-induced increases in local (230, 235) or systemic 
(313) inflammatory cell numbers. 
Although inflammation clearly plays an important role in muscle growth under 
diverse physiological circumstances, it is unlikely that suppressed inflammatory cell 
infiltration alone explains the deleterious effects of COX-2 inhibition on skeletal muscle 
adaptation. In the study conducted by Bondesen et al. (2006), re-growth of the soleus 
muscle following hind limb suspension induced atrophy was associated with 
inflammatory cell infiltration (32). Consistent with the inflammatory cell hypothesis, both 
soleus re-growth and inflammatory cell infiltration of this muscle were impaired in mice 
treated with the COX-2 inhibitor SC-236. On the other hand, reloading of the plantaris 
muscle promoted adaptive re-growth without inducing an inflammatory cell response. 
Nevertheless, COX-2 inhibition attenuated re-growth of the soleus and plantaris muscles 
equally (32). Therefore, COX-2 activity appears sufficient to modulate skeletal muscle 
growth even in the absence of inflammatory cells (32).  
 
1.3.2 Myofibre protein turnover 
 
Skeletal muscle cells express COX 1/2 (304) and PGs are released from skeletal 
muscle tissue perfused in-situ (126, 352) as well as myogenic cell cultures in-vitro (320). 
Thus, prostaglandins synthesized within skeletal muscle cells via COX mediated 
conversion of intracellular arachidonic acid are secreted and act locally in an 
autocrine/paracrine fashion. Treatment of isolated skeletal muscle tissue in-vitro with 
exogenous PGF2a stimulates protein synthesis without influencing protein breakdown 
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(251). On the other hand, exogenous PGE2 increased rates of protein degradation without 
influencing protein synthesis (251).  Therefore, individual prostaglandins may both 
positively and negatively influence local rates of skeletal muscle protein turnover. 
Supporting the potential role of inducible COX metabolites in influencing adaptive 
protein turnover, NSAIDs including indomethacin and meclofenamic acid decrease rates 
of protein synthesis in intermittently stretched muscle tissue isolated in vitro without 
affecting basal protein turnover rates (286). In this model, treatment with exogenous 
PGF2α and PGA1 stimulated protein synthesis in basal muscle, but PGE2 and PGD2 
failed to do so (286). Consistently, increased release of PGF2α from isolated muscle 
subjected to intermittent stretch is highly correlated with acute changes in protein 
synthesis (225).  
 Prostaglandins have also been implicated in the regulation of protein turnover in 
skeletal muscle cell cultures. Utilizing a cell culture system allowing cultured skeletal 
myotubes to be subjected to cyclic mechanical stretch, Vandenburg (1990) noted an 
increased release of PGs into the culture media of strained cells (320). Blockade of 
prostaglandin synthesis with NSAIDs prevented PG release and blocked stretch induced 
increases in myotube protein synthesis (320). Additionally, treatment of cultured 
myotubes with exogenous prostaglandins including PGF2α and PGE2 both stimulated 
protein synthesis in these cells under basal conditions (320). In contrast, others have 
failed to detect changes in protein turnover of myotube cultures in response to exogenous 
PGs (194). The reasons for such conflicting findings are not entirely clear but may relate 
to differences in cell type, treatment duration, or isotope labeling protocol. 
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1.3.3 Satellite cell myogenesis 
 
In addition to influencing protein turnover, prostaglandins have been implicated 
in multiple stages of myogenesis. Treatment of cultured human myoblasts with PGF2α 
and PGE2 was reported to promote cell proliferation and differentiation respectively 
(353). Additionally, various  non specific antagonists of prostanoid synthesis impaired 
proliferation and differentiation of human myoblasts in a manner reversible upon 
exogenous PGF2α and PGE2 treatment (353). Consistent with animal studies specifically 
implicating the inducible COX-2 isoform in skeletal muscle growth/regeneration, the 
COX-2 selective inhibitor, NS-398, reduced basal PGF2α and PGE2 release and impaired 
basal proliferation and differentiation of cultured primary mouse skeletal muscle 
precursor cells (275). PGF2α (139, 149) and PGI2 (29) treatment has also been reported to 
lead to myocyte growth by enhancing cellular fusion events during myogenesis. In 
support of such a role of PGs in myonuclear addition, cultured myogenic precursor cells 
isolated from COX-2-/- mice exhibit impaired fusion as determined by the number of 
myotubes with >3 nuclei following 18 days in differentiation media (278). On the other 
hand, PGD2 at high doses can have deleterious effects on myoblast differentiation and 
fusion (325). 
The mechanisms by which COX-2/PGs exert an influence on skeletal muscle 
growth/regeneration in-vivo remain largely unknown. On the basis of in-vitro studies, 
prostaglandins may play a role in skeletal muscle growth by influencing satellite cells 
and/or rates of protein turnover of pre-existing myofibres. Interestingly, re-growth of the 
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plantaris muscle following hind limb suspension, a model of skeletal muscle growth 
which does not involve myonuclear addition (204), was impaired by COX-2 inhibition 
(32). This suggests that COX-2 appears capable of regulating skeletal muscle growth in-
vivo in part by mechanisms independent of satellite cells. Additionally, ibuprofen 
ingestion blunts skeletal muscle protein synthesis in the 24 hours following resistance 
exercise (317) implicating inhibition of acute translational and/or transcriptional events, 
rather than myonuclear addition (317). Prostaglandins are thought to act as 
autocrine/paracrine signaling molecules by binding to specific G-protein coupled 
extracellular prostanoid receptors (33, 124, 161). Despite this, the signaling pathways 
involved in PG regulation of skeletal muscle prior to the work presented in the 
experimental chapters of this thesis remained largely unknown.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 
22 
 
1.4 Signaling Pathways Regulating Skeletal Muscle Cell Growth 
 
The molecular events that control skeletal muscle protein turnover have become 
the focus of intense research. A large body of work has indicated that the protein kinase 
known as the mammalian target of rapamycin (mTOR) is a key master regulator of 
postnatal cell size (175). mTOR was first discovered as a target of the 
immunosuppressive drug rapamycin, a potent and specific inhibitor of mTOR (260). This 
serine/threonine kinase integrates signals from hormones (159), growth factors (253), 
ambient nutrients (11) and mechanical stimuli (134, 354). The mTOR pathway has been 
established to be critical for normal post natal skeletal muscle growth, and adaptive 
growth of adult skeletal muscle whereas maintenance of basal muscle mass is not 
dependant on the mTOR pathway (25). 
mTOR regulates muscle protein synthesis by phosphorylating downstream 
translational modulators including eIF-4E binding protein (4EBP-1) and p70S6 kinase 
(p70S6K, S6K1) (329). Phosphorylation of 4E-BP1 by mTOR releases it from an 
inhibitory complex with the eukaryote translation initiation factor 4E (eIF4E). This 
allows eIF4E to initiate cap-dependant translation by binding to the scaffolding protein 
eukaryote translation initiation factor 4G (eIF4G) which then binds to the cap structure at 
the 5-end of mRNA transcripts (111). p70S6K functions as a major positive regulator of 
downstream targets involved in mRNA translation including ribosomal protein S6 (rpS6) 
(233, 257), eukaryotic elongation factor 2 (eEF2) kinase (331), and eukaryotic initiation 
factor 4B (eIF4B) (274). Genetic deletion of p70S6K leads to a small mouse phenotype, 
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consistent with the notion that p70S6K plays a major role downstream of mTOR (281). 
Phosphorylation of rpS6, the most well characterized target of p70S6K, has traditionally 
been thought to play an important role in the translation of specific mRNAs containing 5-
terminal oligopyramidine (5’TOP) structure which encodes proteins central to the growth 
process including ribosomal proteins and elongation factors (244). More recently rpS6 
phosphorylation has been confirmed to play an important role in the control of muscle 
cell size (258), although the precise mechanisms by which this may occur have been 
brought into question (199, 259).  
mTOR signaling has been most extensively characterized in response to the 
growth factors insulin and insulin like growth factor-1 (IGF-1) (159, 253) (Figure 1-2). 
IGF-1 and insulin are potent stimulators of skeletal muscle cell hypertrophy in cultured 
skeletal myotubes, an effect which is blocked by co-incubation with rapamycin (159, 
253). The pathway by which insulin or IGF-1 promote mTOR signaling has been 
extensively characterized (267). Binding of insulin or IGF-1 to extracellular receptors 
leads to plasma membrane recruitment of phosphatidylinositol 3-kinase (PI3K) and 
stimulatory phosphorylation of protein kinase B (PKB, also known as Akt) (267). The 
requirement of PI3K/Akt signaling in stimulation of mTOR by growth factors has been 
extensively demonstrated through the use of the PI3K inhibitors LY294002 and 
wortmanin which prevents IGF-1/insulin induced phosphorylation of Akt/p70S6K/4EBP-
1 and muscle cell hypertrophy (159, 253). 
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Figure 1-2: IGF-1/Akt/mTOR pathway 
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1.4.1 Role of mTOR in overload induced skeletal muscle growth 
 
Whilst maintenance of basal skeletal muscle mass appears to be independent of 
mTOR (25), this kinase plays a central role in adaptive skeletal muscle hypertrophy 
(237). For example, synergist ablation overload is associated with induction of mTOR 
signaling and treatment with rapamycin abolishes overload induced  increases in skeletal 
muscle mass and myofibre cross-sectional area (26). Furthermore, passive stretch of 
isolated rat muscle ex-vivo, or cultured myotubes in-vitro stimulates rapamycin sensitive 
mTOR signaling and muscle protein synthesis (130-133, 135). Consistent with these 
animal studies, a large number of papers have reported activation of the mTOR pathway 
in human skeletal muscle following an unaccustomed bout of resistance exercise 
performed in the fasted state (44, 45, 78-80, 82, 84, 89, 92, 108, 112, 142, 152, 167, 254, 
297, 302, 303). The extent of post-exercise p70S6K phosphorylation in particular is 
positively correlated with acute changes in human muscle protein synthesis (108, 167) 
and gains in muscle mass with exercise training (190, 302).  Furthermore, administration 
of rapamycin to human subjects blunts contraction-induced increases in skeletal muscle 
protein synthesis, indicative of a role of mTOR kinase activity in human muscle protein 
turnover (84). Collectively these findings show that mTOR signaling is stimulated during 
post-exercise recovery in human skeletal muscle and this response is required for 
contraction-induced muscle protein synthesis and ultimately skeletal muscle hypertrophy. 
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1.4.2  IGF-1/PI3K/Akt in contraction induced mTOR signaling? 
 
It is well established that increases in skeletal muscle loading result in an 
increased local expression of IGF-1 (2, 69, 351). As discussed above, IGF-1 is known to 
be a potent stimulator of protein synthesis and ultimately skeletal muscle cell hypertrophy 
via the PI3K-Akt-mTOR signaling pathway (253). Thus, until recently it was widely 
assumed that autocrine/paracrine release of IGF-1 may be the underlying mechanism 
responsible for induction of mTOR signaling in response to heightened loading (111). 
Consistent with this hypothesis, in an early study, stretching of myotubes in-vitro was 
found to promote the delayed release of a factor into the culture media which was able to 
activate p70S6K (12). However, more recently the paradigm that resistance exercise 
promotes mTOR signaling via the PI3K/Akt pathway secondary to the systemic or local 
autocrine/paracrine release of IGF-1 has been brought into question (237). 
The first evidence against the PI3K/Akt dependent hypothesis came from studies 
in which passive mechanical stretch of isolated skeletal muscle ex-vivo stimulated rapid 
mTOR dependent signaling in a manner which was not impaired by the PI3K inhibitor 
wortmanin or in muscle isolated from Akt1-/- mice (131, 133). These finding have since 
been confirmed in cultured C2C12 myotubes subjected to cyclic mechanical strain (130, 
135, 211). Thus it appears that neither PI3K activity, nor Akt signaling is required for 
mTOR dependent signaling in response to passive mechanical stimulation. Furthermore, 
in these acute models, conditioned media collected immediately following stretching was 
found to not to be sufficient to stimulate mTOR signaling in basal cells, implying a 
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secreted factor (such as IGF-1) was also not involved (130, 133). A PI3K/Akt 
independent mechanism of mTOR signaling was more recently confirmed in response to 
a bout of eccentric muscle contractions, a model which more closely mimics the loading 
stimulus of human resistance exercise (221). It is important to note that unlike mTOR 
dependent signaling events, stretch induced increases in muscle protein synthesis (133) 
and myotube size (264) have been found to be prevented by incubation with PI3K 
inhibitors. Thus, whilst not required for stretch induced mTOR signaling, basal PI3K 
activity appears at least permissive for mechanically induced muscle cell growth. 
Nevertheless, resistance exercise dose not increase IGF-1 receptor/PI3K signaling above 
basal levels (121) and transgenic mice (MKR) lacking a functional skeletal muscle IGF-1 
receptor exhibit unimpaired phosphorylation of p70S6K (thr389) and muscle hypertrophy 
in response to synergist ablation overload (289).Thus, current evidence suggests that 
induction of the traditional IGF-1/PI3K/Akt pathway is not required for mTOR 
dependent signaling and muscle growth in response to heightened loading. 
The above animal studies provide convincing evidence that mechanical stimuli 
are capable of regulating mTOR dependent signaling via a mechanism that is distinct 
from the traditional PI3K-Akt dependant pathway employed by IGF-1 (253). Consistent 
with this hypothesis, numerous human trials have found signaling at the level of Akt to be 
elevated unaltered (89, 142, 152, 297, 303) or blunted (66, 67, 302) in spite of heightened 
mTOR signaling and muscle protein synthesis. It has been suggested that such upstream 
signaling may in fact not occur when subjects are in a fasted state in the absence of the 
insulin secretion associated with nutrient ingestion (66). Furthermore, physiological 
systemic elevations in purported anabolic hormones including IGF-1 do not augment 
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contraction-induced increases in acute changes in muscle protein synthesis/mTOR 
signaling (335) or training induced muscle hypertrophy/strength (334) in human subjects. 
These findings together with the animal studies discussed above provide evidence to 
suggest that contraction induced mTOR signaling in human skeletal muscle is regulated 
via PI3K/Akt independent pathway. 
 
1.4.3 ERK signaling 
 
In addition to Akt/mTOR signaling, there has been interest in regard to the role of 
mitogen activated protein kinase (MAPK) pathways in regulating exercise-induced 
muscle adaptations (164). Indeed the extracellular receptor kinase (ERK) branch of the 
MAPK pathway has been demonstrated to play a positive role in regulating muscle 
protein synthesis (159, 240, 298) and skeletal muscle cell growth (119, 279, 280, 348). In 
an early study, treatment with the MAPK/ERK kinase (MEK) inhibitor PD98059 was 
shown to inhibit basal and insulin stimulated protein synthesis in L6 myoblasts to an 
extent comparable to that elicited by either the mTOR inhibitor rapamycin or the PI3K 
inhibitor wortmanin (159). More recently, ERK signaling has been implicated in the 
hypertrophic response to variety of stimuli including IGF-1 (119) TNF-α (240), 
clenbuturol (280) and testosterone (348). Furthermore, the maintenance of basal skeletal 
muscle mass appears dependent on ERK signaling (279).   
Whilst a role of ERK in the regulation of transcription is well established (336), 
whether such a role may account for the observed role in the regulation of muscle growth 
has been brought into question. For example, whilst PD98059 was found to prevent the 
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muscle hypertrophy induced by chronic localized infusion of IGF-1 in rats in vivo, this 
was specifically associated with impaired translational capacity (119). As for the possible 
molecular mechanisms underlying these findings, the phosphorylation of eIF4E in basal 
(159, 240) as well as insulin (159) or TNFα (240) stimulated C2C12 myotubes has been 
shown to be ERK dependent. Additionally in other cell types ERK 1/2 signaling regulates 
the translational apparatus via phosphorylation of eIF4B (274), eIF4E (100) and eEF2 
kinase (331). Whether such regulation occurs in skeletal muscle cells has not been 
directly investigated 
In addition to direct regulation of the above translation factors, evidence exists to 
suggest crosstalk between the ERK and mTOR pathways. For example, PD98059 has 
also been shown to impair the phosphorylation of p70S6K at the mTOR dependent 
Thr389 site in cardiomyocytes (146), skeletal myotubes (279) and the skeletal muscle 
tissue of IGF-1 treated rats (119) This regulation may be explained by findings in HEK 
cells that RSK (a downstream effector of ERK) directly phosphorylates and inactivates 
the TSC-2 tumor suppressor, a negative upstream regulator of mTOR (256). Indeed the 
Akt and ERK pathways were recently reported to function through parallel mechanisms 
to promote mTOR dependent signaling via phosphorylation of TSC-2 at distinct residues 
(344). Thus, Akt and ERK converge upstream of mTOR to synergistically regulate 
mTOR dependent signaling (344). Consistent with an important role of ERK signaling in 
mechanically induced mTOR signaling, phosphorylation of TSC-2 at the purported ERK 
dependent site (Ser664) within skeletal muscle was recently reported in response to 
synergist overload (205). Furthermore, phosphatidic acid (PA), a compound involved in 
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PI3K/Akt independent induction of mTOR in response to mechanical load (132, 135, 
221),  was recently found to signal to mTOR via an ERK dependent pathway (343). 
The ERK pathway may also interact with downstream components of the mTOR 
pathway in a manner independent of controlling mTOR kinase activity. Passive 
mechanical stretch of isolated skeletal muscle (133) and synergist ablation overload (205) 
stimulate phosphorylation of p70S6K at both The389 and Thr421/Ser424 residues. 
Unlike mechanically induced phosphorylation of p70S6K Thr389, phosphorylation of the 
Thr421/Ser424 site of p70S6k in response to loading is rapaymycin insensitive (mTOR 
independent) (133, 205). Thus, under these circumstances phosphorylation of p70S6K 
Thr421/Ser424 appears to be mediated via another kinase. Interestingly, in 
cardiomyocytes, phosphorylation of p70S6K at Thr421/Ser424 in response to the 
mitogen phorbol myristate acetate (PMA) (a rapamyin insensitive event) is abolished by 
ERK inhibition (146). More recently, the basal phosphorylation of p70S6K at 
Thr421/Ser424 in skeletal myotubes was also found to be impaired by inhibitors of either 
the ERK or p38 MAPK pathways (66). Whether such regulation is responsible for 
elevated phosphorylation of p70S6K Thr421/Ser424 in response to mechanical load has 
not been directly investigated. Nevertheless heightened phosphorylation of ERK occurs 
in concert with p70S6K Thr421/Ser424 response to passive mechanical stretch (130, 
211), synergist ablation overload (205) and human resistance exercise (44, 59, 66, 83, 84, 
108, 152, 297, 342). Furthermore, contraction induced phosphorylation of ERK and 
p70S6K Thr421/Ser424 in human skeletal muscle during early recovery are closely 
associated and precede subsequent phosphorylation of p70S6K Thr389 (66, 297). Thus it 
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has been hypothesized that ERK signaling may regulate contraction induced 
phosphorylation of p70S6K Thr421/Ser424 in human skeletal muscle (66). 
Finally the ERK pathway has been demonstrated to mediate phosphorylation of 
rpS6 at Ser235/236 in a manner independent of mTOR (257). Consistent with this study 
the early phosphorylation of skeletal muscle rpS6 in response to mechanical overload was 
recently found to be rapamycin insensitive (205). Whilst rapamycin administration 
reduced basal phosphorylation of rpS6 and completely blocked phosphorylation of 
p70S6K Thr389 response, downstream phosphorylation of rpS6 at both Ser235/236 and 
Ser240/244 in response to synergist ablation overload persisted in the presence of 
rapamycin treatment (205). Collectively these data suggest a positive interaction of the 
ERK and mTOR pathways.  
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1.5 Perspectives 
 
Much progress has been made in recent years into our understanding of the 
molecular mechanisms underlying skeletal muscle adaptation. Evidence exists to suggest 
that the inflammatory response may play an important role in adaptive skeletal muscle 
growth and regeneration. Whilst inflammatory cells (most notably macrophages) appear 
to play an important supportive role in this process, locally synthesized inflammatory 
molecules may have direct autocrine/paracrine effects on skeletal muscle 
growth/regeneration independent of infiltrating inflammatory cells.  In particular, as the 
molecular target of NSAIDs, PGs have been implicated as important signaling molecules 
in the local control of muscle cell protein turnover and satellite cell myogenesis. Despite 
this, the molecular mechanisms by which COX/PGs act to influence muscle cell biology 
remain largely unexplored.  
Exercise is a physiological stressor capable of eliciting adaptive changes in muscle 
tissue structure and function with important implications for performance, health and 
disease. A large body of work has characterized the human skeletal muscle signaling 
response during post-exercise recovery, with much of this work focusing on the role of 
mTOR signaling in translational control. Despite this, the upstream contraction sensitive 
signals responsible remain elusive. The physiological role of inflammatory lipid 
mediators as autocrine/paracrine signaling molecules during post-exercise recovery has 
not been investigated. 
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1.6 Aims 
 
This thesis aims to examine the role of inflammatory signaling in the molecular 
regulation of skeletal muscle cell growth with a focus on COX pathway. 
 
The specific aims of the experimental studies which comprise this thesis were: 
 
• To investigate the effect of heightened free arachidonic acid availability via 
exogenous supplementation on prostaglandin synthesis and skeletal muscle cell 
growth in-vitro. 
 
• To investigate translational signaling responses to PGF2α in skeletal muscle cells 
and the role of PGF2α signaling in muscle cell hypertrophy. 
 
• To characterize the human eicosanoid response during recovery from a single 
bout of unaccustomed resistance exercise. 
 
• To determine the effect of NSAID (ibuprofen) administration on exercise-induced 
signaling responses in human skeletal muscle. 
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1.7 Hypotheses 
 
It is hypothesized that: 
 
• Arachidonic acid supplementation will increase the synthesis of pro-inflammatory 
prostaglandins in association with enhanced skeletal muscle cell growth and these 
effects will be prevented by NSAID treatment. 
 
• Exogenous PGF2α treatment will stimulate phosphorylation of key kinases 
implicated in the control of protein translation and PGF2α signaling will be 
functionally important for in-vitro skeletal muscle cell growth. 
 
• Circulating levels of pro-inflammatory eicosanoids will be elevated during  the 
early hours of recovery from an acute bout of resistance exercise and this effect 
abolished by ibuprofen treatment. 
 
• The phosphorylation of key kinases implicated in the control of protein translation 
will be increased in human skeletal muscle during early post-exercise recovery 
and this response will be blunted by ibuprofen administration. 
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2 CHAPTER TWO - ARACHIDONIC ACID SUPPLEMENTATION 
ENHANCES IN-VITRO SKELETAL MUSCLE CELL GROWTH 
VIA A COX-2-DEPENDENT PATHWAY 
 
This work is has been submitted for peer review prior to completion of this dissertation. 
Markworth JF, and Cameron-Smith D. Arachidonic acid supplementation enhances in-vitro skeletal 
muscle cell growth via a COX-2 dependent pathway. American Journal Of Physiology Cell Physiology. 
 
2.1 Introduction 
 
Arachidonic acid (AA) is a polyunsaturated omega-6 fatty acid [20:4(ω6)] present 
in the phospholipids of cellular membranes. AA is cleaved from phospholipid molecules 
via the action of the enzyme phospholipase A2 (PLA2). Upon release, free intracellular 
AA serves as a key transient cell signaling intermediate, undergoing enzymatic 
conversion to pro-inflammatory autocrine/paracrine eicosanoid mediators. 
Cyclooxygenase (COX) and lipooxygenase (5-LOX/15-LOX) enzymes catalyze the 
oxidation of AA to produce the prostaglandins (PGs) (PGD2, PGE2, PGF2α, PGI2 and 
TXA2) and the leukotrienes/lipoxins families of eicosanoids respectively. Non-steroidal 
anti-inflammatory drugs (NSAIDs) exert their anti-inflammatory, analgesic and 
antipyretic action specifically by inhibition of the COX branch of the AA pathway. 
Skeletal muscle cells express the COX genes, COX-1 and COX-2 (304), and locally 
synthesize/release eicosanoids including PGD2 (325), PGE2/PGF2α (224, 276, 278, 320) 
and PGI2 (29). NSAID treatment has recently been associated with deleterious effects on 
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skeletal muscle growth/regeneration (31, 32, 215, 275, 276, 278, 288), consistent with the 
inflammatory response being an important process in adaptive myofibre remodeling (71, 
276, 311). NSAID treatment (198, 275) and COX-2 deficiency (32, 278) also inhibit in-
vitro myogenesis, specifically implicating COX-2 derived PGs as local 
autocrine/paracrine regulators necessary for normal skeletal muscle growth/development.  
Skeletal muscle cell growth typically involves parallel changes in myofibre size 
and myonuclear addition. Myonuclear accretion depends on the activation, proliferation, 
differentiation and fusion of satellite cell derived myoblasts with the growing 
multinucleated cell (178, 196, 210, 263). The fusion events that regulate the formation of 
multinucleated skeletal muscle cells involves two distinct phases: Myoblast-myoblast 
fusion to form small nascent myotubes containing few myonuclei, and subsequent fusion 
of myoblasts with pre-existing multinucleated cells, leading to myonuclear addition and 
increased myotube/myofibre size (138, 148, 231). High exogenous concentrations of 
individual prostaglandins elicit class specific physiological effects on multiple stages of 
skeletal muscle cell growth. For example, PGI2 (29) and PGF2α (139, 149)  enhance early 
and late muscle cell fusion events during myogenesis respectively, leading to enhanced 
myonuclear accretion and increased myotube size. Conversely, PGD2 exerts negative 
effects on skeletal myogenesis, characterized by impairment of myocyte 
differentiation/fusion (325). Similarly, PGF2α and PGE2 have opposing effects on 
skeletal muscle cell protein turnover in pre-existing myotubes/myofibres, acting to 
increase rates of protein synthesis and protein degradation respectively (251).  Although 
the mechanisms by which PGs may influence myogenesis/protein turnover remain poorly 
understood, the type F-prostanoid receptor is coupled to intracellular skeletal muscle cell 
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growth related signaling via the NFATC-2 (139, 149) and mammalian target of 
rapamycin (mTOR) (188) pathways. The collective role of such diverse and often 
opposing effects of prostaglandins on skeletal muscle remains unclear. 
Under physiological circumstances, free intracellular AA is metabolized to form 
multiple eicosanoid species which act in concert to induce a local cellular response. 
Eicosanoid synthesis is dependent on the expression of COX/LOX isoforms and 
downstream synthases and may vary widely across different tissues and/or physiological 
states.  Mechanical stimulation of skeletal muscle cells promotes membrane phospholipid 
cleavage, free intracellular AA accumulation, PG synthesis/release and cellular growth 
(286, 320, 321). Therefore, COX mediated AA metabolism has been implicated in the 
local control of myofibre protein turnover (316, 317) and satellite cell proliferation (185, 
200, 201) following resistance exercise. Conversely, the debilitating skeletal muscle 
wasting associated with chronic inflammatory conditions including cancer cachexia (191, 
285, 294), arthritis (113) and ageing associated sarcopenia (248, 315) are improved by 
NSAID treatment. In contrast to the apparent positive role of PGs in adaptive muscle 
growth, these reports appear indicative of a deleterious effect of PGs on skeletal muscle 
tissue specifically under conditions of chronic systemic low-grade inflammation.  
The divergent reports of NSAIDs on skeletal muscle mass in-vivo may be 
explained by the diverse and often contradictory effects of the individual eicosanoid 
species. By supplying exogenous free AA, the rate limiting step of prostaglandin 
synthesis, PLA2 catalyzed release of AA from membrane phospholipids, can be 
bypassed. The net effect of supplemental AA appears to depend on the cumulative effects 
of the individual eicosanoids synthesized, of which both positive (PGF2α & PGI2) and 
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negative (PGD2 & PGE2) are known to exist. Treatment of isolated skeletal muscle tissue 
with supplemental AA promotes the rapid production of PGF2α and PGE2 and stimulates 
protein turnover (251, 286). Under ex-vivo conditions, supplemental AA increased 
protein degradation in absolute terms to a greater extent than protein synthesis, the net 
result being skeletal muscle protein catabolism (251).  Despite the importance of satellite 
cell myogenesis in skeletal muscle regeneration/hypertrophy (178, 196, 210, 263), and 
recent studies implicating specific individual PGs as important mediators of myoblast 
survival (149), proliferation (32, 198, 224, 275), differentiation (198, 275, 325) and 
fusion (29, 139, 198, 278), no study has investigated the direct net effect of heightened 
free AA availability on these processes. 
 In the present study we show that supplementation with exogenous free AA 
during skeletal myogenesis enhances myotube growth and myonuclear accretion. This 
effect is dependent on metabolism of supplemental AA, and requires COX-2 enzyme 
activity. Despite this, secreted eicosanoids alone, at the levels and concentrations 
produced in response to AA supplementation do not appear sufficient to account for the 
effect of AA on skeletal muscle cell growth. 
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2.2 Materials and Methods 
 
2.2.1 Cell Culture 
 
Myoblasts from the skeletal muscle-derived C2C12 cell line were obtained from 
American Type Culture Collection (ATCC). Proliferating myoblasts were cultured at 37 
˚C, 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM, high glucose, + phenol 
red, + L-glutamine; Gibco) supplemented with 10% fetal bovine serum (FBS; Gibco) and 
antibiotics (penicillin 100 U/ml, streptomycin 100 μg/ml (Gibco)). Cells were grown 
until 100% confluence and then induced to differentiate in the presence experimental 
treatments by transferring cells to DMEM (high glucose, + phenol red, + L-glutamine) 
containing antibiotics and 2% Horse Serum (Gibco). To assess the effect of AA on 
myotube development, arachidonic acid (Cayman Chemicals) or vehicle (0.1% ethanol 
final concentration) was added to differentiation media at the onset of differentiation. To 
assess the effect of AA supplementation on pre-existing myotubes, C2C12 myoblasts 
were allowed to differentiate under typical conditions for 72 hr prior to initiation of AA 
supplementation. Following initiation of AA supplementation, every 24 hr the culture 
media was removed and replaced with fresh differentiation media ± AA. At this time the 
media bathing the cells (conditioned media) was collected, snap frozen and stored at -
80ºC until further analysis.   
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2.2.2 ELISA 
 
Enzyme-linked immunosorbent assay (ELISA) was used to evaluate the 
conditioned differentiation media collected from cells every 24 hrs. PGF2α and PGE2 
levels were determined as suggested by the manufacturer’s protocol (PGF2α ELISA kit, 
PGE2 ELISA kit, Cayman Chemicals). 
2.2.3 Immunohistochemistry 
 
At the indicated times, cultures were fixed in 4% paraformaldehyde/PBS (4% 
PFA) and permeabilized with 0.1% Triton X-100. Cells were blocked in 1% BSA/PBS 
for 1 hr at room temperature and incubated with a primary antibody against sarcomeric 
myosin (MF20, Developmental Studies Hybridoma Bank) overnight at 4˚C. Cells were 
washed in PBS, and then incubated in goat anti-mouse IgG conjugated to Alexa Fluor® 
488 secondary antibody and 4',6-diamidino-2-phenylindole (DAPI) (to visualize nuclei) 
for 1 hr at room temperature. Cells were visualized with an Olympus IX70 fluorescent 
microscope (Olympus, Australia) and digital images were collected using Spot RT slider 
camera and Magnifire Software (Olympus, Australia). Global adjustments to image 
fluorescent signal brightness/contrast were made in photoshop and images were 
overlayed as RGB channels (sarcomeric myosin: green; DAPI: blue) to facilitate 
morphological analysis. 
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2.2.4 Morphological analysis 
 
To assess average myotube diameter, 50 myotubes per well were analysed (3-4 
independent culture wells/group). From each well, 5 fields of view were randomly 
selected and the 10 largest sarcomeric myosin positive multinucleated cells in each field 
were measured at their widest uniform point using Image J software (NIH, Frederick, 
MD). For branching myocytes, each branch was measured as a separate myotube and the 
region where the branches converge was excluded. To assess cell number, the mean total 
number of DAPI stained nuclei was quantified by counting all nuclei within 15-20 fields 
(5 fields in each of 3-4 individual culture wells) per group. To assess myogenic 
differentiation, the number of these nuclei located within sarcomeric myosin-positive 
cytoplasm was determined, and expressed as percentage of total nuclei analysed (% 
differentiation). The fusion index (% fusion) was quantified as the percentage of total 
nuclei that were located within multinucleated cells (sarcomeric myosin+ cells with 
≥2nuclei, thus having undergone fusion). Myonuclear accretion was additionally 
analysed by performing myotube/nuclear number assays (5 fields of view per well, 3-4 
wells/group). Results were expressed as myotube number (myotubes/field of view), 
average number of nuclei per myotube (fused nuclei/myotube no.) as well as the relative 
percentage of nascent (2-4 nuclei) and mature (≥5 nuclei) myotubes. 
 
2.2.5 Protein content quantification  
 
Cells were harvested by scraping in ice cold RIPA lysis buffer (50 mM Tris-HCl, 
pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1mM EDTA with protease 
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inhibitors 1mM PMSF, 10μg/ml aprotinin, 10μg/ml leupeptin & 2mM Na3VO4) and 
rotated for 1 hour at 4˚C. Cell lysates were centrifuged at 13000 g at 4˚C for 15 min and 
the supernatant stored at -80˚C until further analysis. Total protein content of cell culture 
lysates was determined with a BCA-protein kit as per the manufacturer’s protocol 
(Pierce). 
 
2.2.6 DNA extraction/quantification 
 
Cells were harvested by scraping in TRI-Reagent (Ambion Inc).  Chloroform was 
added to the solution, thoroughly mixed, and incubated on ice for 10 min prior to 
centrifugation at 13,000 g at 4ºC for 10 min for phase separation. The upper aqueous 
phase containing RNA was removed and DNA precipitated from the remaining 
interphase/organic phases via ethanol addition and centrifugation at 2000 g at 4ºC for 5 
min. The supernatant was removed and the DNA pellet washed thoroughly in 0.1 M 
trisodium citrate 10% ethanol followed by centrifugation/resuspension in 75% ethanol. 
Samples were centrifuged at 2000 g for 5 min at 4ºC, the supernatant removed and the 
DNA pellet air dried at room temperature for 5-10 min. The DNA pellet was dissolved in 
8mM NaOH and DNA concentration was determined using the NanoDrop 1000 
Spectrophotometer (Thermo Scientific) following the manufacturer’s instructions.  
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2.2.7 Statistical analysis 
 
Statistical analysis was performed using GraphPad Prism 4.1 (GraphPad 
Software). Results are expressed as Mean ± S.E.M. Statistical significance was 
determined using 1 way or 2 way ANOVAs as appropriate. Pair wise comparisons were 
determined with Bonferroni post hoc tests. Differences were considered significant at 
p<0.05. 
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2.3 Results 
2.3.1 Arachidonic acid supplementation increases developing muscle cell size and 
protein accretion during myogenic differentiation 
 
We initially sought to determine the effect of exogenous AA supplementation on 
muscle cell growth during myogenesis. Myoblasts were grown to a high cell density and 
induced to differentiate in the presence or absence of supplemental arachidonic acid. 
Culture treatment media was replenished every 24 hrs and cells were fixed and 
immunostained for sarcomeric myosin to visualize myotube structure 3 days post-
induction of differentiation (Figure 2-1).  Myotubes which formed in the presence of 
increasingly high doses of supplemental AA were noticeably larger and exhibited a 
shortened/thickened phenotype (Figure 2-1A). The effect of supplemental AA on muscle 
cell size was dose dependent with 25 µM AA inducing the maximal response observed. 
Quantitative analysis of myotube diameter found statistically significant increases in size 
when compared to control myotubes with doses of AA ≥3.25 µM (p<0.05) (Figure 2-1B). 
The maximal effective dose tested (25 μM AA) promoted a mean increase in myotube 
diameter of 80.6% (p<0.001 vs. 0 µM) (Figure 2-1B). Analysis of the total protein 
concentration of lysates of cells treated with AA (20 µM) showed significant increases in 
total protein content/well at day 1 (p<0.05), day 2 (p<0.01), and day 3 (p<0.001) of 
differentiation (Figure 2-1C). Exposure to higher tested doses of supplemental AA (50-
100 µM) resulted in a loss of the AA induced growth response and progressive 
detachment of myotubes from the growth surface, possibly indicative of cytotoxicity at 
these doses (data not shown). These data suggest that AA supplementation during 
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myogenesis can enhance skeletal myotube growth in a dose dependant manner, and this 
effect is associated heightened overall total protein accretion.  
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Figure 2-1: AA supplementation during myogenic differentiation enhances myotube size and protein accretion in a dose-
dependent manner.  
A: C2C12 myoblasts were grown to confluence, induced to differentiate in the presence of the indicated dose of supplemental AA 
and immunostained for sarcomeric myosin (green) at day 3 of differentiation. Bar, 100 μm. B: Mean myotube diameter at day 3 of 
differentiation was determined as described in methods. C: Protein concentration of cell lysates (100 µL lysis buffer/well) 
collected from control and AA (20 µM) supplemented cultures at the indicated times throughout differentiation was measured. 
Data are mean ± SEM of 3 independent experiments. Bars with differing script differ significantly (p<0.05)  
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2.3.2 Arachidonic acid induced skeletal muscle cell hypertrophy does not involve 
changes in myoblast proliferation/survival or differentiation 
 
In order to further assess the effect of AA supplementation on various stages of 
myogenesis, cultures were fixed, immunostained for sarcomeric myosin and 
counterstained for DAPI (to visualize myonuclei) at confluence and then every 24 hrs 
throughout differentiation. Whilst control and arachidonic acid treated cultures appear 
morphologically indistinguishable at confluence, after 48-72 hr, obvious visual 
differences in the morphology of developing myotubes become apparent (Figure 2-2A). 
In order to assess whether increased myotube size in response to supplemental AA may 
be attributable to changes in cell density as a result of altered myoblast proliferation 
and/or survival, the total number of DAPI stained nuclei per field of view was counted 
(Figure 2-2B top).  As a second measure of cellular density, the total amount of DNA per 
well was additionally determined (Figure 2-2B 2nd from top). Neither nuclei number nor 
DNA content/well significantly changed throughout 3 days of differentiation under 
normal culture conditions.  Furthermore, at no time point did nuclei number or DNA 
content differ between vehicle and AA treated cultures, suggesting that cell density is not 
influenced by AA (Figure 2-2B top & 2nd top). Thus, the myotube growth response to AA 
supplementation does not appear to be associated with net changes in cellular density. 
In order to assess myoblast differentiation and fusion, the percentage of total 
nuclei located within MHC positive cytoplasm (differentiation index) (Figure 2-2B 2nd 
Bottom), and the percentage of total nuclei within multinucleated (fused) cells (≥2 nuclei) 
(fusion index) (Figure 2-2B bottom) was determined. At confluence, some degree of 
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spontaneous differentiation (~10% of cells) was apparent in control cells with a minimal 
amount of cell fusion occurring (~5% of cells). 24 hrs post serum withdrawal 
approximately 30% of the myoblast population had undergone differentiation and small 
nascent myotubes (2-4 nuclei) were predominant. After 48-72 hr, the differentiation 
index was maximal with approximately 50% of total nuclei located within MHC positive 
cells, the vast majority of which have fused. At all times, differentiation and fusion 
indices were comparable between vehicle and AA treated cultures (Figure 2-2B 2nd 
bottom & bottom). Furthermore, the mRNA and protein expression eMHC as a marker of 
myogenic differentiation was not influenced by AA (data not shown). These findings 
suggest that AA treated cultures are comparable to control in terms of total cell number 
as well as  the rate/extent of myogenic differentiation and myoblast-myoblast fusion to 
form multinucleated cells. 
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Figure 2-2: AA induced myotube growth does not involve changes in cell density or the rate/extent of myogenic 
differentiation, but is associated with heightened myonuclear accretion.  
A: Confluent C2C12 myoblasts were induced to differentiate in the presence of absence of supplemental AA (25 µM) (0.1% 
ethanol vehicle) and immunostained for sarcomeric myosin (green) and DAPI (blue) at the indicated times. Bar, 100 μm. B: 
Total nuclei number (top), DNA content (2nd top), differentiation index (% differentiation) (2nd bottom) and fusion index (% 
fusion) (bottom) were determined at the indicated times. C: Myotube number, the % myotubes ≥5 nuclei and mean 
myonuclei/myotube were measured. Data are mean ± SEM of 3 independent experiments.  
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2.3.3 Arachidonic acid induced myotube growth is associated with heightened 
myonuclear accretion 
 
Despite a comparable proportion of the total cell population undergoing 
differentiation and fusion, obvious visual differences were apparent in the extent of 
myotube multinucleation (number of nuclei per myotube) in AA supplemented cultures 
(Figure 2-2A). To determine changes in myonuclear accretion which may contribute to 
augmented myotube size, the number of myotubes (sarcomeric myosin+ cells with ≥2 
nuclei) per microscopic field of view and the average number of myonuclei per myotube 
(fused nuclei/myotube no.) was counted (Figure 2-2C). When compared to control, AA 
treated cultures contained approximately half the total number of myotubes per field of 
view at day 3 of differentiation (Figure 2-2C, left). As the total number of fused cells was 
comparable to control (see above section), myotubes which formed in the presence of 
supplemental AA contained on average twice as many myonuclei per myotube (Figure 2-
2C, right). Nuclear number assays revealed that the lower myotube number was 
predominantly attributable to the presence of fewer small nascent myotubes (2-4 
nuclei/myotube) in AA treated cultures. Therefore, clustering of fused myonuclei into 
larger less numerous myotubes was accompanied by a reduction in the relative 
percentage of small myotubes present (Figure 2-2C, middle). These data indicate that AA 
supplementation specifically enhances cell recruitment and myonuclear accretion by the 
growing myotubes. 
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2.3.4 A non-metabolizable analogue fails to mimic the effect of AA 
 
In addition to being the metabolic precursor in the biosynthesis of eicosanoids, 
AA has been reported to itself directly influence certain aspects of cellular physiology 
(37). Eicosatetraynoic Acid (ETYA) is a structural analog of AA in which the 4 alkene 
bonds are replaced with alkyne bonds. As a non-metabolizable analog, ETYA acts as a 
non-specific COX/LOX inhibitor by competing with AA for enzyme binding. However, 
certain physiological effects induced by AA have also been previously reported to be 
mimicked by ETYA (7, 93, 117, 157, 347). The effect of AA in such cases has been 
considered to be independent of its metabolism.  In order to investigate whether the effect 
of AA on myotube growth is a direct effect of supplemental AA itself, or alternatively 
mediated downstream of AA metabolism, myoblasts were induced to differentiate in the 
presence of vehicle (0.1% ethanol), AA (25 μM) or ETYA. (25 μM) (Figure 2-3A). AA 
supplementation enhanced myotube size (Figure 2-3B) and myonuclear accretion (Figure 
2-3C-D). Conversely, ETYA failed to mimic the effects of supplemental AA. Rather, 
myotubes which formed in the presence of ETYA exhibited significantly reduced 
myotube diameter, a decreased percentage of myotubes with ≥5 nuclei and increased 
myotube number when compared to vehicle cultures (Figure 2-3B-D). These data suggest 
that AA itself does not directly influence myotube growth; rather this effect is secondary 
to its downstream metabolism. Furthermore, blunted basal growth in the presence of 
ETYA may be indicative of competition with the endogenous free AA present under 
typical control cell culture conditions. 
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Figure 2-3: A non-metabolizable AA analog (ETYA) fails to mimic the effects of AA supplementation on skeletal muscle cell growth. 
A: Confluent C2C12 myoblasts were induced to differentiate in control (0.1% ethanol), AA (25 µM) supplemented or ETYA (25 µM) supplemented media 
prior to immunostaining for sarcomeric myosin (green)/DAPI (blue) at day 3 of differentiation. Bar, 100 µm. B: The mean diameter of myotubes treated with 
vehicle, ETYA or AA was determined. C: Nuclear number assays were performed as in Figure 2-2 to determine the percentage of myotubes containing 2-4 vs. 
≥5 nuclei. D: The number of myotubes per field of view was counted in vehicle, ETYA or AA treated cultures. Data are mean ± SEM of 3 independent 
experiments. *** p<0.001 vs. veh, **p<0.01 vs. veh, * p<0.05 vs. veh  
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2.3.5 COX-2 activity is required for basal myogenesis and AA stimulated skeletal 
muscle cell hypertrophy 
 
The COX enzymes, COX-1 and COX-2, catalyze the synthesis of prostanoids 
from free intracellular AA. In order to assess the requirement for COX activity in basal 
and AA induced skeletal muscle cell growth, COX inhibiting NSAIDs were utilized. 
Confluent myoblasts were induced to differentiate in the presence or absence of a non-
selective COX inhibitor (indomethacin) or a COX-2 selective inhibitor (NS-398) (Figure 
2-4A).  Both indomethacin and NS-398 drastically impaired basal C2C12 myotube 
formation in a dose-dependent manner. These findings show that non-selective and more 
specifically COX-2 selective NSAIDs inhibit in-vitro C2C12 myogenesis similarly to that 
previously reported in primary skeletal muscle cell culture (198, 275).  
In order to assess the requirement of COX activity in AA induced skeletal muscle 
cell growth, confluent myoblasts were induced to differentiate with or without 
supplemental AA in the presence or absence of NSAIDs. Quantitative analysis revealed 
that cultures exposed to indomethacin (200µM) or NS-398 (50 µM) alone throughout 
myogenesis displayed significantly impaired differentiation at day 3 (Figure 2-4C). 
Additionally, indomethacin alone significantly reduced nuclei density when compared to 
vehicle treatment (Figure 2-4B).  In the presence of indomethacin or NS-389, AA failed 
to enhance myotube formation. Rather when NSAIDs were combined with supplemental 
AA, defects in nuclei density and differentiation were greater than with a given dose of 
NSAIDs alone (Figure 2-4B-C). Consistent with our findings in Figure 2-2 AA 
supplementation alone had no effect on basal cell density or % differentiation. These data 
 54 
suggest that COX-2 activity is required for successful early myogenesis and that the 
deleterious effects of COX-2 blockage are amplified at a given NSAID dose in the 
presence of a heightened availability of free AA substrate. 
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Figure 2-4: NSAIDs inhibit basal C2C12 myogenesis and this effect is greater in the presence of supplemental AA.  
A: C2C12 myoblasts were grown to confluence and induced to differentiate in the presence of the indicated dose of a non-selective NSAID (indomethacin, 
0.1% ethanol vehicle) or a COX-2 selective NSAID (NS-398, 0.1% DMSO vehicle). Cells were fixed and immunostained for sarcomeric myosin (green) and 
DAPI (blue) at day 3 of differentiation. Bar, 100  µm. B: The mean total number of nuclei/field of view (B) and differentiation index (% differentiation) (C) 
was determined for cultures treated with NSAIDs or the respective vehicles (0.125% ethanol (indomethacin) or 0.1% DMSO + 0.025% ethanol (NS-398)) in 
the presence or absence of supplemental AA (25 µM). Respective DMSO and ethanol vehicle treated cells did not significantly differ so results were pooled as 
the control bar. *** p<0.001 vs. veh, **p<0.01 vs. veh, * p<0.05 vs. respective veh.
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Post-differentiation AA supplementation stimulates hypertrophy of pre-existing myotubes 
by a COX-2 dependent pathway. 
 
Due to the requirement of COX-2 during early myogenesis, NSAIDs may block 
the effect of supplemental AA on latter stages of growth indirectly by limiting the 
number of fusion competent cells available to support myotube hypertrophy. To further 
test the role of COX-2 in AA stimulated skeletal muscle cell growth without the potential 
confounding influence of NSAIDs on early myogenesis, myotubes were allowed to 
develop for 3 days prior to treatment with AA ± NSAIDs. Following 72 hr of AA 
supplementation cultures were fixed and stained for sarcomeric myosin (day 6 of 
differentiation) (Figure 2-5). Consistent with the hypothesis that AA stimulated growth 
does not involve early myogenesis, supplementation of cells with AA from day 3-6 post-
differentiation promoted dose-dependent increases in myotube size of comparable 
magnitude to that observed during early myogenesis (Figure 2-5B). In contrast to the 
effects of NSAIDs during early myogenesis, exposure to indomethacin or NS-398 from 
day 3-6 of differentiation did not influence normal myotube formation (Figure 2-5A) or 
the size of pre-existing myotubes (Figure 2-5C). Despite this, in co-treatment 
experiments indomethacin (100-200 μM) and NS-398 (50 μM) significantly blocked the 
anabolic effect of AA supplementation on post-differentiation myotube growth (Figure 2-
5C). Lower tested doses of NS-398 (10 μM) and indomethacin (50 μM) were insufficient 
to block the effect of supplemental AA on myotube size (data not shown).  
 
 57 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-5: AA supplementation maintains growth enhancing effects in pre-existing myotubes via a COX-2 sensitive pathway. 
 A: C2C12 myoblasts were differentiated into myotubes for 3 days and then treated with supplemental AA in the presence of absence of 
indomethacin (0.125% ethanol vehicle) or NS-389 (0.1% DMSO + 0.025% ethanol vehicle) for an additional 72 hours before being 
immunostained for sarcomeric myosin (green) and DAPI (blue) (day 6). Bar, 100 µm. B: Myotube diameter was determined for post-
differentiation cultures treated with increasing doses of supplemental AA. Bars with differing script differ significantly (p<0.05). C: Myotube 
diameter was determined for post-differentiation cultures treated supplemental AA (25 µM) in the presence or absence of indomethacin (100-200 
µM) or NS-398 (50 µM). Respective DMSO and ethanol vehicle treated cells did not significantly differ so results were pooled as the control bar 
*** p<0.001 vs. veh, **p<0.01 vs. veh, * p<0.05 vs. veh  
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2.3.6 Conditioned media from AA supplemented cultures fails to mimic the effects of 
direct AA supplementation  
A number of secreted autocrine/paracrine factors, including growth factors 
cytokines and eicosanoids (PGE2, PGF2α, PGI2, PGD2) have previously been implicated 
in the control of muscle cell growth. In order to determine whether the effect of AA on 
skeletal muscle cell growth is mediated by a secreted autocrine/paracrine factor, 
conditioned media was collected from vehicle and AA supplemented cells every 24 hrs 
and fed to differentiating muscle cell cultures grown in parallel (Figure 2-6). As 
expected, direct AA supplementation markedly enhanced muscle cell growth (Figure 2-
6A). AA stimulated muscle cell growth was associated with marked increases in the 
secretion of PGF2α/PGE2 by a COX dependent (indomethacin sensitive) pathway (Figure 
2-6C). Despite this, myotube diameter and the percentage of myotubes with ≥5 nuclei did 
not differ significantly between cells treated with conditioned media from AA 
supplemented cultures and those treated with conditioned media from non-AA 
supplemented cultures (Figure 2-6B). Similarly, neither group of conditioned media 
treated cells differed in these markers of myotube growth when compared vehicle donor 
cultures. Similar results were found in experiments performed post-differentiation (data 
not shown). These data suggest that secreted eicosanoids at the concentrations 
synthesized and released by cells stable in cell culture medium fail to mimic the effect of 
supplemental AA on skeletal muscle cell size or myonuclear accretion. Furthermore, AA 
induced muscle cell growth appears to be independent of the actions of previously 
identified stable secreted autocrine/paracrine myoblast recruitment factors (50, 137). 
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Figure 2-6: AA supplementation greatly increases PG release; however PG containing conditioned media fails to mimic 
the effects of direct AA supplementation. 
 A: C2C12 myoblasts were induced to differentiate in the presence or absence of direct AA (25 µM) supplementation (top 
row of images). Every 24 hrs conditioned differentiation medium from these donor cultures was collected and fed to 
confluent myoblast cultures grown in parallel (bottom row of images). Cells were immunostained for sarcomeric myosin 
(green)/DAPI (blue) at day 3 of differentiation. Bar, 100 µm. B: Nuclear number assays and quantification of myotube 
width were performed  to determine the percentage of myotubes containing 2-4 vs. ≥5 nuclei (left panel) and the mean 
myotube diameter (right panel). C: PGF2α (left panel) and PGE2 (right panel) concentrations present in conditioned media 
collected AA ± indomethacin supplementation as determined by ELISA analysis. AA supplementation was performed 
either during (days 0-3) or post-differentiation (days 3-6). PGF2α/PGE2 data shown is from the 24-48hr 
supplementation/collection period. Data are mean ± SEM of 3 independent experiments. *** p<0.001 vs. veh, **p<0.01 vs. 
veh, * p<0.05 vs. respective veh.  
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2.4 Discussion 
 
Phospholipid hydrolysis, leading to AA release and intracellular accumulation, is 
a key cellular process in the control of inflammation and cell signaling (37). Unesterified 
intracellular AA is metabolized by multiple COX and LOX mediated pathways to form a 
diverse array of potential downstream bioactive mediators (e.g. prostanoids, leukotrienes 
and lipoxins). The present study was undertaken to determine the effect of heightened 
free AA availability on in-vitro skeletal muscle cell growth. AA supplementation 
stimulated dose dependent increases in myotube size and myonuclear accretion, without 
influencing total cell number, or the rate/extent of myogenic differentiation. These effects 
were associated with heightened PGE2/PGF2α secretion, required metabolism of 
supplemental AA, and were dependent on COX-2 enzyme activity. Contrary to the 
hypothesis that heightened secretion of downstream prostaglandins, acting via their 
extracellular receptors would mediate the AA response, conditioned media collected from 
AA supplemented cells failed to influence skeletal muscle cell growth.  
Supplementation of proliferating skeletal myoblast cultures with a range of fatty 
acids including AA was previously reported to increase cell number (176). Additionally, 
the positive effect of exogenous PGF2α treatment on myoblast fusion/myotube size 
during myogenic differentiation was previously attributed to an increased myoblast pool 
as a result of enhanced myoblast survival (149). We thus hypothesized that changes in 
cell density that may occur as a result of altered myoblast proliferation and/or survival 
may explain the AA induced myotube growth response observed in the present study. 
Contrary to this hypothesis, we found that the effect of supplemental AA on skeletal 
muscle cell growth consistently occurred in the absence of any net change in the 
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population of fusion competent cells which may indirectly influence developing myotube 
size.  
Despite previous reports of diverse effects of individual PGs on early myogenesis 
(29, 325), AA induced skeletal muscle cell growth was also not associated with any net 
changes in the rate or extent of myoblast differentiation (% differentiation) or myoblast-
myoblast fusion (% fusion). Once mononucleated differentiated myoblasts fuse to form 
small nascent myotubes containing few myonuclei, subsequent increases in myotube size 
depend on the recruitment of additional myonuclei by the growing multinucleated cell. 
Myonuclear accretion of growing myotubes (nuclei/myotube) was greatly enhanced by 
AA supplementation in the present study. In AA supplemented cultures whilst the total 
number of nuclei within fused (≥ 2 myonuclei) sarcomeric myosin+ cells was comparable 
to control, these fused myonuclei clustered within fewer larger myotubes. These fusion 
specific effects are reminiscent of the role of exogenous provision of the prostanoids 
PGF2α (139, 149) and PGI2 (29) in in-vitro skeletal muscle cell growth previously 
reported. The mechanisms by which skeletal muscle cell fusion occur are incompletely 
understood, but may involve the release of a myoblast recruitment factor such as IL-4 
which acts to enhance the recruitment of differentiating mononucleated cells by large 
hypertrophying myotubes (50, 137).  Although the underlying mechanism involved 
remains to be determined, our data reveal arachidonic acid as among a growing list of 
stimuli including creatine (219), PGF2α (139, 149), IL-4 (50, 137) and intracellular 
pathways including mTOR (228) and NFAT-C2 (136, 231)  that appear to regulate 
myotube size via control of fusion related myonuclear accretion. 
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In addition to being the metabolic precursor to a diverse range of eicosanoids, AA 
itself is purported to possess biological activity, independent of its downstream 
metabolism (37). In particular, provision of exogenous AA has been reported to directly 
influence MAPK signaling (7), intracellular Ca2+ concentrations (110, 347), and Na+/K+ 
currents (93, 117, 157) in other cells types, all of which may be relevant to the control of 
skeletal muscle cell growth.  In these studies the effect of supplemental AA was reported 
to be mimicked by the non-metabolisable AA analog ETYA (7, 93, 110, 117, 157, 347). 
Thus, an important consideration in the present study was whether the effects observed 
were a direct result of AA itself or its downstream metabolism. We found that ETYA did 
not mimic the response to exogenous AA supplementation on skeletal muscle cell 
growth, and rather had opposite effects on developing myotube size/myonuclear content. 
Therefore, consistent with our findings utilizing COX inhibiting NSAIDs (discussed 
below) the effect of AA supplementation on skeletal muscle cell growth appears 
secondary to the formation of downstream eicosanoids.  As a structural analog, ETYA 
functions as a non-selective COX/LOX inhibitor by competing with AA for enzyme 
binding sites. Thus, the negative effect of ETYA on basal myotube size further suggests 
that AA present under control cell culture conditions may contribute to basal cell growth. 
Consistent with the hypothesis that NSAIDs may negatively influence skeletal 
muscle growth via deleterious effects on satellite cell myogenesis (185, 198, 201, 206, 
215, 275), we found basal C2C12 myogenesis to be impaired by NSAID treatment. These 
findings support an important role of the COX pathway in early myogeneis, despite the 
lack of an effect of AA supplementation on this stage of muscle development. The 
observation the NS-398, a purported COX-2 selective inhibitor, was sufficient to inhibit 
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myoblast differentiation specifically implicates the inducible COX-2 isoform in basal 
myogenesis. This finding is consistent with previous studies specifically implicating 
COX-2 in in-vitro myogenesis as a result of NS-398 sensitivity (198, 275) or genetic 
COX-2 ablation (32, 278). In the presence of COX-2 inhibition, AA treatment also failed 
to influence myotube size or myonuclear accretion. Surprisingly, the blockade of 
myogenesis induced by a given NSAID dose was actually found to be consistently 
greater in the presence of supplemental AA. This was unexpected given that the negative 
effect of NSAIDs on myogenesis has previously been thought to be attributable to a 
decrease in the basal release of PGF2α or PGE2 (278). In the present study, secreted 
PGF2α and PGE2 were greatly reduced by AA+NSAID co-treatment, but were not 
entirely abolished and remained above basal levels. Our findings therefore suggest that 
other factors such as accumulation of excess intracellular free AA substrate and/or 
diversion of surplus AA via parallel COX-independent pathways may be contributing 
factors in the negative influence of NSAIDs on myogenesis under certain circumstances. 
 As NSAIDs inhibit the early stages of basal myogenesis, they may indirectly 
prevent AA induced myotube growth by reducing cell density and % differentiation, thus 
limiting the availability of differentiated myogenic cells available to undergo fusion. In 
order to assess the requirement of COX enzyme activity in AA stimulated myotube 
growth without the influence of the potentially confounding effects of NSAIDs on early 
myogenesis, AA supplementation was additionally tested in post-fusion myotube 
cultures. Our findings indicate that COX activity is not required for the maintenance of 
healthy mature myotube/myofibre mass, as NSAID treatment had no effect on basal post-
fusion myotube size  This is in contrast to the effect of NSAIDs to increase the mass of 
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atrophied skeletal muscle in states of chronic inflammatory disease (113, 182, 191, 248, 
285).  The positive effects of AA on myotube size on the other hand were found to persist 
in pre-existing myotubes with post-fusion AA supplementation. Despite the lack of an 
effect of NSAIDs on basal myotube size, AA stimulated increases in cell size were 
entirely prevented by indomethacin or NS-398 co-treatment. Thus, COX-2 appears to 
play a role in mediating growth of pre-existing myotubes in response to AA, independent 
of its established role in early myogenesis. The hypertrophic effect of supplemental AA 
in pre-existing myotubes appears at odds with an earlier report of a net catabolic effect in 
terms of rates of protein turnover in response to acute free exogenous AA exposure in 
skeletal muscle tissue isolated ex-vivo (251). Differences in experimental conditions (ex-
vivo vs. in-vitro) and AA treatment regimes (acute vs. chronic) may explain these 
differences.  
COX produced prosanoids are thought to mediate many of the pathological and 
physiological effects associated with free AA release/metabolism, including cell 
signaling and inflammation.  PGs are synthesized intracellularly from free AA and 
thought to act predominately as secreted autocrine/paracrine factors by binding to class 
specific extracellular prostanoid receptors (318). The primary PGs (PGD2, PGE2, PGF2α, 
PGI2 and TXA2) are short lived molecules in-vivo, undergoing rapid enzyme dependent 
degradation to form a complex array of PG metabolite products. In in-vitro incubations 
however, PGE2, PGF2α, PGD2 and 6-keto-PGF1α (the non-enzymatic product of PGI2) 
can accumulate within the culture media to easily detectable levels (29, 224, 276, 278, 
320, 325). In the present study, AA supplementation greatly increased the 
synthesis/release of both PGE2 and PGF2α by skeletal muscle cells. These PGs 
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accumulated in the culture medium to relatively high concentrations (30-40 nM during 
myogenesis) within 24 hr incubation in the presence of supplemental AA. Despite this, 
when fresh cells grown in parallel were treated with PG containing conditioned media, no 
significant effects on cell morphology were apparent. On this basis, despite previous 
reports with exogenous PGs, the levels of eicosanoids released endogenously during AA 
incubation appear to have little effect. This was surprising given the NSAID sensitive 
nature of AA induced hypertrophy. There may be disparity between requirement for 
COX activity and the role of downstream PGs in mediating COX dependent effect. For 
example, stretch induced increases in protein turnover are NSAID sensitive, but much 
higher concentrations of exogenous PGF2α and PGE2 than that produced physiologically 
during mechanical stimulation are required to influence muscle protein turnover (320). In 
another study, exogenous PGF2α concentrations of ≥1µM were reported to be required to 
significantly influence skeletal muscle cell fusion/growth in cultured skeletal muscle cells 
in-vitro (139).  Such concentrations are substantially higher than were detected in cell 
culture media, even in the presence of high doses of supplemental AA employed in the 
present investigation. Eicosanoids do undergo degradation under typical cell culture 
conditions, some more rapidly than others (186). Thus, growing cells may be exposed to 
significantly higher concentrations of secreted eicosanoids than remain in conditioned 
media following incubation. Additionally, the active prostanoid species PGI2 and TXA2 
are rapidly and non-enzymatically degraded to biologically inactive products 6-keto-
PGF1α and TXB2. Thus, conditioned culture media treatment experiments can not 
discount the potential contribution of these factors to muscle cell growth. 
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In conclusion the findings of the present study show that an increased availability 
of free AA, and subsequent oxidation by the COX-2 pathway, has a net stimulatory effect 
on in-vitro skeletal muscle cell growth. This effect appears distinct from the role of COX-
2 in early myogenesis, as AA supplementation of post-differentiation myogenic cells also 
promotes hypertrophy of pre-existing myotubes by a NSAID sensitive pathway.  
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3 CHAPTER THREE - PROSTAGLANDIN F2α STIMULATES 
PI3K/ERK/mTOR SIGNALING AND MYOTUBE 
HYPERTROPHY 
This work has been published prior to completion of this dissertation 
Markworth JF, and Cameron-Smith D. Prostaglandin F2alpha stimulates PI3K/ERK/mTOR signaling and 
skeletal myotube hypertrophy. American Journal Of Physiology Cell Physiology 300: C671-C682, 2011. 
 
3.1 Introduction 
 
The cyclooxygenase (COX) enzymes, COX-1 and COX-2, catalyze the synthesis 
of lipid mediators known as prostaglandins (PGs) from cellular arachidonic acid. PGs are 
potent mediators of inflammation (63), and blockade of PG synthesis with COX 
inhibiting non-steroidal anti-inflammatory drugs (NSAIDs) is common following skeletal 
muscle injury (295, 323). Recently, inhibition of COX mediated PG synthesis has been 
reported to have deleterious effects on skeletal muscle regeneration (31, 275, 276, 278), 
re-growth of atrophied myofibres (32), and overload induced skeletal muscle hypertrophy 
(215, 288). Thus, PGs have been implicated to play an important role in adaptive 
remodeling of skeletal muscle tissue under diverse physiological circumstances. 
Mammalian skeletal muscle growth involves increases in both myofibre cross-
sectional area and myonuclear content. Myonuclei are post-mitotic and thus myonuclear 
accretion depends on the activation, proliferation, differentiation and fusion of muscle 
precursor cells (MPCs) with the growing multinucleated cell. PGs may influence MPCs 
as they have been implicated in multiple stages of myogenesis in vitro including 
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myoblast proliferation/differentiation (198, 275), survival (149), and fusion (139, 278). 
The role of PGs in skeletal muscle growth/regeneration can be distinguished from effects 
solely on MPCs however. For example, inhibition of COX-2 in vivo has been reported to 
impair re-growth of the plantaris muscle following hind limb suspension (32), a model of 
skeletal muscle growth which does not involve myonuclear accretion (204). Examination 
of the molecular mechanisms by which PGs influence skeletal muscle cell growth is 
important to elucidate the role of the COX pathway in adaptive remodeling of skeletal 
muscle tissue. 
Prostaglandin F2α (PGF2α), one of the five primary PGs, has previously been 
implicated in hypertrophic growth of cardiomyocytes (5, 168, 169) and vascular smooth 
muscle cells (75, 109, 156, 243, 247). PGF2α predominantly acts via binding to specific 
type F prostanoid receptors (FP receptor) (318). Despite abundant expression in skeletal 
muscle tissue (223), few studies have investigated the cellular responses downstream of 
the FP receptor in skeletal muscle cells. PGF2α has recently been reported to promote 
nascent myotube fusion/myonuclear accretion during skeletal myotube development 
(139, 278), by a mechanism involving the calcium-regulated transcription factor nuclear 
factor of activated T cells complex 2 (NFATC-2) (139, 149). Interestingly, PGF2α may 
also influence growth of pre-existing skeletal myotubes/myofibres, independent of the 
recruitment of additional myonuclei, by influencing protein turnover (251, 320). 
However, no study has investigated the molecular mechanisms by which PGF2α may 
influence skeletal muscle cell anabolism. 
The mammalian target of rapamycin (mTOR) pathway is a key regulator of 
postnatal cell size that integrates signals from growth factors (54), amino acids (11) and 
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mechanical stimuli (134). mTOR acts via phosphorylating downstream translational 
modulators including p70S6 kinase (p70S6K), eukaryotic  initiation factor 4E binding 
protein 1 (4EBP-1) (329) and eukaryotic initiation factor 4G (eIF4G) (28, 324). p70S6K 
has been traditionally thought to function as a major positive regulator of ribosomal 
protein S6 (rpS6) which plays an important role in the translation of specific mRNAs 
containing 5-terminal oligopyramidine (5’TOP) structure which encodes proteins central 
to the growth process including ribosomal proteins and elongation factors (244), although 
this mechanism has more recently been brought into question (199). In addition to 
mTOR, the extracellular receptor kinase (ERK) branch of the mitogen activated protein 
kinase pathway (MAPK) has recently been implicated in the regulation of skeletal muscle 
anabolism (99, 119, 159, 240, 279, 280). Moreover, emerging data suggest positive 
interaction of the ERK and mTOR pathways in the control of skeletal muscle 
hyperterophy under certain circumstances (119, 240, 256, 257, 279). 
In the present study we examined the cellular response to PGF2α in C2C12 
myotubes. Our data indicate that PGF2α is a potent and direct stimulator of key growth 
related signaling via the PI3K/ERK/mTOR pathway. Consistently, we provide evidence 
to suggest that PGF2α stimulates post-differentiation growth of mature skeletal myotubes 
and that this effect is mediated by the mTOR signaling pathway. 
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3.2 Materials and Methods 
3.2.1 Cell Culture 
 
Myoblasts from the mouse skeletal muscle-derived C2C12 cell line were obtained 
from American Type Culture Collection (ATCC). Myoblasts were cultured at 37 ˚C, 5% 
CO2 in high glucose Dulbecco’s modified Eagle’s medium (DMEM; Gibco) 
supplemented with 10% fetal bovine serum (FBS; Gibco) and antibiotics (penicillin 100 
U/ml, streptomycin 100 µg/ml (Gibco)). Cells were grown until confluence and then 
transferred to high glucose DMEM supplemented with antibiotics and 2% Horse Serum 
(HS; Gibco) to induce differentiation. For analysis of cell morphology PGF2α (1 µM) 
(Sigma-Aldrich) fluprostenol (Cayman Chemicals) (1 µM) or vehicle (0.005% ethanol) 
was added to differentiation media at the indicated times in the presence or absence of 
AL8810 (1 µM) or rapamycin (50 nM) and treatment media was replenished every 24 hr. 
For signaling experiments, differentiation media was switched to serum-free high glucose 
DMEM that did not contain antibiotics for 3 hr prior to addition of treatments. PGF2α, 
fluprostenol, or vehicle was then added to the cultures for the time and dose indicated. 
Where indicated, cells were pre-treated with vehicle (0.1% DMSO), 50 nM rapamycin 
(Calbiochem) in DMSO, 25 µM PD98059 (Calbiochem) in DMSO or 5-20 µM 
LY294002 (Calbiochem) in DMSO for 30 min prior to the addition of PGF2α. 
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3.2.2 Morphological Analysis 
 
C2C12 myotube cultures were fixed in 4% formaldehyde and permeabilized in 
0.1% Triton X-100. Cells were blocked in 1% bovine serum albumin (BSA)/phosphate 
buffered saline (PBS) for 1 hr at room temperature and incubated with an antibody 
against embryonic Myosin Heavy Chain (EMyHC) (F1.652, Developmental Studies 
Hybridoma Bank) overnight at 4˚C. Cells were washed in PBS, and then incubated in 
goat anti–mouse immunoglobulin G (IgG) conjugated to horse-radish peroxidise (HRP) 
secondary antibody for 1 hr at room temperature. Antibody binding was detected using 
the VECTOR SG perioxidase substrate kit (Vector Laboratories). Cells were visualized 
with an Olympus IX70 microscope (Olympus) and digital images were collected using 
Spot RT slider camera and Magnifire Software (Olympus). For myotube diameters 
approximately 100 myotubes per well were analysed. From each well (3 per group) 10 
fields were randomly selected and the 10 largest MHC-positive multinucleated cells in 
each field were measured using Image J software (NIH, Frederick, MD). For branching 
myocytes, each branch was measured as a separate myotube and the region where the 
branches converge was excluded. For analysis of myotube area, total MHC positive area 
(μm2) per field of view was quantified using image J. The number of myotubes (≥2 
nuclei) per field of view was counted and results were expressed as the mean area (μm2) 
per myotube. To assess differentiation, the total number of nuclei within MHC-positive 
cytoplasm in each field was quantified by counting 15 fields (5 fields in each of 3 wells) 
per group. Fusion was analysed by performing nuclear number assays. The number of 
nuclei within each individual myotube was counted for 100-150 myotubes per well (5 
fields containing with 20-30 myotubes). Results were expressed as the average number of 
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nuclei per myotube as well as the percentage of myotubes containing 2-4 nuclei or ≥5 
nuclei. 
3.2.3 Immunoblotting 
 
 
Cells were harvested by scraping in ice cold RIPA lysis buffer (50 mM Tris-HCl, 
pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA with 
protease/phosphatase inhibitors 1 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 
mM Na3VO4 & 1mM NaF) and rotated for 1 hour at 4˚C. Cell lysates were centrifuged at 
13000 g at 4˚C for 15 min and the supernatant stored at -80˚C until further analysis. Total 
protein content of cell culture lysates was determined with a BCA-protein kit (Pierce). 
Aliquots containing 20 µg protein were suspended in Laemmli buffer, boiled, and 
subjected to SDS/PAGE. Proteins were transferred to a PVDF membrane, and blocked in 
5% BSA/ Tris Buffer Saline/1% Tween 20 (TBST) for 2 hr, followed by overnight 
incubation at 4˚C with primary antibodies [p-Akt (Ser473), p-p70S6K (Thr389), p70S6K 
(Thr421/Ser424), p-eIF4G (Ser1108), p-ERK 1/2 (Thr202/Tyr204); Cell Signaling] under 
gentle agitation. Membranes were washed for 30 min with TBST and probed with an 
anti-rabbit IgG conjugated to HRP secondary antibody for 1 hr at room temperature. 
Membranes were then washed for 30 min in TBST and protein bands were visualized 
using Western Lighting enhanced chemiluminescence reagent (PerkinElmer Life 
Sciences). Signals were captured using a Kodak Digital Science Image Station 440CF 
(Eastman Kodak Company), and densitometry band analysis undertaken with Kodak 
Molecular Imageing Software (Version 4.0.5, ©1994-2005 Eastman Kodak Company). 
Equal protein loading was determined by immunoblotting for actin (Sigma). 
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3.2.4 Statistical Analysis 
 
Statistical analysis was performed using GraphPad Prism 4.1 (GraphPad 
Software). Results are expressed as Mean ± S.E.M. Comparisons between two groups 
were made using t-tests. Analyses of multiple groups were performed using a one or two-
way ANOVA as appropriate with Bonferroni’s post hoc analysis. Differences were 
considered significant at p<0.05. 
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3.1 Results 
3.1.1 PGF2α increases C2C12 cell size and myonuclear content during differentiation 
 
Previous studies have identified PGF2α as a regulator of skeletal muscle cell 
growth during myotube development (139, 149). Thus, we initially sought to 
quantitatively measure the effect of PGF2α on the size of C2C12 myotubes during 
myogenic differentiation. To determine if the effect of PGF2α is mediated via the FP 
receptor, a specific FP receptor agonist (fluprostenol) was additionally utilized. 
Myoblasts were induced to differentiate for 24 hr before addition of drug treatments and 
immunostained for EMyHC following 4-5 days of differentiation (Figure 3-1A). Cells 
differentiated in the presence of either fluprostenol or PGF2α were found to be 
significantly larger than vehicle controls with greater mean myotube area (p<0.001, 
Figure 3-1B) and wider myotube cross sectional diameter (p<0.001, Figure 3-1C). The 
effect of PGF2α and fluprostenol was comparable with no significant difference observed 
between drugs treatments. These data suggest that FP receptor stimulation can increase 
C2C12 myotube size during myogenic differentiation. 
In order to assess whether the above findings could be attributed to heightened 
differentiation, the absolute number of nuclei within myosin heavy chain positive 
cytoplasm was counted. The number of differentiated nuclei per field of view did not 
differ between vehicle and drug treated cultures suggesting the differentiation was 
comparable between cultures (Figure 3-1D). To determine changes in myonuclear 
content which may contribute to cellular growth, the number of myonuclei within each 
individual myotube (≥2 nuclei) was counted. Drug treated cultures showed an increase in 
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the average number of nuclei per myotube suggesting that growth was associated with 
myonuclear accretion (Figure 3-1E). Furthermore, PGF2α and fluprostenol treated 
cultures displayed an increased proportion of myotubes containing ≥5 nuclei with a 
corresponding decrease in those containing 2-4 nuclei indicative of enhanced cell fusion 
(Figure 3-1F).   
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Figure 3-1: FP receptor agonists increase myotube size and myonuclear content during myogenic differentiation.  
A: C2C12 myoblasts were induced to differentiate for 24hr, treated with vehicle, PGF2α (1 μM) or fluprostenol (1 μM) and immunostained for EMyHC at the 
indicated times. Bar, 100 μm. B: Mean myotube area (μm2) was determined as described in methods for cultures treated with vehicle, PGF2α (1 μM) or 
fluprostenol (1 μM) after 96-120hr C: Myotube diameter (μm) was assessed in cultures treated with vehicle, PGF2α (1 μM) or fluprostenol (1 μM) after 96-120hr. 
D: The total number of nuclei per field of view within EMyHC-positive cells was counted following treatment with vehicle, PGF2α (1 μM) fluprostenol (1 μM) for 
96-120 hr. E: Cells were treated with vehicle, PGF2α (1 μM) fluprostenol (1 μM) and the number of nuclei within individual mytubes at the indicated times were 
assessed. F: The percentage of myotubes containing 2-4 vs. ≥5 nuclei was determined following treatment with vehicle, PGF2α (1μM) or fluprostenol (1 μM) for 
96-120 hr. Data are mean ± SEM of 3 independent experiments. *** p<0.001 vs. veh, **p<0.01 vs. veh, * p<0.05 vs. ve
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3.1.2 PGF2α increases the size of pre-existing myotubes independent of myonuclear 
addition 
 
In order to distinguish between the effects of PGF2α on nascent myotubes 
undergoing fusion and those on existing multinucleated myotubes, confluent myoblasts 
were switched to low serum media and allowed to fuse normally for 72 hr prior to 
addition of PGF2α. Following a further 72 hr in the presence of experimental treatments, 
cells were fixed, stained for EMyHC, and assessed for morphological changes (Figure 3-
2A). PGF2α treated myotubes exhibited significant hypertrophy as evidenced by 21% 
wider cross sectional diameter (38.3 μm vs. 48.1 μm; p<0.001) (Figure 3-2B). These 
findings suggest PGF2α can influence the size of pre-existing myotubes when added to 
post-fusion myotube cultures. 
In-order to determine if the above results could be attributed to an effect of PGF2α 
on residual myoblasts or nascent myotubes, rather than mature cells, differentiation and 
nuclei number assays were performed as in Figure 3-1D-F. No difference was observed 
in the number of differentiated nuclei per field between vehicle and PGF2α treated 
cultures suggesting that PGF2α did not promote differentiation of residual myoblasts 
(Figure 3-2C). Moreover, the average number of nuclei per myotube (Figure 3-2D), and 
the relative proportion of myotubes containing 2-4 nuclei vs. greater than 5 nuclei (Figure 
3-2E) did not differ between vehicle and PGF2α treated cultures. These data further 
suggest that the effect of PGF2α on pre-existing myotubes can be distinguished from 
effects on myonuclear accretion. 
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Figure 3-2: PGF2α increases the diameter of mature myotubes without influencing myonuclear 
accretion. 
A: C2C12 myoblasts were differentiated into myotubes for 3 days and then treated with PGF2α (1 µM) 
for an additional 72 hours before being immunostained for EMyHC. Bar, 100 µm. B: The diameter of 
myotubes treated with vehicle or PGF2α was determined following 72 hrs in the presence or absence of 
PGF2α. C: The total number of nuclei within EMyHC-positive cells was counted for vehicle and PGF2α 
(1 µM) treated cultures. Nuclear number assays were performed as in Figure 3-1 to determine the 
number of nuclei per myotube (D) and the percentage of myotubes containing 2-4 vs. ≥5 nuclei (E). Data 
are mean ± SEM of 3 independent experiments.  
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3.1.3 The effect of PGF2α on post-fusion myotube size is mediated by the FP receptor 
and involves mTOR 
 
To assess the mechanisms by which PGF2α may influence myotube size, day 3 
myotube cultures were treated with PGF2α or fluprostenol in the presence or absence of 
pharmacological inhibitors and stained for EMyHC at day 6 (Figure 3-3A). Both PGF2α 
and fluprostenol treatment increased myotube width to a comparable extent (Figure 3-
3B), independent of any change in differentiation or myonuclear accretion (data not 
shown), suggesting that the effect of PGF2α on myotube width is mediated by the FP 
receptor. To further confirm these findings, cells were co-treated with AL8810, a 
competitive inhibitor of the FP receptor (114). In the presence of AL8810, neither PGF2α 
nor fluprostenol significantly influenced myotube diameter (Figure 3-3B). Interestingly, 
myotubes incubated in the presence of AL8810 were also found to be significantly 
thinner than those maintained in differentiation media alone, indicating that FP receptor 
signaling contributed to basal myotube growth. 
In order to examine the mechanism by which PGF2α may influence myotube size, 
rapamycin was utilized as a specific inhibitor of mTOR. Previous studies have 
established that rapamycin has distinct effects to block differentiation/fusion during 
myotube formation (90, 91, 228, 282, 340) and blunt post-fusion hypertrophy (26, 229, 
253). In preliminary experiments (data not shown) addition of rapamycin to cells ≤24 hr 
following serum withdrawal dramatically impaired myotube formation. When 
administered at 2-3 days following serum withdrawal however, mature myotubes formed 
normally (Figure 3-3A, bottom panels). In order to assess the role of mTOR in post-
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fusion myotube hypertrophy, cells were treated with PGF2α or fluprostenol in the 
presence or absence of rapamycin at day 3 of differentiation. Cultures treated with 
rapamycin alone were comparable to vehicle in terms of the total number of 
differentiated nuclei and percentage of nascent (2-4 nuclei) vs. mature (≥5 nuclei) 
myotubes (data not shown). Despite normal maturation, rapamycin treated myotubes 
exhibited an elongated appearance and were notably thinner (Con 41.6 µm vs. Rap 27.0 
µm, p<0.001), suggesting suppression of post-fusion increases in myotube size by 
rapamycin (Figure 3-3B). In contrast to the effect of fluprostenol or PGF2α alone, addition 
of FP receptor agonists to rapamycin treated cultures did not influence myotube width 
(Figure 3-3B). These data suggest that mTOR is required for PGF2α induced increases in 
myotube diameter.  
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Figure 3-3: PGF2α mediates mTOR dependent hypertrophy via the FP receptor. 
 A: 3-day differentiated C2C12 myotube cultures were treated with vehicle, PGF2α (1 μM) or 
fluprostenol (1 μM) in the presence or absence of AL8810 (1 μM) or rapamycin (50 nM) for 72 hr 
and immunostained for EMyHC. B: The myotube diameter was determined for C2C12 cells treated 
as indicated for 72 hr. Data are mean ± SEM of 3 independent experiments. *** p<0.001 vs. veh, 
**p<0.01 vs. veh * p<0.05 vs. veh.  
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3.3.4 PGF2α stimulates dose and time dependent phosphorylation of ERK/p70S6K but 
not Akt in C2C12 myotubes 
 
 On the basis of our morphological findings we sought to examine the direct effect 
of PGF2α on growth related signaling pathways in differentiated C2C12 myotubes. 
Treatment with PGF2α (1 μM) induced rapid and transient phosphorylation of 
downstream targets of mTOR including p70S6K (Thr389 & Thr421/Ser424) and eIF4G 
(Ser1108) independent of any apparent change in the phosphorylation of Akt (Ser473) 
(Figure 3-4A). Maximal phosphorylation of p70S6K and eIF4G in response to PGF2α 
treatment was observed at 15 min and remained elevated above baseline at 30 min. 
PGF2α also induced robust time dependent phosphorylation of ERK 1/2 MAPKs 
(Thr202/Tyr204) which peaked following 5 min of stimulation and had returned towards 
baseline by 30 min (Figure 3-4A).  
To examine the dose response of PGF2α stimulated signaling events, C2C12 
myotubes were exposed to increasing concentrations of PGF2α (0-10 μM). Heightened 
dose-dependent phosphorylation of ERK, p70S6K and eIF4G, but not Akt, were evident 
following exposure to increasing doses of PGF2α (Figure 3-5A). A maximal response was 
observed with 1 μM PGF2α and doses in excess of this (10 μM) were found to induce no 
greater signaling response. To further characterize the dose-response relationship 
between FP receptor stimulation and intracellular signaling, C2C12 myotubes were 
treated with increasing concentrations of the more selective FP receptor agonist 
fluprostenol (0-10 µM). Heightened phosphorylation of ERK, p70S6K and eIF4G were 
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evident in C2C12 myotubes exposed to increasing doses of fluprostenol (Figure 3-5B). 
The intracellular signaling response to fluprostenol was dose-dependent with a maximal 
phosphorylation response observed with 100 nM and a plateau occuring at higher doses.  
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Figure 3-4: PGF2α stimulates time dependent mTOR and ERK signaling in C2C12 myotubes.  
C2C12 myotubes (5-7 days post-differentiation) were treated with 1 μM PGF2α for up to 30 min. 
Following treatment cells were lysed and analyzed by western blot with phosphorylation specific 
antibodies. Shown are representative blots of 3 independent experiments.  
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Figure 3-5: Dose-response of intracellular signaling induced by FP receptor agonists. 
A: C2C12 myotubes (5-7 days post-differentiation) were treated for 15 min with increasing concentrations of 
PGF2α (0.01 nM-10 μM). B: C2C12 myotubes were treated for 15 min with increasing concentrations of 
fluprostenol (0.01 nM- 10 μM). Following treatment cells were lysed and analyzed by western blot with 
phosphorylation specific antibodies. Top panels show representative blots. Graphs depict the mean ± SEM of 3 
independent experiments. 
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3.1.4 PGF2α stimulated signaling responses are PI3K dependent 
 
We next examined the upstream pathway by which PGF2α induces intracellular 
signaling events by pre-treating myotube cultures with pharmaceutical inhibitors prior to 
PGF2α stimulation. Consistent with the above results, treatment with PGF2α in the 
presence of the DMSO vehicle significantly stimulated phosphorylation of ERK1/2, 
p70S6K and eIF4G without influencing the phosphorylation of Akt (Figure 3-6A-B). In 
order to assess the requirement of upstream phosphoinositide 3-kinase (PI3K) signaling 
in the cellular response to PGF2α, myotube cultures were pre-treated with the PI3K 
inhibitor LY294002 prior to stimulation with PGF2α. Doses of 5-20 µM LY294002 
entirely abolished the basal phosphorylation of p70S6K, without influencing the basal 
phosphorylation of ERK or eIF4G. When cells were stimulated with PGF2α, LY294002 
pretreatment (≥5 μM) completely prevented heightened phosphorylation of 
p70S6K/eIF4G and partially prevented heightened phosphorylation of ERK1/2. Unlike 
PGF2α, stimulation with insulin promoted robust increases in the phosphorylation of Akt 
and as expected this effect was entirely prevented by pre-treatment with LY294002 
(Figure 3-6C). Collectively, these data suggest that PGF2α acts via a PI3K dependent, but 
Akt independent, pathway to elicit downstream signaling responses to 
ERK/p70S6K/eIF4G. 
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Figure 3-6: Akt independent PGF2α signaling is mediated via PI3K. 
C2C12 myotubes (5-7 days post-differentiation) were pre-treated with vehicle or LY294002 (5-20 μM) for 30 min before 
stimulation with PGF2α (1 μM)  or insulin (100 nM) for a further 15 min. Following treatment, cells were lysed and analyzed by 
western blotting. A: Fold change in phosphorylation of Akt (Ser473), eIF4G (Ser1108), p70S6K (Thr389), and ERK-2 (Tyr204) 
following stimulation with PGF2α (1 μM)  in the presence of absence of  the indicated dose of LY294002. Values are mean ± 
SEM of 3 independent experiments. *** p<0.001 vs. veh, **p<0.01 vs. veh * p<0.05 vs. veh. B: Representative western blot of 
cells stimulated with PGF2α (1 μM)  in the presence or absence of the indicated dose of LY294002. C: Representative western 
blot of C2C12 myotubes stimulated with insulin (100 nM) as a positive control in the presence of absence of the indicated dose 
of LY294002. 
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3.3.5 The effect of FP receptor agonists on intracellular signaling involves MEK/mTOR 
 
To assess the involvement of mTOR in FP receptor signaling responses, cells 
were pre-treated with rapamycin prior to stimulation with PGF2α (Figure 3-7A) or 
fluprostenol (Figure 3-7B). As expected, rapamycin abrogated the basal phosphorylation 
of p70S6K and eIF4G without influencing basal ERK phosphorylation. Consistently, 
when cells were stimulated with PGF2α or fluprostenol, rapamycin pretreatment entirely 
prevented heightened phosphorylation of p70S6K and eIF4G, whereas stimulation of 
ERK1/2 was unaffected by rapamycin. Collectively, these findings suggest that FP 
receptor signaling to p70S6K/eIF4G and ERK are mTOR dependent and independent 
respectively. 
Given the apparent Akt independent, but LY294002/rapamycin sensitive, nature 
of PGF2α signaling responses, alternative pathways upstream of mTOR were analyzed. 
As PGF2α was found to be a potent stimulator of ERK phosphorylation we were 
particularly interested in the potential contribution of the ERK pathway to influence 
mTOR signaling. To assess the contribution of this pathway, PD98059, an inhibitor of 
MEK (the MAPKK acting upstream of ERK) was utilized (Figure 3-7A & 7B). As 
expected, pre-treatment with PD98059 abolished the basal phosphorylation of ERK1/2 
and entirely prevented heightened ERK phosphorylation in response to FP receptor 
stimulation. Interestingly, blockade of MEK-ERK signaling with PD98059 also 
significantly suppressed the basal phosphorylation of p70S6K and entirely blocked 
heightened p70S6K/eIF4G signaling in response to FP receptor stimulation. These 
findings suggest that basal and PGF2α induced mTOR signaling events in C2C12 
myotubes are partially and entirely dependent on MEK/ERK signaling respectively.  
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Figure 3-7: The effect of PGF2α on intracellular signaling is mediated via the FP receptor and involves MEK/mTOR.  
C2C12 myotubes (5-7 days post-differentiation) were pre-treated with vehicle, rapamycin (50 nM) or PD98059 (25 
μM) for 30 min prior to stimulation with PGF2α (1 μM)  or fluprostenol (1 μM) for 15 min. A: Cells were treated with 
PGF2α (1 μM) in the presence of absence of rapamycin or PD98059. B: Cells were treated with fluprostenol  (1 μM) 
in the presence of absence of rapamycin or PD98059. Following treatments cells were lysed and subjected to 
western blot analysis. Top panels show representative blots. Graphs depict the mean ± SEM of 3 independent 
experiments. *** p<0.001 vs. veh, **p<0.01 vs. veh * p<0.05 vs. veh.  
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3.4 Discussion 
Anti-inflammatory strategies are common to alleviate pain and inflammation 
following skeletal muscle damage. The inflammatory response may however play an 
important physiological role in adaptive remodeling of skeletal muscle tissue. Blockade 
of COX mediated PG synthesis adversely affects skeletal muscle adaptation, although the 
mechanisms by which this occurs are poorly understood. In the present study, we 
identified that PGF2α, a major product of the COX pathway, is a potent and direct 
stimulator of growth related signaling via a FP receptor-PI3K/ERK/mTOR pathway in 
skeletal myotubes. Consistently, we found that PGF2α stimulates post-fusion myotube 
growth via the FP receptor and that this effect is mTOR dependent. 
Despite the recent accumulation of evidence implicating the COX pathway in 
diverse situations of skeletal muscle remodeling in vivo (31, 32, 215, 275, 276, 278, 288), 
the mechanisms by which PGs influence skeletal myocyte growth remain largely 
unknown. Previous in vitro studies have focused on the role of PGs to influence 
myonuclear accretion during myotube formation (139, 149, 278). In particular, PGF2α has 
recently been shown to enhance the fusion of multinucleated skeletal muscle cells not by 
stimulating initial myotube formation, but rather by promoting cell fusion with pre-
existing nascent myotubes (139, 149). Consistently, myoblasts from COX2-/- mice 
differentiate normally but are unable to form mature myotubes; a defect which is 
reversible by supplementation with exogenous PGF2α (278). In agreement with these 
studies, our results showed that PGF2α treatment of C2C12 cells 24 hr after serum 
withdrawal, a stage at which nascent myotubes are predominant, leads to enhanced size 
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and myonuclear content of developing myotubes. Increased cell size in the presence of 
PGF2α under these conditions was associated with heightened myonuclear accretion. 
The role of the COX pathway in skeletal myofibre adaptation in vivo can be 
distinguished from effects solely on MPCs. For example, re-growth of atrophied 
plantaris myofibres following hindlimb suspension, a model of skeletal muscle growth 
which does not involve myonuclear addition (204), has been reported to be impaired by 
the COX-2 inhibitor SC-236 (32). Furthermore, ibuprofen, a nonselective COX inhibitor, 
blunted acute (≤24 hrs) post-exercise increases in PGF2α levels (316) and skeletal muscle 
protein synthesis (317), indicative of impaired translational and/or transcriptional events 
rather than myonuclear accretion. Consistent with a myoblast independent role of PGF2α 
in skeletal muscle growth, we observed that post-fusion treatment of skeletal myotubes 
with PGF2α increased C2C12 myotube diameter independent of changes in differentiation 
and/or myonuclear accretion. The effect PGF2α on myotube diameter was mimicked by 
the specific FP receptor agonist fluprostenol and prevented by co-treatment with the 
competitive FP receptor antagonist AL8810. Collectively these data suggest that FP 
receptor signaling influences post-fusion size of mature skeletal myotubes independent of 
its previously characterized role in cell fusion. Consistent with our findings are previous 
reports of anabolic growth in response to PGF2α in mononucleated cells including 
cardiomyocytes (5, 168, 169) and vascular smooth muscle cells (75, 109, 156, 243, 247) 
which undergo hypertrophy exclusively via cellular protein accretion. 
Investigation of the mechanisms by which FP receptor stimulation influenced 
myotube growth revealed that the effect of PGF2α was blocked by rapamycin co-
treatment, demonstrating involvement of the mTOR signaling pathway. Although the 
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precise mechanisms by which mTOR influences skeletal muscle cell growth in vivo are 
unclear, mTOR is central to the initiation stage of translation, enabling protein synthesis 
(253). When administered to skeletal myoblast cultures however, rapamycin has also 
been also been shown to block myogenic differentiation (90, 91, 228, 282, 340). 
Moreover, the effect of rapamycin on early differentiation has been shown to be able to 
be mechanistically distinguished from a sequential post-differentiation role of mTOR in 
the fusion of nascent myotubes (228).  In the present study, no effects on 
differentiation/fusion were evident in response to rapamycin when added at day 3 of 
differentiation, confirming that myogenesis was complete prior to the addition of drug 
treatments. On this basis, the effects of drug treatments on myotube size in the present 
study do not appear to be attributable to changes in differentiation or myonuclear 
accretion. 
Very few studies have investigated signaling downstream of the FP receptor in 
skeletal muscle cells. FP receptor stimulation has been found to be coupled to 
mobilization of intracellular Ca+ and subsequent nuclear translocation of NFATC-2 in 
nascent skeletal myotubes (139). Recently, the inhibitor of apoptosis protein BRUCE as a 
potential transcriptional target of NFATC-2 has been suggested to be responsible for the 
effect of PGF2α on skeletal myotube fusion (149). Importantly, NFATC-2 translocation in 
response to Ca+ occurs only in nascent, but not mature myotubes (1). Thus, whilst 
NFATC-2 has been shown to play an important role in skeletal myotube development 
(136, 139, 231), it is inconsistent with our findings of post-fusion myotube growth in 
response to FP receptor stimulation. To our knowledge no previous study has 
investigated the intracellular signaling pathways downstream of the FP receptor in mature 
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myotubes/myofibres. Our investigation of the cellular responses to PGF2α in C2C12 
myotubes identified a novel link between the FP receptor and induction of intracellular 
growth related signaling. We found that PGF2α stimulated an intracellular signaling 
response characterized by heightened phosphorylation of ERK/p70S6K/eIF4G. On the 
other hand we observed no apparent change in the phosphorylation of Akt, a major 
upstream regulator of mTOR signaling, in response to PGF2α. This response was 
mimicked by FP receptor stimulation with fluprostenol suggesting that PGF2α signaling 
occurs via the FP receptor rather than as a result of a non-specific effect of PGF2α at high 
treatment doses. The rapamycin sensitive nature of heightened p70S6K/eIF4G 
phosphorylation in response to FP receptor agonists further suggested that mTOR was 
indeed the upstream kinase responsible.  These data establish PGF2α as a novel regulator 
or skeletal muscle mTOR signaling as has been previously reported for anabolic stimuli 
including insulin/IGF-1 (253), amino acids (11), energy status (158) and mechanical 
strain (134). In agreement with our findings are previous studies in which FP receptor 
agonists have been reported to stimulate mTOR signaling in vascular smooth muscle cells 
(243, 247), cardiomyocytes (168) and luteal cells (10). Thus, the present data support 
studies in other cell types and establish a novel link between the FP receptor and mTOR 
signaling in skeletal myotubes which may play an important role in skeletal muscle 
growth. 
Under many, but not all circumstances (133), coupling of extracellular signals to 
the mTOR pathway in skeletal myotubes is thought to involve PI3K as evidenced by the 
effects of PI3K inhibitors such LY294002 or wortmanin to block downstream responses. 
Indeed, in the present study we found PGF2α induced signaling responses to be 
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LY294002 sensitive, suggesting involvement of PI3K downstream of the FP receptor. 
This finding is consistent with previous reports in which PGF2α stimulated mTOR 
signaling events in vascular smooth muscle cells (243) and cardiomyocytes (168) were 
found to be prevented by the PI3K inhibitor wortmanin.   Interestingly, despite an 
apparent role of PI3K in PGF2α signaling, in the current study we observed no effect of 
FP receptor agonists on the phosphorylation of Akt, a major downstream effector of PI3K 
(106). Thus, whilst both insulin and PGF2α signal to mTOR via a LY294002 sensitive 
(PI3K dependent) pathway, our data suggest that unlike insulin, PGF2α does not stimulate 
Akt phosphorylation. In agreement with this hypothesis, stimulation of mTOR signaling 
by PGF2α has recently been reported to occur independent of Akt phosphorylation in 
bovine luteal cells (10) and cardiomyocytes (168). An alternative explanation would be 
that as reported previously, wortmanin/LY294002 can in fact inhibit mTOR kinase 
activity (41). We however observed that LY294002 also inhibited PGF2α stimulated ERK 
phosphorylation whereas rapamycin did not. These findings further support an upstream 
mTOR independent role of PI3K in FP receptor signaling. It is important to note that 
whilst class 1A PI3Ks are well established to act downstream of tyrosine kinase receptors 
(i.e. insulin/IGF-1 receptor), multiple isoforms of PI3K exist and LY294002 is 
nonspecific in its action (341). As such, the particular PI3K isoform involved in skeletal 
muscle PGF2α signaling remains to be determined.  
The apparent Akt independent nature of FP receptor signaling events prompted us 
to investigate alternative mechanisms acting upstream of mTOR. Consistent with 
previous reports in other cell types (10, 109, 168, 243, 247, 349), we found PGF2α to 
stimulate ERK signaling in skeletal myotubes. Interestingly, recent studies have 
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established that the MEK/ERK pathway may contribute to mTOR dependent signaling 
events under certain circumstances (256, 257). We thus sought to investigate the role of 
this pathway in mediating downstream signaling responses. Notably, our findings from 
experiments utilizing PD98059 suggested positive interaction between the MEK-ERK 
and mTOR pathway in skeletal muscle cells under both basal and FP receptor stimulated 
conditions. PD98059 was found to completely block the effect of FP receptor agonists on 
mTOR signaling. In agreement with our findings are previous studies in which inhibition 
of MEK/ERK signaling was reported to block PGF2α stimulated mTOR signaling in other 
cell types (10, 243). These findings support a number of recent studies which have 
reported Akt independent regulation of mTOR signaling by the ERK MAPK pathway 
(146, 256, 257).  Furthermore, these findings add to emerging data implicating the 
MEK/ERK pathway as an important upstream regulator of mTOR signaling in skeletal 
muscle cells (119, 279). 
In conclusion the results described here establish PGF2α to be an important ligand 
contributing to mTOR signaling in skeletal muscle tissue via a PI3K/ERK dependent 
pathway. PGF2α is produced by skeletal muscle tissue in response to loading/injury and 
thus may be an important link between skeletal muscle damage/inflammation and 
subsequent growth signaling in vivo. These findings suggest that anti-inflammatory 
strategies such as non-steroidal anti-inflammatory drugs which block COX mediated 
PGF2α production, may negatively influence the normal adaptive signaling responses to 
skeletal muscle loading/damage. 
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4 CHAPTER FOUR - HUMAN EICOSANOID RESPONSE TO 
RESISTANCE EXERCISE AND IBUPROFEN TREATMENT 
 
4.1 Introduction 
Eicosanoids are biologically active lipid mediators synthesized endogenously 
from the essential arachidonic (AA) and eicosapentaenoic (EPA) fatty acids. 
Phospholipase A2 catalyzes the release of fatty acid precursors from cellular membranes 
in response to cellular perturbation (mechanical trauma, infection, cytokines or growth 
factors). Oxidation of free intracellular fatty acids via parallel cyclooxygenase (COX) and 
lipoxygenase (LOX) pathways produces the prostaglandins (PG)/thromboxanes (TX) 
(from COX) and leukotrienes (LT, from 5-LOX). These autocrine/paracrine factors are 
released into the extracellular environment where they signal to local target cells via 
binding to cell surface eicosanoid receptors. PG (e.g. PGE2) and LT (e.g. LTB4) species 
play an important stimulatory role in the acute inflammatory process by controlling local 
blood flow, vasculature permeability, platelet aggregation, leukocyte 
activation/chemotaxis, and sensitizing neural afferents to pain. AA derived eicosanoids 
including PGD2, PGE2, PGF2α, PGI2, TXA2 and LTB4, LTC4, LTD4, LTE4 are pro-
inflammatory.  EPA derived equivalents, the series 3 PGs (PGD3, PGE3, PGF3α, PGI3 
and TXA3) and series 5 LTs (LTB5, LTC5, LTD5, LTE5), whilst sharing cellular effects, 
exhibit significantly reduced agonist activity (partial agonist/antagonist) at eicoasnoid 
receptors and are thus less inflammatory or anti-inflammatory. 
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Intense or unaccustomed muscular contractions, especially those which involve a 
large eccentric component, are known to result in exercise-induced skeletal muscle injury 
(53, 105). The resulting inflammatory response has been proposed to exacerbate acute 
myotrauma and contribute to symptoms of exercise-induced muscle injury including loss 
of function and delayed onset muscle soreness (DOMs) (269, 308, 309). Anti-
inflammatory treatments such as cryotherapy, compression, nutritional supplements, and 
use of non-steroidal anti-inflammatory drugs (NSAIDs) are thus common recovery 
practices post-eccentric exercise (22, 52, 140). Despite this few studies have 
characterised the eicosanoid response to exercise-induced muscle injury, with much of 
the available data focusing on PGE2 due to its pro-inflammatory and hyperalgesic 
properties. Elevated circulating PGE2 has been detected concurrent to the onset of DOMs 
24-72 hrs following compound resistance exercise (300, 319). In contrast, no change in 
circulating PGE2 levels were found following eccentric isolation knee extensor (60, 61) 
or elbow flexor (20, 38, 129) exercise. Similarly, downhill running has been found to 
have either no effect (42), or no greater effect than level surface high intensity running 
(232), on circulating PGE2 levels.  On the basis of these studies, a definitive link between 
elevated circulating PGs and symptoms of exercise-induced muscle injury is unclear. 
Eicosanoids may play an important physiological role in post-exercise recovery. 
Heightened intramuscular PGF2α, but not PGE2 was detected in human skeletal muscle 
biopsies 24 hrs post eccentric exercise (316). Intramuscular PGF2α has been proposed to 
positively contribute to the skeletal muscle protein synthesis response to resistance 
exercise (317). Skeletal muscle COX-2 expression is increased as early as 4-5 hrs post-
eccentric exercise (202, 332) suggesting that eicosanoids may be important signaling 
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molecules in the early post-exercise period. Consistent with these observations, we 
recently found that in skeletal muscle cells in-vitro that PGF2α is a novel upstream ligand 
regulating mTOR signaling (188); a pathway essential in the control of muscle protein 
turnover. Studies investigating the eicosanoid response to exercise induced muscle 
damage have focused on time points ≥24 hrs into recovery and the possibility of an acute 
response has not been investigated. 
Conflicting findings exist with regard to the effect of NSAIDs on the human 
skeletal muscle response to exercise. Whereas oral ingestion of the non-selective COX 
1/2 inhibitor ibuprofen blocked skeletal muscle protein synthesis post resistance exercise 
(317), local indomethacin (another non-selective NSAID) infusion did not (202). 
Furthermore, whilst ibuprofen and indomethacin have deleterious effects on human 
skeletal muscle protein turnover (317) and satellite cell myogenesis (185, 201), 
respectively, COX-2 selective drugs appear to have no such effects (43, 230). Ibuprofen 
has been reported to exert COX independent anti-inflammatory effects, including 
inhibition of 5-LOX generated LTB4 (144, 162, 261, 322). Skeletal muscle cells express 
the LTB4 receptor and respond to LTB4 with enhanced growth in-vitro (296), indicative 
of a possible role of LT signaling in skeletal muscle tissue. The LT response to exercise 
has received considerably less attention than PG response, and the effect of ibuprofen on 
LTs in the post-exercise period has not been investigated previously. 
For effective regeneration to occur post-injury, acute inflammation must resolve 
and tissue homeostasis be restored. Resolution of inflammation, once thought to be a 
passive process, is now recognized to be actively regulated by a range of pro-resolution 
factors (15, 272, 273).  In addition to the classical pro-inflammatory eicosanoids, 
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polyunsaturated fatty acids are precursors for a number of novel pro-resolution/anti-
inflammatory lipid mediators including the AA derived lipoxins (LXs), and the EPA (E-
series)/ docosahexaenoic acid (DHA) (D-series) derived resolvins (RVs) (291). Acute 
phase pro-inflammatory signals are now known to be coupled to the sequential induction 
of LX and RV biosynthesis; a phenomenon termed lipid mediator class switching (180). 
The effect of exercise-induced muscle injury and NSAID treatment on these novel 
eicosanoid species is unknown. 
In the present study we investigated the human eicosanomic profile changes to a 
single bout of resistance exercise with and without ibuprofen ingestion. Resistance 
exercise stimulated an acute inflammatory lipid mediator response characterized by a 
rapid increase in TXA2 synthesis followed by heightened circulating levels of AA and 
EPA derived LTs/PGs peaking 1-2 hrs into recovery. Elevated levels of several markers 
of LX and RV synthesis were also observed during post-exercise recovery. Ibuprofen 
administration prevented exercise-induced increases in TXB2/PGs/LTs and this was 
associated with a diminished anti-inflammatory/pro-resolution lipid mediator response.  
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4.2 Materials and Methods  
 
4.2.1 Participants 
 
 
Sixteen healthy males subjects (Table 1) volunteered and provided informed 
written consent to participate in the study; after the nature, purpose and risks of the study 
were explained. Exclusion criteria deemed that participants had not engaged in lower 
body resistance training for a period >6 months, and had no history of chronic anti-
inflammatory use. Current use of medications or a previous history of a diagnosed 
condition or illness that would endanger the participants during strenuous exercise and/or 
anti-inflammatory drug treatment also excluded the participants from participation. All 
procedures involved in this study were formally approved by the Deakin University 
Human Research Ethics Committee. 
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Table 4-1: Clinical trial subject characteristics.  
Values are means ± SEM, n=8/group. 
 
 Demographics Strength (1 RM) 
 Age (y) Height (m) Weight (kg) BMI Squat (kg) Leg Press (kg) Leg Extension 
 
Placebo 23.9 ± 1.3 1.89 ± 0.03 86.9 ± 4.6 24.5 ± 1.2 94.88 ± 5.47 237.63 ± 16.68 236.38 ± 17.52 
Ibuprofen 23.0 ± 0.5 1.89 ± 0.03 89.1 ± 4.5 24.8 ± 0.8 91.88 ± 6.08 239.38 ± 15.00 196.25 ± 22.35 
 NS NS NS NS NS NS NS 
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4.2.2 Familiarisation 
 
 
Participants underwent a familiarisation session one week prior to clinical trial 
commencement. Participants were instructed on correct exercise technique and 
underwent repetition maximum strength testing to determine experimental exercise load 
(80% of 1 repetition maximum (1RM)). The maximal weight that subjects could lift for 
3-6 repetitions (3-6 RM) on the barbell squat, leg press and leg extension exercises was 
determined. Participants 1RM was estimated from multiple RM testing results using the 
Brzycki equation and 80% of subjects estimated 1 RM was determined. Participants were 
instructed to abstain from any vigorous physical activity in the following week prior to 
the experimental trial day. 
 
4.2.3 Experimental protocol 
 
 
The evening prior to the exercise trial day participants were provided with a 
standardised meal (CHO 57%, FAT 22%, PRO 21%) which they were required to 
consume before 10:00 pm. Participants arrived the following morning (7:00 AM day 1) in 
a fasted state. During 30 minutes of supine rest a catheter was inserted in the anticubital 
vein to allow venous blood sampling. Participants were randomly allocated to either the 
experimental (1200 mg/day oral ibuprofen) (N=8) or the placebo group (capsules 
identical in appearance containing powdered sugar in place of ibuprofen) (N=8). 
Participants ingested the first dose of ibuprofen (400 mg) upon arriving to the laboratory 
on day 1, immediately prior to baseline blood/muscle sampling. Participant’s rested 
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supine following collection of resting muscle biopsy/blood samples for approximately 
10-15 min at which time the exercise protocol commenced. Following a  10 min warm up 
consisting of light cycling and 1 low resistance warm up set on each exercise, participants 
performed 3 sets each of 8-10 repetitions to voluntary failure of bilateral barbell smith 
rack squat, 45 degree leg press and seated knee extension at 80% of their pre-determined 
1RM. Participants rested for 1 minute between exercises and 3 minutes between sets.  
Following completion of the exercise bout subjects rested supine throughout a 3 
hr recovery period. Participants were then provided with a pre-prepared standardised 
meal to be consumed at the laboratory (CHO 71%, FAT 13%, PRO 16%). Additional 
snacks and a standardized evening meal (CHO 64%, FAT 27%, PRO 18%) were 
provided for subjects to consume throughout the remainder of the trial day. Participants 
were instructed not to consume any additional food or drink than that provided. Two 
additional 400 mg Ibuprofen doses were provided which subjects were instructed to 
ingest at 2:00pm and 8:00pm on the evening of the trial day (1200 mg total daily dose).  
Participants were instructed to consume the food provided prior to 10:00 pm and returned 
to the laboratory the following morning at ~9 am (24 hrs post-exercise) for follow up 
testing. 
4.2.4 Blood/muscle biopsy sampling 
 
 
Venous blood samples were drawn at rest, immediately post-exercise, 30 min 
intervals throughout 3 hrs of recovery and 24 hrs post-exercis. All blood samples were 
drawn through an indwelling catheter into VACUETTE serum separator tubes. Whole 
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blood was allowed to clot at room temperature and was then centrifuged at 1000 g for 10 
min. Serum was collected and stored at -80°. 
 Skeletal muscle biopsy samples were also collected for additional analysis 
presented in chapter 5. All muscle biopsies were taken from the vastus lateralis 
musculature under local anaesthesia (Xylocaine 1%) by percutaneous needle biopsy 
technique modified to include suction. Biopsies were taken at baseline, immediately post-
exercise and at 3 hrs and 24 hrs of recovery. Biopsies 1 and 4 were taken from the 
dominant leg and biopsies 2 and 3 from the contralateral (non-dominant leg). Sequential 
biopsies were obtained through a separate incision 5cm proximal to the previous site. All 
skeletal muscle biopsy samples were immediately frozen in liquid nitrogen.  
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4.2.5 Sample preparation and LC-MS analysis of lipid mediators 
 
Serum samples (0.5 ml) were spiked with 10 ng (in 10 µl) of 15(S)-HETE-d8 as 
internal standard for recovery and quantitation and mixed thoroughly. The samples were 
then extracted for PUFA metabolites using C18 extraction columns as described earlier 
(186). Briefly, the internal standard spiked samples were applied to conditioned C18 
cartridges, washed with water followed by hexane and dried under vacuum. The 
cartridges were eluted with 0.5 ml methanol. The eluate was dried under a gentle stream 
of nitrogen. The residue was redissolved in 50 µl methanol-25 mM aqueous ammonium 
acetate (1:1) and subjected to LC-MS analysis. 
HPLC was performed on a Prominence XR system (Shimadzu) using Luna C18 
(3µ, 2.1x150 mm) column. The mobile phase consisted of a gradient between A: 
methanol-water-acetonitrile (10:85:5 v/v) and B: methanol-water-acetonitrile (90:5:5 
v/v), both containing 0.1% ammonium acetate. The gradient program with respect to the 
composition of B was as follows: 0-1 min, 50%; 1-8 min, 50-80%; 8-15 min, 80-95%; 
and 15-17 min, 95%. The flow rate was 0.2 ml/min. The HPLC eluate was directly 
introduced to ESI source of QTRAP5500 mass analyzer (ABSCIEX) in the negative ion 
mode with following conditions: Curtain gas: 35 psi, GS1: 35 psi, GS2: 65 psi, 
Temperature: 600 ˚C, Ion Spray Voltage: -1500 V, Collision gas: low, Declustering 
Potential: -60 V, and Entrance Potential: -7 V. The eluate was monitored by Multiple 
Reaction Monitoring (MRM) method to detect unique molecular ion – daughter ion 
combinations for each of the 125 transitions (to monitor a total of 144 lipid mediators) 
with 5 msec dwell time for each transition. Optimized Collisional Energies (18 – 35 eV) 
and Collision Cell Exit Potentials (7 – 10 V) were used for each MRM transition. The 
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data was collected using Analyst 1.5.2 software and the MRM transition chromatograms 
were quantitated by MultiQuant software (both from ABSCIEX). The internal standard 
(15-HETE-d8) signal in each chromatogram was used for normalization for recovery as 
well as relative quantitation of each analyte. 
 
4.2.5 LC-MS Analysis of ibuprofen and arachidonic acid in serum 
 
Arachidonic acid and deuterated arachidonic acid standards for LCMS analysis 
were purchased from Cayman Chemicals. Ibuprofen and butylated hydroxytoluene 
(BHT) were purchased from Sigma Aldrich and ammonium acetate was obtained from 
Univar. Hexane, citric acid, ethyl acetate and methanol were purchased from Merck and 
acetonitrile was obtained from Honywell.  
Arachidonic acid and ibuprofen were extracted by adding 0.75 ml of methanol to 
serum samples (0.5 ml) followed by the addition of 0.75 ml of acetonitrile containing 100 
ng/mL of deuterated arachidonic acid (as internal standard, IS) and 10% of BHT. 
Mixtures were vortexed for 30 seconds and centrifuged at 10 000 rpm for 10 min at 0ºC 
(Beckman Coulter 22R centrifuge). Supernatant was transferred to fresh glass tubes, 
evaporated under a stream of nitrogen at room temperature and reconstituted in 75 µL of 
methanol containing 10 mM ammonium acetate. Chromatography was performed using 
an Agilent binary HPLC system consisting of an Agilent 1200 LC pump, an Agilent 1200 
well plate auto-sampler and Luna phenyl hexyl (3 µm, 2.0 mm internal diameter and 150 
mm length) column (Phenomenex) equipped with a Phenomenex Security guard column 
of the same packing material; both maintained at a column temperature of 50°C. The 
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mobile phase A and B consist of water/10 mM ammonium acetate and acetonitrile/10 
mM ammonium acetate, respectively at a flow rate of 200 µL/min.  Samples (10 µL) 
were injected onto the column and eluted using the following gradient profile; initial 
composition was 21% B which was increased to 50% B in 10 minutes, held at 50% B for 
1.5 min, returned to 21% B over 0.5 min and the column re-equilibrate for 3 min. 
Mass spectrometry was performed using Agilent Jet Stream Triple Quad 6460 
with negative mode electrospray ionization, voltage of 4000 V, gas temperature of 250ºC 
and sheath gas temperature of 220ºC. Nebulizer pressure was 30 psi, nozzle voltage was 
500, nebulizer gas flow and sheath gas flow was maintained at 7 L/min. Ibuprofen, 
arachidonic acid and the deuterated arachidonic acid internal standard were quantified 
using MRM with 20 msec dwell time for each transition. MRM transitions of m/z 205 to 
160.8, m/z 303 to 259 and m/z 310 to 266 were monitored for the ibuprofen, arachidonic 
acid and deuterated arachidonic acid, respectively. Optimum fragmentor voltage of 70 
and 173 V and collision energy of 10 and 9V were used for the ibuprofen and arachidonic 
acid MRM transition.  LCMS data were processed by Agilent MassHunter software 
version 3. The deuterated arachidonic acid signal was used for normalization of each 
sample. 
 
4.2.6 Statistical analysis 
 
Statistical analysis was performed using PRISM v5.03 (GraphPad PRISM). 
Group means were compared using a 2-way mixed model ANOVA with repeated 
measures for time to detect the effects of exercise and drug (placebo vs. ibuprofen). 
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Following significant main effects or significant interactions between drug and exercise 
factors, bonferroni post-hoc was used to determine the significance of pair-wise 
comparisons.  Data is presented as mean ± standard error of mean (SEM). 
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4.3 Results 
 
4.3.1 Ibuprofen 
 
 
 Ibuprofen was not present in any serum samples obtained from subjects at 
baseline prior to initiation of NSAID treatment (Figure 4-1A). Ibuprofen was detected 
during post-exercise recovery for all subjects who ingested the NSAID capsules and was 
absent in the serum of any of those who ingested the placebo treatment (Figure 4-1A). 
Mean ibuprofen concentrations in the NSAID group ranged from 16.85 ± 0.46 μg/mL 
immediately post-exercise to 22.52 ± 4.03 μg/mL at 2hrs or recovery (p<0.05 vs. 
immediately post-exercise) (Figure 4-1A). The mean peak concentration (Cmax) of serum 
ibuprofen in the NSAID group was 25.65 ± 3.78 μg/mL, and this peak circulating level 
was observed at a mean time to peak concentration (Tmax) of 101.25 ± 17.87 min post-
exercise. Ibuprofen concentrations had returned to near basal levels by 24hrs post-
exercise (~12 hrs following the final ibuprofen dose). 
 
4.3.2 Arachidonic acid 
 
 
 Circulating free AA, the major substrate for eicosanoid biosynthesis, displayed a 
significant main effect for exercise (p<0.001) and no significant exercise by drug 
interaction (p=0.1741). Serum AA increased significantly (p<0.05) above baseline levels 
in both the placebo and ibuprofen groups at 90 min post-exercise (PLA +20.92% & IBU 
+29.91%) (Figure 4-1B). AA concentrations peaked 2.5 hrs (IBU +69.81%; p<0.001) to 3 
hrs (PLA +75.64%; p<0.001) into recovery with comparable mean increases above 
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baseline levels in both groups observed (Figure 4-1B). Serum AA was no longer 
significantly elevated above baseline at 24 hrs post-exercise for either group (PLA 
+17.52% & IBU -9.06%; both p>0.05).  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1: Ibuprofen and arachidonic acid response to resistance exercise ± ibuprofen treatment.  
A: Pharmacokinetics of ibuprofen in human serum during the post-exercise period following ibuprofen administration. 
Mean peak serum concentration = Cmax.  Mean time to peak serum concentration =Tmax. B: Percentage change in circulating 
human serum arachidonic acid during post-exercise recovery. Values are means ± SEM. ***p<0.001, **p<0.01, *p<0.05 vs. 
pre-exercise.  
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4.3.3 Series 2 Prostanoids 
 
Thromboxanes: TXB2, the inactive circulating metabolite of TXA2, as well as 
12(S)-HHTrE, another non-enzymatic decomposition product of TXA2, showed 
significant exercise by drug interactions (p<0.01).  Serum TXB2 (Figure 4-2A) and 
12(S)-HHTrE (Figure 4-2B) increased in the placebo group only immediately post 
(p<0.01), 1 hr post (p<0.05), 2 hr post (TXB2:  p<0.05 & 12(S)-HHTrE: p<0.001) and 3 
hr post-exercise (TXB2: p<0.05 & 12(S)-HHTrE: p<0.001) (Figure 4-2A & 2B). TXB2 
and 12(S)-HHTrE did not differ between groups at baseline (p>0.05), but were 
significantly elevated in the placebo group vs. the ibuprofen group immediately post 
(p<0.01), 2 hr post (TXB2:  p<0.05, 12(S)-HHTrE: p<0.001) and 3 hr post-exercise 
(TXB2:  p<0.05, 12(S)-HHTrE: p<0.001).  
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Figure 4-2: Thromboxane response to resistance exercise ± ibuprofen treatment.  
Serum TXB2 (A) and 12-(S)-HHTrE (B) responses post-resistance exercise ± ibuprofen administration. Values are 
means ± SEM. ***p<0.001, **p<0.01, *p<0.05 vs. pre-exercise. ###p<0.001, ##p<0.01, #p<0.05 vs. placebo group. 
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Prostaglandins: Detected serum major primary PGs including PGD2 (Figure 4-
3A) and PGE2 (Figure 4-3B), as well more stable circulating metabolites of PGE (15-
keto-PGE2 (Figure 4-3C), & PGA2 (Figure 4-3E)) and PGF2α (15-keto-PGF2α (Figure 4-
3F)) also displayed significant (p<0.05) or borderline significant (15-keto-PGE2; 
p=0.066) exercise by drug interactions. Significant increases from baseline were found in 
the placebo group peaking at 1 hr (15-keto-PGF2α: p<0.001) or 2 hr (PGD2: p<0.001, 
PGE2: p<0.01, 15-keto-PGE2: p<0.01 & PGA2: p<0.001) post-exercise and returning to 
baseline levels by 24 hrs recovery (p>0.05) (Figure 4-3A-E).  No significant changes 
post-exercise were found for the ibuprofen group with the exception of PGD2 which 
displayed a significant (p<0.01), albeit blunted and delayed increase from baseline levels 
at 24 hr of recovery (Figure 4-3A). 
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Figure 4-3: Series 2 (AA derived) prostaglandin response to resistance exercise ± ibuprofen treatment. . 
Serum PGD2 (A), PGE2 (B), 15-keto-PGE2 (C), 13,14dh-15kPGE2 (D), PGA2 (E) and 15-keto-PGF2α (F) responses 
post-resistance exercise ± ibuprofen administration. Values are means ± SEM. ***p<0.001, **p<0.01, *p<0.05 vs. 
pre-exercise.  
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4.3.4 Series 3 Prostanoids 
 
 
The EPA derived COX product PGE3 and its more stable downstream 
endogenous metabolite 15-keto-PGE3 displayed significant main exercise effects (PGE3: 
p<0.0001 & 15-keto-PGE3: p<0.01) and strong trends towards significant exercise by 
drug interactions (PGE3: p=0.08, 15-keto-PGE3: p= 0.12). Post-hoc tests revealed that 
PGE3 increased significantly from pre-exercise levels at 2 hrs (p<0.001), 3 hrs (p<0.01) 
and 24 hrs (p<0.05) post-exercise in the placebo group, but did not reach statistical 
significance (p>0.05) for the ibuprofen group at any time point (Figure 4-4A). Similarly, 
15-keto-PGE3 increased significantly immediately post (p<0.01) and 1 hr (p<0.001) post-
exercise in the placebo group only (Figure 4-4B).  On the other hand 15-deoxy-D12,14-
PGJ3 and TXB3,  downstream circulating metabolites of PGD3 and TXA3 respectively, 
showed significant main effects of exercise (p<0.0001) with highly comparable responses  
over time (p=0.92 & p=0.99 exercise by drug interactions respectively). Post-hoc tests 
showed that both 15-deoxy-D12,14-PGJ3 (PLA p<0.05, IBU p<0.01,) and TXA3 (PLA 
p<0.001, IBU p<0.05) increased significantly in both groups  2 hrs post-exercise with no 
differences between groups at any time point. 
 
 
 
 
 
 
 
 116 
 
 
 
 
 
 
 
Figure 4-4: Series 3 (EPA derived) prostaglandin response to resistance exercise ± ibuprofen treatment.  
Serum PGE3 (A), 15-keto-PGE3 (B), 15-deoxy-D12,14-PGJ3 (C), and TXB3 (D) responses post-resistance exercise ± 
ibuprofen administration. Values are means ± SEM. ***p<0.001, **p<0.01, *p<0.05 vs. pre-exercise.  
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4.3.5 Leukotrienes 
 
 
Series 4 LTs: Markers of AA derived LTA4 synthesis via the 5-LOX pathway,  
including LTA4’s primary biologically active enzymatic product LTB4 (Figure 4-5A) and 
the LTA4 non-enzymatic hydrolysis products 5,12-DiHETE (6-trans-12-epi Leukotriene 
B4) (Figure 4-5B) and 5(S),6(S)-DiHETE (Figure 4-5C) displayed significant (LTB4 & 
5(S),6(S)-DiHETE: p<0.05) or borderline significant (5,12-DiHETE: p=0.068) drug by 
exercise interactions.  LTB4 (p<0.01), 5,12-DiHETE (p<0.05) and 5(S),6(S)-DiHETE 
(p<0.05) increased significantly from baseline at 1 hr post-exercise in the placebo group 
and remained significantly elevated at 2 hrs of recovery (p<0.001). No significant 
changes from baseline occurred in response to exercise in the ibuprofen group at any time 
point (Figure 4-5A-C) (p>0.05). 
Series 5 LTs: Markers of EPA derived LTA5 synthesis via 5-LOX, including the 
primary biologically active enzymatic product LTB5 (Figure 4-5D) and the non-
enzymatic hydrolysis product 5,12-DiHEPE (Figure 4-5E) similarly displayed significant 
exercise by drug interactions (p<0.05). Both LTB5 (p<0.01) and 5,12-DiHEPE (p<0.001) 
were significantly elevated above baseline at 2 hr post-exercise in the placebo group with 
no significant change from baseline observed in the ibuprofen group. 
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Figure 4-5: Leukotriene response to resistance exercise ± ibuprofen treatment.  
Serum LTB4 (A), 5,12-DiHETE (B), 5(S),6(S)-DiHETE (C) and  LTB5 (D) responses post-resistance exercise ± ibuprofen administration. Values 
are means ± SEM. ***p<0.001, **p<0.01, *p<0.05 vs. pre-exercise.  
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4.3.6 Lipoxins 
 
 
15-HETE; the initial product of 15-LOX pathway metabolism of AA, as well as 
its enzymatic downstream metabolite 15-OxoETE were found to show main effects for 
exercise (p<0.0001) with no significant exercise by drug interactions (15-HETE: p=0.90 
& 15-OxoETE: p=0.72). 15-HETE increased significantly immediately post exercise in 
both the placebo (p<0.001) and ibuprofen groups (p<0.01) (Figure 4-6A). 15-OxoETE 
was significantly elevated above basal levels at 24 hrs post-exercise in both the placebo 
group (p<0.001) and ibuprofen group (p<0.05) (Figure 4-6B). 
Serum LXA4 and LXB4 showed a main effect for time (LXA4: p<0.01 & LXB4: 
p<0.05) with no significant exercise by drug interaction (LXA4: p=0.23 & LXB4: 
p=0.20). Nevertheless, post-hoc tests indicated that LXA4 was only significantly elevated 
above baseline levels at 1 hr post-exercise in the placebo group (p<0.05) with the change 
in the ibuprofen group not reaching statistical significance (p>0.05) (Figure 4-6C). 
Similarly, LXB4 was significantly increased immediately post (p<0.001), 30 min post 
(p<0.05), 1 hr post (p<0.05), and 2 hr post exercise (p<0.05) in the placebo group only 
(Figure 4-6D). The ibuprofen group exhibited a delayed/blunted elevation in LXB4 at 24 
hrs post exercise (p<0.05) (Figure 4-6D).  
Isomers of LXA4 (Figure 4-6E) and LXB4 (Figure 4-6F) achieved significant 
exercise by drug interactions (LXA4: p<0.01, LXB4: p<0.05). Both LXA4 (p<0.001) and 
LXB4 (p<0.01) isomers increased significantly 2 hrs post exercise in the placebo group 
only (Figure 4-6E & F). LXA4 isomer levels were also significantly higher in the placebo 
group at 2 hrs of recovery compared to the ibuprofen group (Figure 4-6E). Only the 
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LXA4 isomer was found to differ from baseline in the ibuprofen group, and this effect did 
not reach statistical significance until 24 hrs of recovery (p<0.01) (Figure 4-6E). 
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Figure 4-6: Lipoxin response to resistance exercise ± ibuprofen treatment. . 
Serum 15-HETE (A), 15-OxoETE (B), LXA4 (C), LXB4 (D), LXA4 isomer 1 (E) and LXB4  isomer 1 (F) 
responses post-resistance exercise ± ibuprofen administration. Values are means ± SEM. ***p<0.001, 
**p<0.01, *p<0.05 vs. pre-exercise. #p<0.05 vs. placebo group. 
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4.3.7 Resolvins 
 
 Serum levels of the DHA derived RvD1 (Figure 4-7A) were low and data 
obtained for 13 of the total 16 subjects contained missing values precluding repeated 
measures analysis over time. Available data did however showed a tendency for higher 
mean serum levels of RvD1 in the placebo group at 2 hrs (PLA n=5, IBU n=6) and 3 hrs 
(PLA n=4, IBU=6) post exercise (p=0.03 and p=0.08 by unpaired t-tests respectively) 
(Figure 4-7A). A more consistently detectable isomer of RvD1 showed a significant main 
effect for time (p<0.0001) and a trend towards a significant drug by time interaction 
(p=0.12) (Figure 4-7B). RvD1 isomer levels increased significantly at 2 hrs post-exercise 
in both the placebo (p<0.001) and ibuprofen (p<0.01) groups (Figure 4-7B) 
An isomer of the EPA derived RvE1 was found to be present at undetectable-low 
levels in baseline serum samples taken from both the placebo and ibuprofen groups 
(Figure 4-7C). At 2 hr, 3 hr and 24 hr post-exercise however the levels of this RvE1 
isomer were consistently detectable in both groups, indicative of an increase post-
exercise. Repeated measures 2 way-ANOVA was performed on the 2-24 hr time-points 
only (for which a full data set was available). A significant interaction between exercise 
and drug ingestion was found (p<0.05). RvE1 isomer levels were significantly higher in 
the placebo group at 2 hr post exercise compared to the ibuprofen group (p<0.05) (Figure 
4-7C). 
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Figure 4-7: Resolvin response to resistance exercise ± ibuprofen treatment.  
Serum RvD1 (A), RvD1 isomer (B) and RvE1 isomer 3 (C) responses post-resistance exercise ± ibuprofen 
administration. Values are means ± SEM. ***p<0.001, **p<0.01, *p<0.05 vs. pre-exercise. #p<0.05 vs. placebo group. 
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4.4 Discussion 
 
The present study investigated the effect of ibuprofen treatment on human 
eicosanomic profiles during recovery from resistance exercise. Serum TXB2 increased 
immediately post-exercise followed by AA/EPA derived PGs and LTs peaking ~2 hrs 
into recovery. AA and EPA/DHA derived lipid mediators implicated in the active 
resolution of inflammation including the LXs and RVs also increased during post-
exercise recovery. Ibuprofen treatment suppressed the acute inflammatory eicosanoid 
response and this was associated with diminished induction of purported anti-
inflammatory/pro-resolution mediators. These findings identify a complex eicosanoid 
response in acute post-resistance exercise recovery which may play an important role in 
inflammatory and adaptive responses to skeletal muscle damage. 
Despite the well established role of lipid mediator species in mediating aspects of 
inflammation, the eicosanoid response to exercise-induced muscle injury has remained 
largely uncharacterized. By the use of LC-MS employed in the present study, multiple 
eicosanoid species can be simultaneously analyzed in a single biological sample. This 
circumvents potential issues arising from other detection methodologies such as ELISA 
and RIA, including the time, monetary cost, and sample volume requirements of running 
multiple single target assays, as well as eliminating the potential for cross-reactivity 
between similar eicosanoid species.  
The vast majority of previous studies have utilized commercially available ELISA 
kits and thus focused on a select few eicosanoids of interest. The most investigated 
eicosanoid species in response to exercise-induced muscle injury has been PGE2, likely 
attributable to its pro-inflammatory/hyperalgesic properties and interest in their possible 
 125 
role in underlying symptoms of DOMs. Whilst some studies have reported elevated 
circulating PGE2 concurrent with the onset of DOMs 24-72 hrs post exercise-induced 
muscle injury (300, 319), others have found no such response (20, 38, 42, 60, 61, 129, 
232). The reasons for this are unclear, but may be related to differences in the intensity of 
skeletal muscle loading (down hill running (42, 232) vs. resistance exercise (300, 319)) 
and the volume of active muscle mass (unilateral/isolation (20, 38, 60, 61, 129) vs. 
bilateral/compound exercises (300, 319). In the present study, the vast majority of 
detected eicosanoids, including PGE2, were no longer significantly elevated in human 
serum at 24 hrs post-exercise, a time at which subjects were experiencing substantial 
DOMs. 
Eicosnoids are important autocrine/paracrine signaling molecules which may play 
a key role in the acute physiological responses to exercise. During and immediately 
following continuous sub-maximal exercise, heightened circulating levels of PGE2 (68, 
173, 216, 232, 326), PGF2α (68, 74), and 6-keto-PGF1α (49, 68, 95, 173, 197, 209, 249, 
328) have been reported previously. This response is short lived and appears involved in 
the regulation of cardiovascular (CV) changes (muscle hyperemia and CV presser reflex) 
with exercise rather than muscle damage/inflammation (35, 36, 56, 58, 62, 64, 153, 212, 
265, 270). In contrast, in the present study, circulating free AA and serum PG markers 
were unchanged immediately post-resistance exercise, but elevated 2-3 hrs into recovery. 
These findings are indicative of an eicosanoid response to exercise-induced muscle injury 
which greatly precedes the peak onset of DOMs (24-48 hrs post-exercise). In support of 
our data, circulating PGE2 was previously reported to be increased 2 hrs following 
intense stretch-shortening cycle exercise (76), and elevated intramuscular PGF2α has been 
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observed as early as 5-6 hrs post-resistance exercise (314). In contrast to the relatively 
delayed PG response, in the present study serum markers of TXA2 production increased 
markedly immediately post-exercise and remained elevated throughout recovery. TXA2 
is the major prostanoid generated by platelets, which under physiological conditions 
synthesize TXA2 via constitutively expressed COX-1 without an ability or requirement 
for transcriptional induction of COX-2. Thus, the TX2 response is likely indicative of 
platelet COX-1 activity and may reflect an acute pro-aggregatory cardiovascular platelet 
response to intense physical exertion as reported previously during maximal aerobic 
exercise (95, 173, 195, 197). 
AA is the predominant substrate utilized for PG and TX synthesis in humans, 
however, EPA can also serve as a COX substrate for synthesis of the series 3 prostanoids. 
In the current study, EPA derived PGs displayed a delayed and longer lasting response to 
exercise than their AA derived equivalents. For example, EPA derived PGs remained 
elevated above baseline at 3hr (15-deoxy-D12,14-PGJ3 ) and 24 hr (PGE3 and TXB3) of  
recovery. The significance of this temporal response is unclear, but given the relatively 
anti-inflammatory nature of the series 3 PGs, it may potentially be involved in a 
withdrawal of pro-inflammatory signals conducive with inflammation resolution and 
tissue growth/regeneration.  
Ibuprofen is a non-selective NSAID, the main mechanism of action of which is 
purported to be inhibition of both COX-1 and COX-2 activity. The PGE2 and TXA2 
responses to resistance exercise in the present study were entirely blocked by ibuprofen 
ingestion, indicating that the dosing regimen was effective. Surprisingly, the exercise-
induced increase in serum levels of some (PGE3, 15-keto PGE3), but not other (15-
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deoxy-D12,14-PGJ3 and TXB3) EPA derived prostanoids was blocked by ibuprofen 
ingestion. The extent of COX inhibition may vary across different tissues which 
synthesise specific prostanoids due to differences in membrane phospholipid composition 
and/or prostanoid synthase expression. 
LTs are potent chemoattractants produced by the metabolism of AA via the COX 
independent 5-LOX pathway (291).  A previous human study failed to find any 
significant changes in circulating LTB4 0-1 hr following moderate intensity running, high 
intensity running, or downhill running (232). In contrast, increases in plasma LTC4 and 
LTB4 were observed in humans immediately following high intensity running (127). To 
our knowledge the LT response to exercise-induced muscle injury (resistance or eccentric 
exercise) has not been investigated.  We observed increases at 1-2 hrs post-resistance 
exercise in serum LTB4, as well as non-enzymatic hydrolysis products of LTA4 (5,12-
DiHETE & 5(S),6(S)-DiHETE). Serum levels of the 5-LOX derived EPA equivalents 
LTB5 and 5,12-DiHEPE were also increased 2 hrs post exercise. Elevated circulating AA 
observed in the post-exercise period may serve to drive LT synthesis. Additionally, 5-
LOX activity depends both on the expression of the 5-LOX enzyme and an integral 
membrane protein termed 5-LOX activating protein (FLAP). The mRNA expression of 
both 5-LOX and FLAP was previously reported to be increased in whole blood 2 hrs 
following high intensity running exercise (127). Circulating leukocytes are a major 
source of LT biosynthesis and are thus a likely contributor to the serum LT response 
observed in the present study. Additionally, skeletal muscle cells themselves express 5-
LOX (355) and thus liberated intramuscular AA is likely converted to LTs as well as 
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PGs, which may act in concert to mediate the acute local inflammatory response to 
myotrauma. 
Ibuprofen has been previously found to have non COX-selective anti-
inflammatory effects including inhibition of LT biosynthesis, albeit at relatively higher 
concentrations than required for blockade of PG biosynthesis (144, 162, 322). Consistent 
with these studies we found that ibuprofen appeared to blunt the LT response to 
resistance exercise. This finding may have important implications for previous human 
NSAID studies. For example, oral ibuprofen ingestion was reported to impair the skeletal 
muscle protein synthesis response to resistance exercise (317) whereas oral COX-2 
specific inhibitors (43) or local infusion of a different non-specific COX inhibitor 
(indomethacin) (202) failed to do so. Differences in study design may explain the block 
of protein synthesis with ibuprofen ingestion (317) but not with indomethacin infusion 
(202). However, based on our data ibuprofen may have COX independent anti-
inflammatory effects in humans including inhibition of 5-LOX. Skeletal muscle cells 
express the LTB4 receptor and respond to exogenous LTB4 treatment with enhanced in-
vitro growth (296). Thus, blockade of exercise-induced LTB4 synthesis with ibuprofen 
observed in the present study may potentially contribute to the previously reported effects 
of ibuprofen treatment during post-exercise recovery.  
Specialized active pro-resolving lipid mediators, namely the LXs, RVs, and 
protectins have been shown to play an important active role in active withdrawl of pro-
inflammatory signals, restoration of homeostasis and promotion of tissue repair (102, 
272, 291). To our knowledge the present study is the first to profile the LX/RV response 
to resistance exercise. A number of LX and RV species increased in human serum during 
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post-exercise recovery and blockade of early pro-inflammatory signals (TXs/PGs/LTs) 
with ibuprofen treatment was associated with a diminished pro-resolution (LX/RV) 
mediator response. Unlike PGs and LTs which are synthesized intracellular, LXs and 
RVs are generated through transcellular LOX enzyme interactions. For example 15-LOX 
expressing cells (e.g. epithelial cells and monocytes) convert free AA to 15-HETE which 
is secreted and can subsequently be taken up and converted by 5-LOX expressing cells 
(e.g. neutrophils) to LXA4/LXB4. Alternatively, LXA4/LXB4 can be synthesized from 5-
LOX generated LTA4 by sequential oxidation by platelet 12-LOX. Although NSAIDs 
such as ibuprofen do not inhibit 12/15-LOX activity directly, biosynthesis of LXs and 
RVs is dependent on the induction of inflammation (272). For example, LX and RV 
biosynthesis requires the cell to cell interactions which occur during inflammation (e.g. 
neutrophils/platelets) (262). Additionally, elevated PGE2 and PGD2 levels have been 
shown to switch on the transcription of 15-LOX in neutrophils which promotes a shift 
from LT to LX/RV biosynthesis, phenomenon termed lipid class switching (180). 
Consistently, our results show that the acute inflammatory signals during post-exercise 
recovery appear to be coupled to the sequential induction of pro-resolution lipid 
mediators. 
In conclusion the data presented here characterize the acute eicosanoid response 
to exercise-induced muscle injury in humans. Peak induction of pro-inflammatory 
mediators including AA derived PGs and LTs occurred in the early hours of post-exercise 
recovery. Inhibition of inflammatory events with ibuprofen treatment was associated with 
a diminished release of purported pro-resolution mediators including LXs and RVs. It is 
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proposed that this diverse range of eicosanoids may play an important role the in 
inflammatory and adaptive signaling during post-exercise recovery.  
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5 CHAPTER FIVE – EFFECT OF IBUPROFEN 
ADMINISTRATION ON CONTRACTION-INDUCED 
SIGNALING IN HUMAN SKELETAL MUSCLE 
 
5.1 Introduction 
 
Resistance exercise increases the rate of skeletal myofibre protein synthesis 
during acute post-exercise-recovery, a response which appears indicative of long term 
increases in muscle mass and strength with resistance exercise training (122, 337, 339). 
Exercise-induced muscle damage and the associated inflammatory response have been 
proposed as one possible mechanistic link between exercise, protein synthesis, and 
muscle hypertrophy (269). The cyclooxygenase enzymes, COX-1 and COX-2, catalyse 
the initial step in biosynthesis of the prostaglandins (PGD, PGE, PGF, PGI & TXB); 
autocrine/paracrine bioactive lipid mediators which play a central role in the 
inflammatory response. Blockade of PG synthesis with COX inhibiting non-steroidal 
anti-inflammatory drugs (NSAIDs) has been found to have deleterous effects on animal 
models of skeletal muscle growth/regeneration (8, 30, 32, 203, 215, 222, 275, 277, 288) . 
Although human data is lacking, administration of the over the counter NSAID ibuprofen 
was reported to block the human muscle protein synthesis response to eccentric exericse 
(316, 317). The molecular mechanisms by which NSAIDs may influence human muscle 
protein synthesis have not been investigated. 
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Protein synthesis is thought to be tightly regulated at the level of mRNA 
translation and the mamilian target of rapamycin (mTOR) kinase plays an important role 
in the control of translation (143, 306, 330). Human post-exercise protein synthesis is 
blocked by rapamycin administration, indicative of a causal role of mTOR kinase activity 
(84).  mTOR phosphorylates downstream effectors including p70 S6 kinase 1 (p70S6K) 
and eukaryotic initiation factor 4E binding protein (4E-BP1). In particular, p70S6K 
phosphorylation coincides with elevated post-exercise protein turnover, and is correlated 
with the magnitude of acute changes in muscle protein synthesis (108, 167) and 
ultimately gains in muscle mass with exercise training (190, 302). Downstream targets of 
p70S6K include ribosomal protein S6 (rpS6 Ser235/236 & rpS6Ser 240/244) (233, 257) 
as well as eukaryotic elongation factor 2 (eEF2) kinase (331), and eukaryotic initiation 
factor 4B (eIF4B) (274).  rpS6 phosphorylation plays an important role in the control of 
muscle cell size (258), although the mechanisms by which this may occur have been 
brought into question (199, 259). 
 Whilst much work has focused on the role of mTOR, the extracellular receptor 
kinase (ERK) branch of the mitogen activated protein kinase (MAPK) pathway has also 
been found to be important in the control of muscle protein synthesis (99, 119, 159, 240, 
298) and skeletal myofibre size (279, 280). ERK 1/2 signaling regulates the translational 
apparatus via phosphorylation of eIF4B (274), eIF4E (100) and eEF2 kinase (331). 
Additionally, ERK 1/2 and/or the downstream effector ribosomal protein S6 Kinase 
(RSK) can directly phosphorylate kinases both upstream (TSC) (183, 252, 256) and 
downstream of mTOR (p70S6K Ser424/thr421 & rpS6 Ser235/236) (146) (233, 257). In 
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this way ERK 1/2 signaling regulates translational control via both mTOR dependent and 
independent mechanisms. 
The traditional paradigm that resistance exercise promotes mTOR signaling via 
the PI3K/Akt pathway secondary to the systemic or local autocrine/paracrine release of 
IGF-1 has recently been brought into question (237). Post-exercise Akt phosphorylation 
in human subjects has been found to be elevated (45, 59, 78, 79, 81, 83, 84, 108, 112, 
255), unaltered (89, 142, 152, 297, 303) or blunted (66, 67, 302) in spite of heightened 
mTOR signaling and muscle protein synthesis. Furthermore, animal studies show that 
neither a functional skeletal muscle IGF-1 receptor (289, 346) nor PI3K/Akt signaling 
(121, 130-133, 135, 205, 221)  is required for muscle load induced mTOR signaling. 
ERK 1/2 are rapidly phosphorylated in human skeletal muscle post-exercise (44, 59, 66, 
83, 84, 108, 152, 297, 342), indicative of a possible synergistic role in the control of 
muscle protein synthesis. Consistent with this hypothesis, elevated mTOR kinase activity 
following myofibre mechanical overload persists in the presence of PI3K/Akt blockade 
due to intact phosphorylation of the purported ERK dependent TSC Ser664 site (205). 
Additionally, in this model the early phosphorylation of p70S6K Ser424/thr421, rpS6 
Ser235/236 and rpS6 Ser240/244 are rapamycin resistant (mTOR independent) (205). 
The upstream pathways responsible for exercise-induced ERK response and the role of 
ERK/mTOR pathway crosstalk in the human translational signaling response to exercise 
is unknown. 
We recently reported that PGF2α stimulates ERK dependent mTOR signaling in 
skeletal myotubes in-vitro, establishing PGF2α as an important previously 
uncharacterized upstream modulator of the mTOR pathway in skeletal muscle cells (188). 
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PGF2α is known to increase in skeletal muscle tissue during post-exercise recovery (316), 
and blockade of this response with NSAID treatment is associated with a diminished 
muscle protein synthesis response to exercise (317). Furthermore, NSAIDs have been 
implicated in deregulation of ERK signaling in other cell types (226, 227). The influence 
of NSAID treatment on ERK signaling in human skeletal muscle has not been 
investigated. Given the apparent relationship between exercise, NSAIDs, and muscle 
protein synthesis (316, 317), in the present study we sought to investigate the effect of 
NSAID administration on skeletal muscle translation signaling responses in human 
subjects in-vivo.  
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5.2 Materials and Methods  
 
5.1.1 Participants 
 
 
Refer chapter 4. 
5.1.2 Familiarisation 
 
 
Refer chapter 4. 
5.1.3 Experimental protocol 
 
 
Refer chapter 4. 
5.1.4 Muscle biopsies 
 
 
Skeletal muscle biopsy samples were collected from the vastus lateralis 
musculature under local anaesthesia (Xylocaine 1%) by percutaneous needle biopsy 
technique modified to include suction. Biopsies were taken at prior to exercise (baseline), 
immediately post-exercise, and following 3 hrs and 24 hrs of recovery. Biopsies 1 and 4 
were taken from the dominant leg and biopsies 2 and 3 from the contralateral (non-
dominant leg). Sequential biopsies were obtained through a separate incision 5cm 
proximal to the previous site. All skeletal muscle biopsy samples were immediately 
frozen in liquid nitrogen.  
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5.1.5 Tissue processing and immunoblotting 
 
 
Tissue was homogenized in ice cold RIPA lysis buffer (50 mM Tris-HCl, pH 7.4, 
150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA with 
protease/phosphatase inhibitors 1 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 
mM Na3VO4 & 1mM NaF) and rotated for 1 hour at 4˚C. Homogenates were centrifuged 
at 13000 g at 4˚C for 15 min and the supernatant stored at -80˚C until further analysis. 
Total protein content of cell culture lysates was determined with a BCA-protein kit 
(Pierce). Aliquots containing 50 µg protein were suspended in Laemmli buffer, boiled, 
and subjected to SDS/PAGE. Proteins were transferred to a PVDF membrane, and 
blocked in 5% BSA/ Tris Buffer Saline/1% Tween 20 (TBST) for 2 hr, followed by 
overnight incubation at 4˚C with primary antibodies [p-Akt (Ser473), p-p70S6K 
(Thr389), p70S6K (Thr421/Ser424), p-ERK 1/2 (Thr202/Tyr204), p-RSK (Ser380), p-
rpS6 (Ser240/244), p-STAT-3 (Tyr705 & p-p38MAPK (Thr380/Tyr382), total ERK1/2, 
total rpS6, total p70S6K; Cell Signaling] under gentle agitation. Membranes were washed 
for 30 min with TBST and probed with an anti-rabbit IgG conjugated to HRP secondary 
antibody for 1 hr at room temperature. Membranes were then washed for 30 min in TBST 
and protein bands were visualized using Western Lighting enhanced chemiluminescence 
reagent (PerkinElmer Life Sciences). Signals were captured using a Kodak Digital 
Science Image Station 440CF (Eastman Kodak Company), and densitometry band 
analysis undertaken with Kodak Molecular Imageing Software (Version 4.0.5, ©1994-
2005 Eastman Kodak Company). Equal protein loading was determined by stripping and 
rerpobing for total ERK1/2, total rpS6 and total p70S6K. 
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5.2 Results 
 
5.3.1 Akt 
 
 
The phosphorylation of Akt Ser473 displayed a main effect of exercise  
(p<0.001), with no significant drug effect or exercise by drug interaction. Overall (after 
collapsing for group) Akt Ser473 phosphorylation increased significantly at 3 hrs post-
exercise compared to baseline (p<0.05) and 0 hr post-exercise (p<0.01) (Figure 5-1A). 24 
hrs post exericse Akt Ser473 phosphorylation was no longer significantly elevated above 
baseline (p>0.05) but remained significantly elevated above the 0 hr post timepoint 
(p<0.01). No other significant differences between groups were observed.  
 
 
 
 
 
 
 
 
 
Figure 5-1: Akt signaling response to resistance exercise ± ibuprofen treatment.  
Phosphorylation of Akt (Ser473) (A) post-resistance exercise ± ibuprofen administration. Values are means ± SEM. 
# Main effect of time vs. pre-exercise p<0.05. 
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5.3.2 ERK/RSK 
 
 
Phosphorylation of ERK 1/2 Thr202/Tyr204 displayed a significant exercise by 
drug interaction (p<0.05). p-ERK 1/2 Thr202/Tyr204 increased significantly from 
baseline levels in both the placebo and ibuprofen groups immediately post exercise (PLA 
p<0.001; IBU p<0.05) (Figure 5-2A). p-ERK 1/2 Thr202/Tyr204 remained elevated 
above baseline in the placebo group, but not the ibuprofen group, at both 3 hr post (PLA 
p<0.001; IBU p>0.05) and 24 hr post exercise (PLA p<0.001; IBU p>0.05). p-ERK 1/2 
Thr202/Tyr204 did not significantly differ between groups immediately post-exercise, 
but was significantly greater in the placebo group compared to the ibuprofen group at 3 
hrs post (p<0.01) and 24 hrs post-exercise (p<0.05) (Figure 5-2A). 
Phosphorylation of RSK Ser380 displayed a significant exercise by drug 
interaction (p<0.05). p-RSK Ser380 increased significantly above baseline levels in both 
the placebo (p<0.001) and ibuprofen groups (p<0.001) immediately post-exercise with no 
difference between groups (Figure 5-2B). At 3 hrs post exercise p-RSK Ser380 remained 
significantly elevated above baseline in the placebo group (p<0.001), but not the 
ibuprofen group (p>0.05) (Figure 5-2B). At this time p-RSK Ser380 in the ibuprofen 
group was significantly blunted compared to the placebo group. 24 hrs post-exercise p-
RSK Ser380 had returned to baseline levels for both groups, with no significant 
difference between groups. 
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Figure 5-2: MEK/ERK signaling response to resistance exercise ± ibuprofen treatment.  
Phosphorylation of ERK (Thr202/Tyr204)) (A) and RSK (Ser380) post-resistance exercise ± ibuprofen administration. 
Values are means ± SEM. ***p<0.001, **p<0.01, *p<0.05 vs respective pre-exercise timepoint. 
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5.3.3 p70S6K 
 
 
The phosphorylation of p70S6K Thr389 was influenced by exercise similarly in 
both groups (main effect of exercise p<0.01, no exercise by drug interaction). Overall 
(after collapsing for group) exercise significantly increased the phosphorylation of 
p70S6K Thr389 above baseline levels at 3 hrs post-exercise (Figure 5-3A). No other 
significant differences between time-points were observed. 
Phosphorylation of p70S6K Ser424/Thr421 displayed a significant exercise by 
drug interaction (p<0.01). p-p70S6K Ser424/Thr421 increased significantly above 
baseline in both the placebo (p<0.001) and ibuprofen (p<0.001) groups immediately post 
exercise with no difference between groups (p>0.05) (Figure 5-3B). 3 hrs post-exercise p-
p70S6K Ser424/Thr421 remained elevated in both groups (PLA p<0.001; IBU p<0.01), 
although the ibuprofen group response was significantly blunted (p<0.001 PLA vs. IBU) 
compared to the placebo group. 24 hrs post exercise p-p70S6K Ser424/Thr421 was 
comparable between the placebo and ibuprofen groups and no longer significantly 
differed from baseline. 
 
5.3.4 RpS6 
 
 
 Rp-S6 Ser240/244 phosphorylation displayed a significant exercise by drug 
interaction (p<0.001). Immediately post-exercise p-S6 Ser240/244 was unchanged in 
both the placebo and ibupfrofen groups and did not differ between groups (Figure 5-3C). 
3 hr post-exercise p-S6 Ser240/244 was significantly increased in both the placebo 
(p<0.001) and ibuprofen (p<0.01) groups, although the ibuprofen group response was 
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significantly blunted when compared to the placebo group. 24 hrs post-exercise p-S6 
Ser240/244 had returned to pre-exercise levels with no significant difference between 
groups. 
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Figure 5-3: p70S6K/rpS6 signaling response to resistance exercise ± ibuprofen treatment.  
Phosphorylation of p70S6K (Thr389) (A), p70S6K (Thr421/Ser424) (B) and rpS6 (Ser240/244) (C) post-resistance 
exercise ± ibuprofen administration. Values are means ± SEM. ***p<0.001, **p<0.01, *p<0.05 vs respective pre-
exercise timepoint. ### main effect of time p<0.001. 
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5.3.5 STAT-3 
 
 
Phosphorylation of STAT-3 Tyr705 displayed a significant main effect of 
exercise (p<0.0001) with no effect of drug or exercise by drug interaction.  Analysis of 
the main effect of time (colapsing over group) showed that overall p-STAT-3 Tyr705 
increased at 3 hrs post-exercise vs. baseline and immediately post-exercise levels (Figure 
5-4A). 24 hrs post exercise p-STAT-3Tyr 705 did was no longer elevated above baseline. 
 
5.3.6 p38 MAPK 
 
 
Phosphorylation of p38MAPK Thr380/Try382 displayed a significant main effect 
of exercise (p<0.0001) with no effect of drug or exercise by drug interaction.  Analysis of 
the main effect of time (colapsing over group) showed that overall p-p38 
MAPKThr380/Try382  increased immediately post-exercise (p<0.001) and at 3hrs post-
exercise (p<0.05) vs. baseline (Figure 5-4A). 24 hrs post exercise p- p38MAPK 
Thr380/Try382 was no longer elevated above baseline. 
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Figure 5-4: Cytokine related signaling response to resistance exercise ± ibuprofen treatment.  
Phosphorylation of STAT3 (Tyr705) (A) and p38MAPK (Thr380/tyr382) (B) post-resistance exercise ± ibuprofen 
administration. Values are means ± SEM.. # Main effect of time p<0.05, ### main effect of time p<0.001. 
 
 145 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-5: Representative western blots depicting the signaling response to resistance exercise ± 
ibuprofen treatment.  
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5.4 Discussion 
 
 
The present study was undertaken to determine the effect of NSAID 
administration on contraction-induced skeletal muscle signaling in humans. The novel 
findings from this study are as follows: (1) The immediate post-exercise signaling 
response, characterized by phosphorylation of ERK 1/2 Thr202/Tyr204, RSK Ser380 and 
p70S6K Ser424/Thr421 was not significantly influenced by ibuprofen ingestion prior to 
exercise; (2) At 3 hrs of recovery, the phosphorylation of ERK 1/2 Thr202/Tyr204 and 
RSK Ser380 was completely blocked by ibuprofen treatment whilst phosphorylation of 
p70S6K Ser424/Thr421 and p-S6 Ser240/244 was significantly suppressed; (3) ibuprofen 
had no influence the phosphorylation of AktSer474 or p70S6K Thr389 which peaked 3 
hrs post-exercise in both groups. These findings indicate that the intramuscular signaling 
response following a bout of resistance exercise is, in part, ibuprofen sensitive, and 
suggest that COX activity is mechanistically important in regulating sustained 
contraction-induced ERK signaling. Additionally, despite intact mTOR kinase activity 
(as evidenced by normal phosphorylation of p70S6K Thr389) in those receiving 
ibuprofen treatment, diminished ERK signaling may have contributed to the deregulation 
of kinases downstream of mTOR known to be important in translational regulation. 
The cellular response to resistance exercise has been widely studied in recent 
years and mTOR signaling has been well characterized in the early hours of recovery 
(330).  Given the apparent role of mTOR in mediating exercise-induced muscle protein 
synthesis (84), and studies also implicating COX/PGs in the control of protein turnover 
(225, 251, 286, 316, 317, 320, 321), we sought to investigate the effect of ibuprofen 
treatment on post-exercise signaling events. The paradigm that resistance exercise up-
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regulates mTOR signaling via the PI3K/Akt pathway secondary to the systemic or local 
autocrine/paracrine release of IGF-1 has recently been brought into question (237). 
Neither a functional skeletal muscle IGF-1 receptor (289, 345), nor PI3K activity (121, 
205, 221) is required for contraction/overload induced phosphorylation of p70S6K 
Thr389.  Also systemic elevations in purported anabolic hormones (i.e. IGF-1) are not 
involved in exercise-induced mTOR signaling/protein synthesis (335) or phenotypic 
adaptations to resistance exercise training in humans (334, 338). Nevertheless, consistent 
with some previous studies showing increased in Akt phosphorylation in response to 
exercise (45, 59, 78, 79, 81, 83, 84, 108, 112, 255), we did observe a modest albeit 
significant increase in the phosphorylation of Akt Ser474 at 3 hrs post-exercise. In 
contrast, immediately post-exercise p-Akt Ser473 tended to be modestly decreased, as 
has also been previously observed (66, 67, 302). Ibuprofen administration had no 
influence on the p-Akt Ser473 response to exercise suggesting that COX/PGs do not 
contribute to exercise-induced Akt signaling. 
Whilst early human studies indicated that post-exercise feeding was required for 
phosphorylation of p70S6K at Thr389 (and thus full activation) to occur (21, 155), our 
findings are consistent with a large body of work showing that exercise of sufficient 
intensity/volume is sufficient to induce phosphorylation of p70S6K Thr389 in the fasted 
state (44, 45, 78-80, 82, 84, 89, 92, 108, 112, 142, 152, 167, 254, 297, 302, 303). In the 
present study, phosphorylation of p70S6K Thr389 was elevated at 3 hrs of recovery to a 
comparable extent in both groups and thus appears to be unaffected by ibuprofen 
treatment. Eccentric contractions are known to induce phosphorylation of the p70S6K 
Thr389 residue by a mTOR kinase dependent (rapamycin sensitive) (221) pathway. 
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Therefore, our data suggest that ibuprofen treatment has no direct influence on mTOR 
kinase activity during post-exercise recovery. This finding is in agreement with the 
findings of a previous study which showed that the COX-2 selective NSAID NS-398 
impaired skeletal muscle growth in response to synergist ablation overload without any 
apparent negative effect on p70S6K Thr389 phosphorylation (215). We previously 
reported (chapter 2) that exogenous PGF2α stimulated mTOR dependent phosphorylation 
of p70S6K Thr389 in C2C12 myotubes in-vitro (188). On this basis of the present 
findings however, it appears that other signals are responsible for contraction induced 
p70S6K Thr389 phosphorylation in humans in-vivo. 
The activity of p70S6K is controlled by multiple phosphorylation events.  Whilst 
phosphorylation at Thr389 correlates best with p70S6K activity in-vivo, phosphorylation 
at Ser424/Thr421 is thought to activate p70S6K via relief of pseudosubstrate suppression. 
Consistent with previous reports, in the placebo group we found phosphorylation of 
p70S6K Ser424/Thr421 to be heightened immediately post-exercise and sustained 
throughout the acute post-exercise period (0-3 hrs) (66, 83, 89, 155, 163, 297, 302). As 
noted by other workers previously (66, 297), the robust immediate phosphorylation of 
p70S6K Ser424/Thr421 preceded subsequent phosphorylation at the p70S6K Thr389 site 
by a matter of hours, indicative of the action of different upstream kinases. Consistent 
with this hypothesis, it was recently shown that the early myofibre p70S6K Thr389 
response to synergist ablation overload is rapamyin sensitive (mTOR dependent) whereas 
phosphorylation of p70S6K Ser424/Thr421 is not (205). Both ERK and p38 MAPK 
pathways were shown to be able to contribute to phosphorylation of p70S6K 
Ser424/Thr421 in C2C12 myotubes (66). In the present study, phosphorylation of 
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ERK1/2 Thr202/Tyr204 and its downstream target RSK Ser380 occurred simultaneous to 
p70S6K Ser424/Thr421 in the immediate post-exercise period. The rapid post-exercise 
phosphorylation of ERK 1/2 Thr202/Tyr204, RSK Ser380 and p70S6K Ser424/Thr421 
occurred to a comparable extent in both the placebo and ibuprofen groups (although there 
was a tendency for ERK 1/2 to be suppressed.). Following 3 hrs recovery however, 
phosphorylation at these sites was entirely (ERK 1/2 Thr202/Tyr204 & RSK Ser380) or 
partially (p70S6K Ser424/Thr421) blocked by ibuprofen treatment. These findings 
suggest that ERK signaling during post-exercise recovery is, in part, ibuprofen sensitive. 
Also the delayed phosphorylation of p70S6K at purported MAPK dependent residues 
Ser424/Thr421 are partially (although not entirely) dependent on inflammatory signaling. 
Consistent with our findings are previous reports of a negative effect of NSAIDs on ERK 
signaling in other cell types (226, 227). 
The phosphorylation of rpS6 Ser240/244 was unchanged immediately post-
exercise, but significantly elevated in both groups at 3 hrs of recovery. This is in 
agreement with numerous previous studies reporting that resistance exercise in the fasted 
state is sufficient to induce phosphorylation of rpS6. Peak elevation of rpS6 at 
Ser240/244 coincided with phosphorylation of p70S6K at Thr398; consistent with the 
notion that p70S6K is thought to be the chief upstream kinase responsible for 
phosphorylating of this residue (257). Nevertheless, despite a lack of effect of ibuprofen 
treatment on p70S6K Thr389, ibuprofen significantly blunted contraction induced 
phosphorylation of rpS6 Ser240/244. This finding suggests that p70S6K activity was 
significantly impaired by ibuprofen administration despite intact mTOR kinase activity.  
Consistently, contraction induced phosphorylation of rpS6 Ser240/244 has been found to 
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be partially rapamycin resistant (mTOR independent) in rodent skeletal muscle (205). 
Thus, it appears that contraction induced phosphorylation of p70S6K Ser424/Thr421, via 
ERK may be important for p70S6K activity and downstream signaling to rpS6 in-vivo. 
The lack of an effect of ibuprofen on signaling responses immediately post-
exercise in the present study may be related to the dosing regime employed. Subjects 
ingested the 1st dose of ibuprofen (400 mg) pre-exercise immediately prior to baseline 
muscle/blood sampling. As previously reported, this protocol was sufficient to elevate 
serum ibuprofen levels within the effective therapeutic range immediately post-exercise, 
and maintain these levels throughout 3 hrs recovery (chapter 4). However, we cannot 
discount that potentially ibuprofen sensitive events may have occurred during the 
exercise bout, which could conceivably be involved in the immediate post-exercise 
signaling responses. However, as previously reported (chapter 4) circulating eicosanoids 
were not elevated in these subjects until 2-3 hrs of recovery, consistent with the notion 
that the COX/PG response to resistance exercise is temporally unrelated to early 
signaling events.  
In summary, the contraction-induced increases in ERK1/2 signaling are inhibited 
in healthy human subjects following ibuprofen treatment. Despite apparently intact 
mTOR kinase activity, diminished ERK1/2 signaling is associated with deregulated 
p70S6K-rpS6 signaling. We conclude that contraction induced signaling in human 
skeletal muscle in-vivo is, in part, ibuprofen dependent, implying that COX/PGs play a 
key role in post-exercise growth signaling. Additionally, these findings provide evidence 
to of cross talk between the ERK1/2 and mTOR signaling pathways in human skeletal 
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muscle in-vivo which we hypothesise may be important in the control of exercise-induced 
muscle protein synthesis. 
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6 CHAPTER SIX – CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1 Introduction 
 
 
Skeletal muscle tissue undergoes functional and structural adaptation in response to 
altered use. Progressively overloading the musculoskeletal system through resistance 
exercise training is an effective means by which to gain, preserve or restore skeletal 
muscle mass in order to enhance athletic performance, alter body aesthetics, 
improve/restore musculoskeletal health. In contrast, clinical settings of inactivity (i.e. 
immobilization, microgravity), disease (i.e. cachexia) and ageing (i.e. sarcopenia) are 
characterized by skeletal muscle atrophy. The maintenance or restoration of skeletal 
muscle mass has important clinical implications for disease prevention and quality of life. 
Therefore, understanding the mechanisms underlying skeletal muscle 
growth/regeneration is of great importance. Inflammation has emerged as an important 
component of adaptive skeletal muscle growth. Despite this, molecular links between 
inflammation and skeletal muscle adaptation remain largely uncharacterized. 
 Recent research has been focused on the COX/PG pathway, the molecular target 
of NSAIDs, in skeletal muscle growth/regeneration. This pathway is implicated in the 
inflammatory response by controlling local blood flow, leukocyte chemotaxis, vascular 
permeability and platelet aggregation. Additionally, locally synthesized inflammatory 
molecules have been implicated as having direct autocrine/paracrine effects on skeletal 
muscle cell biology, independent of their actions on inflammatory cells. The molecular 
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links between these inflammatory lipid mediators and control of skeletal muscle cell 
growth have however not been characterized. 
 
The specific aims of the experimental studies which comprise this thesis were: 
 
• To investigate the effect of heightened free AA availability via exogenous 
supplementation on PG synthesis and skeletal muscle cell growth in-vitro. 
 
• To investigate translational signaling responses to PGF2α in skeletal muscle cells 
in-vitro and the role of PGF2α signaling in muscle cell hypertrophy. 
 
• To comprehensively characterize human eicosanomic profiles during recovery 
from a single bout of unaccustomed resistance exercise and determine the impact 
of NSAID (ibuprofen) treatment on this response. 
 
• To determine the effect of NSAID (ibuprofen) administration on exercise-induced 
skeletal muscle translational signaling responses in human subjects. 
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6.2 Summary of Major Findings  
 
The broad aim of the thesis was to investigate the role of inflammatory signaling in 
the molecular control of skeletal muscle cell growth. The results describe an important 
role of COX derived inflammatory molecules in translational signaling and hypertrophic 
growth of skeletal myotubes in-vitro, characterize the impact of exercise on human 
circulating eicosanomic profiles, and show that contraction induced signaling events in 
human skeletal muscle are, in part, dependent on inflammatory signaling molecules. 
These data establish a novel mechanistic link between inflammatory and adaptive 
signaling pathways, and ultimately the control of muscle cell size. These findings are of 
importance in physiological settings of skeletal muscle growth/regeneration. A summary 
of the major findings of the studies comprising this thesis are outlined below. 
In chapter two it was shown that the net effect of heightened endogenous 
synthesis of pro-inflammatory lipid mediators by provision of free exogenous AA is a 
hypertrophic myotube phenotype. The stimulatory effects of arachidonic acid on myotube 
growth were not attributable to a direct effect of AA itself and required COX-2 enzyme 
activity, specifically implicating the PG class of downstream lipid mediators. 
Furthermore, the role of COX-2 activity in AA stimulated hypertrophy was 
mechanistically distinguished from the previously characterized role of COX-2/PGs 
during early myogenesis. These findings show that an increased availability of free AA, 
and associated endogenous pro-inflammatory PG synthesis, is sufficient to stimulate 
skeletal myotube hypertrophy. 
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As previous studies had specifically implicated PGF2α in the positive control of 
muscle protein turnover, in chapter 3 we investigated the translational signaling response 
to exogenous PGF2α administration and the role of PGF2α signaling in skeletal muscle 
hypertrophy. We identified that PGF2α signals via the FP receptor and an Akt 
independent PI3K-ERK-mTOR dependent pathway to enhance to phosphorylation of key 
downstream kinases essential in the control of protein translation. The signaling response 
to PGF2α was observed at low nanomolar doses comparible to endogenous levels released 
from myoblast cultures in response to provision of AA (chapter 2). Consistently PGF2α 
treatment stimulated myotube hypertrophy (albeit at higher relative doses), a response 
which is dependent on FP receptor ligand binding and mTOR kinase activity. These 
findings show that PGF2α signals via MEK/ERK in an Akt independent manner to 
regulate mTOR dependent signaling and skeletal myotube hypertrophy.  
In chapter 4 we characterized the eicosanomic lipid mediator profile in human 
serum at rest and following a single bout of unaccustomed resistance exercise using LC-
MS lipidomic analysis. We found that classical pro-inflammatory eicosanoids including 
the TXs, PGs and LTs were elevated  early during post-exercise recovery. Ibuprofen 
treatment not only suppressed the COX-dependent prostanoid response, but was also 
found to have non-COX specific anti-inflammatory effects including blockade of 5-LOX 
generated leukotrienes. Furthermore, blockade of the acute inflammatory response with 
ibuprofen administration was also associated with a diminished response of purported 
anti-inflammatory/pro-resolution factors including the AA derives LXs and the 
EPA/DHA derived RVs. These findings characterize a rapid endogenous lipid mediator 
to exercise-induced skeletal muscle injury in human subjects which we hypothesise may 
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play an important role in inflammatory and adaptive molecular signaling responses in 
post-exercise recovery. Furthermore, these findings identify a previously uncharacterized 
link between acute pro-inflammatory signals and the induction of pro-resolution 
pathways during post-exercise recovery 
In chapter 5, we sought to asses the impact of ibuprofen administration on 
contraction induced translational signaling events in human skeletal muscle. Post-
exercise signaling responses were found to be, in part, ibuprofen sensitive. Whilst mTOR 
kinase activity (as evidenced by phosphorylation of p70S6K Thr389) was not influenced 
by ibuprofen administration, the phosphorylation of ERK/RSK and kinases downstream 
of mTOR implicated in translational control (p70S6K Thr421/Ser424 and rpS6 
Ser240/244) were significantly blunted during post-exercise recovery in those receiving 
the ibuprofen treatment. It is proposed that local inflammatory signaling may play an 
important synergistic role in the molecular control of intracellular pathways involved in 
post-exercise muscle protein synthesis. Future studies utilizing simultaneous 
determination of intracellular signaling and rates of protein synthesis/degradation are 
required to confirm the physiological relevance of these molecular findings. As identified 
in chapter 4, the number of ibuprofen sensitive bioactive lipid species is large and 
evidently not strictly limited to the prostaglandins. Additionally, ibuprofen may have 
direct or indirect effects on signaling independent of inflammatory lipid mediators. On 
this basis, the precise ibuprofen sensitive signals contributing to contraction induced ERK 
signaling remain to be determined.  
 The results of this thesis expand our current knowledge of the signaling 
mechanisms underlying the control of skeletal muscle cell growth. We have identified 
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previously uncharacterized links between inflammatory lipid mediators, contraction-
induced signaling events and ultimately the molecular control of muscle cell size. Due to 
the complex nature of the human inflammatory lipid mediator profile during post-
exercise recovery and the important role of such factors in the local control of muscle cell 
growth further research is warranted to characterize the role of inflammatory signaling in 
skeletal muscle growth and regeneration. 
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6.3 Future Directions and Considerations 
 
This thesis characterizes the role of inflammatory lipid mediators as potentially 
important local signaling mediators in the molecular control of skeletal muscle cell 
growth. Additionally, our data identify a complex inflammatory lipid mediator response 
during the early hours of post-exercise recovery and suggest that contraction-induced 
signaling events in human skeletal muscle are, in part, mediated by inflammatory 
signaling. Whilst these studies begin to characterize the link between inflammatory 
mediators and the molecular pathways controlling adaptive skeletal muscle hypertrophy, 
considerable work is necessary to characterize these mechanisms further. In this section, 
details of considerations and potential future directions that arise from this work in order 
to further advance our understanding of these pathways will be discussed. 
 
6.3.1 Eicosanomic profiling of cultured skeletal muscle cells 
 
The capacity of skeletal muscle cells to synthesise various eicosanoid species is 
incompletely understood. Skeletal mucle cells have been shown to synthesise/release the 
COX products PGD2, PGE2 and PGF2α and 6-keto-PGF1α (29, 224, 276, 278, 320, 325).  
Whether skeletal muscle cells have the capacity to locally synthesize TXA2, which can 
be measured by quantification of its inactive product TXB2 is less clear. Additionally, the 
LOX  metabolites 5-HETE, 12-HETE and 15-HETE which are precursors for LT and LX 
biosynthesis  have been detected in muscle cell lysates (284). However, whether LT 
and/or LX species are synthesized locally from these intermediates by skeletal muscle 
cells to our knowledge has not been investigated. Characterization of the eicosanomic 
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profile of skeletal muscle cells is important to identify locally synthesized lipid mediators 
which may play an important role in autocrine/paracrine inflammatory and adaptive 
muscle tissue signaling response. Furthermore, as highlighted by our in-vivo findings 
NSAIDs may have systemic non COX -selective effects on inflammatory lipid mediator 
biosynthesis including direct or indirect influencing of 5-LOX and/or 15-LOX activity. 
Therefore, a compreshensive analysis of the effects of various NSAIDs on the skeletal 
muscle cell eicosanoid biosynthesis will assist in the eludication of the mechanisms by 
which anti-inflammatory agents influence skeletal muscle cell growth/regeneration. 
 
 
6.3.2 Effect of eicosanoid receptor antagonists on arachidonic acid induced skeletal 
muscle cell growth 
 
Our data on the effects of AA supplementation in-vitro show that the cumulative 
effect of heightened local endogenous pro-inflammatory eicosanoid synthesis is a 
hypertrophic myotube phenotype. Despite this, the mechanisms downsteam of COX-2 
mediating this response are unclear. PG rich conditioned media collected from AA 
supplemented cells could not mimic the effects of direct AA supplementation on cell 
growth.  The metabolism of eicosanoids is relatively limited in-vitro and PGs accumulate 
in cell culture media to easily detectable levels (29, 224, 276, 278, 320, 325). 
Nevertheless, eicosanoids do undergo degradation under typical cell culture conditions, 
some more rapidly than others (186). Thus, growing cells may be exposed to significantly 
higher concentrations of secreted eicosanoids than remain in conditioned media following 
incubation. Additionally, the active prostanoid species PGI2 and TXA2 are rapidly and 
 160 
non-enzymatically degraded to biologically inactive products 6-keto-PGF1α and TXB2. 
Whilst the PGI2 and TXA2 synthesis can be measured by quantification of these 
degradation products, conditioned culture media treatment experiments can not discount 
the contribution of these factors to muscle cell growth. On this basis further studies are 
needed to characterize the specific downstream events by which elevated flux of AA 
through the COX-2 pathway is coupled to skeletal myotube hypertrophy. 
 
 
6.3.3 Pro-resolution vs. anti-inflammatory treatment of skeletal muscle injury: Effects 
on myofibre growth/regeneration 
 
Anti-inflammatory drugs are commonly administered in the treatment soft tissue 
injury. As discussed in chapter 1 of this thesis, available data from animal models is 
indicative of a deleterious effect of NSAID treatment on skeletal muscle 
growth/regeneration. An issue that has remained unaddressed is the potential role of pro-
resolution mediators in soft tissue healing/adaptation. Acute pro-inflammatory signals are 
coupled to the induction of active resolution and thus traditional anti-inflammatory 
treatments have been proposed to interfere with this process (102, 272, 273). Indeed, our 
LC-MS human eicosanomic analysis identified that purported pro-resolution lipid 
mediators are responsive to exercise-induced skeletal muscle injury and that inhibition of 
pro-inflammatory signals with NSAID administration was associated with a diminished 
resolution mediator response (chapter 4). A recent area of interest is the use of synthetic 
versions of endogenous pro-resolution factors in the pharmacological treatment of 
inflammatory disease and pain (102, 125, 350). Such novel interventions may be used to 
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treat symptoms associated with soft tissue injury without the deleterious effects that have 
been associated with anti-inflammatory treatments. Furthermore, on the basis of the role 
these endogenous factors have on restoration of homeostasis, it may be hypothesized that 
pro-resolution treatment may in fact have beneficial effects on tissue 
growth/regeneration. Thus, future studies are needed to assess the effects of pro-
resolution treatment in models of skeletal muscle growth and regeneration. In light of the 
apparent links between inflammation, resolution and restoration of homeostasis such 
studies will have significant clinical applicability. 
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6.4 Conclusions 
 
In summary, the major findings of this thesis are as follow: 
 
• Heightened availability of free AA and associated local endogenous pro-
inflammatory lipid mediator synthesis stimulates skeletal myotube hypertrophy 
via a COX-2 dependent pathway. 
 
• PGF2α stimulates skeletal muscle mTOR signaling via a PI3K/ERK dependent 
pathway. 
 
• Eicosanoids including PGs, LTs, LXs and RVs are elevated during the early hours 
of post-exercise recovery and this inflammatory/resolution lipid mediator 
response is blunted by NSAID treatment. 
 
• Contraction induced translational signaling responses in human skeletal muscle 
are, in part, mediated by inflammatory signaling. 
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